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Abstract
The primary cause o f death in cancer patients is the development of 
metastatic secondary tumours in distal organs. This is a complex process during 
which metastatic tumour cells need to overcome the natural barriers impeding 
access to vascular or lymphatic pathways: importantly they also need to alter the 
extracellular environment to allow ectopic cancer growth in distant locations. 
These events generally require the direct participation of released and exposed 
matrix metalloproteinases (MMPs), a family of related zinc-dependent proteases.
Regulation of MMP activity is known to occur by modulation of gene 
expression, via zymogen activation and inhibition by tissue inhibitors o f 
metalloproteinases (TIMPs). It is now evident, however, that modulation o f 
intracellular trafficking, membrane sorting and cell surface release can also 
regulate MMP activities. These latter topics are still not well understood and, for 
this reason, represent the main aims of the present study.
In particular, it has clearly emerged that MT1-MMP, a membrane-type 
MMP, is essential for the growth for human cancers, and acts by disrupting the 
three-dimensional matrix, which would otherwise impede cell proliferation. 
Ablation of the gene encoding MT1-MMP causes the most significant phenotype 
among the MMP knockout mice, and suggests that the activity of MT1-MMP 
cannot be substituted by any of the other members of the family. For this reason, 
the main focus of my PhD thesis is the regulation of MT1-MMP activity.
Here I show that, in a melanoma cell line, the majority (80%) of MT1- 
MMP is sorted to detergent-resistant membrane fractions; however, it is only the 
minor (20%) detergent-soluble fraction of MT1-MMP that undergoes intracellular
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processing to the mature form. Also, this processed MT1-MMP is the sole form 
responsible for ECM degradation in vitro. Finally, furin-dependent processing of 
MT1-MMP is shown to occur intracellularly after exit from the Golgi apparatus 
and prior to arrival at the plasma membrane. It is thus proposed that the 
association of MT1-MMP with different membrane subdomains might be crucial 
in the control of its different activities: for instance in cell migration and invasion 
and other less defined roles such as MTl-MMP-dependent signaling pathways.
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CHAPTER 1
Introduction
Pericellular proteolysis and cell migration are pivotal events in 
development, vascular remodeling, wound healing, inflammatory responses, and 
cancer invasion. As part of these processes, different cell types need to traverse 
basement membrane barriers and move across interstitial, basement membrane, or 
temporary matrices. An invasive cell phenotype can be triggered by altered 
interactions of cellular receptors with extracellular matrix (ECM) components and 
soluble factors. Limited proteolysis by cell surface proteinases such as membrane- 
type matrix metalloproteinases (MT-MMPs) allows cells to make their way 
through the modified matrix. This movement implies continuous ECM 
attachments and detachments by adhesion receptors. Cell surface proteinases not 
only remodel ECM components, but also modify pericellular growth factors or 
their binding proteins and other cell surface proteins, including receptors or other 
proteolytic enzymes. Therefore, when MT-MMPs are targeted to the leading edge 
of migrating cells, proteolysis may not only clear the way for movement, but may 
also provide cells with directional cues by modifying the environment in the 
direction of movement.
In the introduction that follows, I will review in-depth the role MT- 
MMPs play in ECM remodeling. This presupposes a basic knowledge of ECM 
constituents. Hence, I will briefly describe its general structure and the main 
characteristics of its most important components, and also the molecules that 
matrix components use to interact with cells that make the matrix or are supported 
by it.
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1.1 Extracellular matrix
The ECM consists of collagens, glycoproteins, proteoglycans, and 
glycosaminoglycans (Aumailley and Gayraud, 1998; Zagris, 2001). It is a highly 
organized fibrillar meshwork, which serves as substratum for cell adhesion and 
migration. ECM also constitutes a barrier that maintains tissue integrity, impedes 
cell migration, and regulates molecular diffusion and transfer of stimuli. In 
addition, ECM forms a dynamic cellular microenvironment, which plays an 
important role in the determination of cell phenotype (Boudreau and Bissell, 
1998; Streuli, 1999). It mediates the passage of information to and from other 
cells directly through its components and by storing and modulating the function 
of growth factors/cytokines and other regulatory factors including processing 
enzymes and their inhibitors.
As I shall describe below, the specialized ECMs of interstitial connective 
tissues and basement membranes are two structurally and functionally distinct 
ECM categories (Fig. 1.1). The main features these two classes have in common 
is that their basic structure is defined by a collagen scaffold, although the 
collagens that make up the scaffold are quite different, as is their three- 
dimensional architecture (Bosman and Stamenkovic, 2003). Various adhesive 
glycoproteins, including laminins, and proteoglycans adhere to the scaffold and 
interact with the cells in, or adjacent to, the matrix. Interaction with these cells is 
through matrix receptors, of which the integrins constitute the most important 
class (for a review, Miranti and Brugge, 2002).
1.1.1 Interstitial matrix
Interstitial matrix surrounds, and is formed by, connective tissue cells 
such as fibroblasts, osteoblasts, chondrocytes, and macrophages. It consists of a 
m eshw ork  o f p ro te in  f ib e rs  em bedded  in an am o rp h o u s  
glycosaminoglycan/proteoglycan substance (Aumailley and Gayraud, 1998).
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Fig. 1.1. U ltrastructure of the extracellular m atrix (reproduced from 
Bosman and Stamenkovic, 2003). The basement membrane with its lamina 
lucida (LL) and lamina densa (LD) is found adjacent to an epithelial cell (E). 
The interstitial matrix contains collagen fibrils and is in close proximity to the 
basement membrane anchoring fibrils, composed of type VII collagen (scale 
bar 0.1 pM).
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The composition and molecular architecture of matrices differs 
substantially among tissues like bone, cartilage, tendons, ligaments, dermis, vessel 
walls, and the stroma of parenchymal organs (i.e. liver, kidney, etc.).
Collagens are the most abundant structural components of interstitial 
ECM in all tissues (Aumailley and Gayraud, 1998; Prockop and Kivirikko, 1995) 
and are divided in two main groups (for a more detailed classification, see Table 
1. 1):
1) F ibrillar collagens (types I, II, III, V, and XI) are the most important 
molecules in conferring mechanical strength. They are synthesized and secreted as 
procollagens with large globular N- and C-terminal propeptides, which are 
proteolytically processed to generate mature collagen. These triple-helical 
molecules, composed of three a-chains with series of Gly-X-Y triplet sequences, 
are highly resistant to proteolysis. In tissues, individual 2 nm thick collagen 
molecules assemble into 20-200 nM diameter fibrils. Covalent crosslinking 
stabilizes these fibrils so that they associate laterally to form fibers. Type I 
collagen is the major component of collagen fibrils in a variety of tissues 
including bone, skin, tendon, and other fibrous tissues. It is a heterotrimer of two 
a  1(1) and one a2(I) chains. Type II collagen, the main component of cartilage, is 
a homotrimer al(II)3 . Type III [al(III)3] and V [al(V ), a2(V), a3(V)] collagens 
form heterotypic fibrils with type I collagen in soft connective tissues. In bone, 
type I collagen is accompanied by type V and XI [a l(X I) , a2(IX ), a3(XI)] 
collagens. Type XI collagen also forms heterotypic fibrils with type II collagen 
(for a review, see Ottani et al., 2002).
2) N on-fib rilla r collagens form a rather heterogeneous group 
(Aumailley and Gayraud, 1998; Prockop and Kivirikko, 1995). Fibril-associated 
collagens with interrupted triple-helices (FACIT-collagens, type IX, XII, XIV, 
XVI, and XIX) are found in association with collagen fibrils. Type VI collagen 
forms microfibrils in most stromal connective tissues. The network-forming 
collagens are found in hypertrophic cartilage (type X), subendothelial matrices
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(type VIII), and basement membranes (type IV). Long-chain collagen (type VII) 
is a component of anchoring fibrils, which stabilize the attachment of basement 
membranes and epithelia to underlying stroma. In addition, collagens with a 
transmembrane domain (type XIII and XVII), multiplexin (multiple triple-helix 
domain and interruptions) collagens (type XV and XVIII), and other proteins 
containing triple-helical domains have been characterized (Prockop and 
Kivirikko, 1995).
Table 1.1. Some types of collagen and their properties 
(reproduced from Alberts B., 2002)
Type Molecular Polymerized Tissue
Formula Form Distribution
Fibrillar I [cxl (I)]2a2(I) fibril Bone, skin, 
tendons,
ligaments, cornea, 
internal organs
II [ctl(II)]3 fibril Cartilage, 
invertebral disc, 
notochord, 
vitreous humor of 
the eye
III [al(III)]3 fibril Skin, blood 
vessels, internal 
organs
V [al(V )]2a2(V) and 
a  1 (V)a2(V)a3(V)
fibril 
(with type I)
As for type I
XI a l  (XI)a2(IX)a3(XI) fibril 
(with type II)
As for type II
Non-fibrillar IX al(IX )a2(IX )a3(IX ) lateral 
association with 
type II fibrils
Cartilage
XII [al(X II)]3 lateral 
association with
Tendons, 
ligaments, some
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type I fibrils other tissues
Network-forming IV [al(IV )]2a2(IV) sheetlike
network
Basal lamina
VII [al(V II)]3 anchoring
fibrils
Beneath stratified
squamous
epithelia
Transmembrane XVII [al(X V II)]3 not known Hemidesmosomes
Others XVIII [al(XVIII)]3 not known Basal lamina 
around blood 
vessels
Note that types I, IV, V, IX  and XI are each composed o f two or three types o f a  chains, whereas 
types II, III, VII, XII, XVII and XVIII are composed o f only one type o f a  chain each. Only 11 types 
o f collagen are shown, but about 20 types o f collagen and about 25 types o f a  chains have been 
identified so far.
Elastic fibers confer elastic properties to tissues like lung, dermis, and 
large blood vessels (Rosenbloom et al., 1993). Elastin, the main component of 
elastic fibers, is a hydrophobic and extensively crosslinked protein, resistant to 
harsh physical treatments and to most proteinases. The elastic fibers interact with 
microfibrils consisting of fibrillins, other glycoproteins, and proteoglycans 
(Debelle and Tamburro, 1999; Saharinen et al., 1999).
Various glycoproteins are present in the interstitial ECMs. Fibronectin 
and vitronectin are structural ECM glycoproteins also present in plasma, which 
mediate cell attachment to the ECM (Tryggvason et al., 1987). Fibronectins are 
high-molecular mass (235-270 kDa) glycoproteins that form disulfide-linked 
dimers and fibrillar structures. Extensive alternative splicing of a single gene 
generates different forms of fibronectins. They are composed of three types of 
repeats, and other functional domains. Fibronectins interact with cell surface 
integrin receptors principally through an RGD-sequence. They also bind to 
different matrix components including collagens, fibrin, and proteoglycans. 
During development, adhesion of embryonic cells to fibronectin is essential for
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their migration through fibronectin rich matrixes (George et al., 1993). Upon cell 
transformation, decreased synthesis and enhanced proteolytic degradation 
downregulates fibronectins at the cell surface and within the ECM (Tryggvason et 
al., 1987; Vartio et al., 1983b). Many other glycoproteins associate with various 
structural ECM elements. Chondronectin, for example, is a cell-associated 
glycoprotein in cartilage, which promotes the attachment of chondrocytes to type 
II collagen. Thrombospondins, tenascins, and SPARC (secreted protein, acidic 
and rich in cysteine) are capable of mediating both adhesive and anti-adhesive 
interactions and can induce disassembly of focal contact structures (Murphy- 
Ullrich, 2001).
Proteoglycans (PGs) and  glycosaminoglycans (GAGs) constitute the 
amorphous substance of interstitial ECM, a highly hydrated, gel-like “ground 
substance” in which the fibrous proteins are embedded. The polysaccharide gel 
resists compressive forces on the matrix while permitting the rapid diffusion of 
nutrients, metabolites, and hormones between the blood and the tissue cells. The 
collagen fibers both strengthen and help organize the matrix, and elastin fibers 
give it resilience.
PGs consist of a core polypeptide chain, in which serine and threonine 
residues have O-linked GAG chains of heparan, keratan, dermatan, or chondroitin 
sulfate (Iozzo, 1998). The turnover of PGs is faster than that of collagens, with 
half-lives in tissues of a few days to several weeks. PGs not only form structural 
frameworks and act on matrix organization, but also play a role in the modulation 
of variety of biological processes including cell growth, adhesion, and invasion 
(Schwartz, 2000). Many ECM-associated growth factors, such as FGF and VEGF 
family members, bind to heparan sulphate PGs (Taipale and Keski-Oja, 1997). 
Small, leucine-rich PGs, such as decorin and fibromodulin, bind to ECM 
components and participate in the regulation of collagen fibrillogenesis and 
organization of the matrix (Iozzo, 1999). They also bind TGF-(3 and may thus 
modulate the biological effects of this growth factor (Yamaguchi et al., 1990).
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Aggregan and versican, the main chondroitin sulphate PGs of cartilage and 
noncartilagenous tissues, respectively, interact with glycoproteins and hyaluronic 
acid to create extensive networks (Wight et al., 1992). Cell surface-associated 
PGs such as glypicans, syndecans, and CD44 modulate cell adhesion. Recent 
evidence indicates the importance of cleaving some of these PGs (e.g. syndecan- 
1, CD44) in promoting tumor invasion and metastasis (reviewed in Inki and 
Jalkanen, 1996; Nagano and Saya, 2004).
1.1.2 Basement membrane
The term basement membrane is often used to describe the composite of 
the basal lamina and the layer of anchoring collagen fibrils tethering the basal 
lamina to the underlying connective tissue. Basal laminae (BL) are specialized 
extracellular matrix sheets that separate epithelial and endothelial cell layers from 
the underlying cells of the collagenous stroma (Timpl, 1996). BL have more than 
simple structural roles, however. They are able to determine cell polarity, 
influence cell metabolism, organize the proteins in adjacent plasma membranes, 
promote cell survival, proliferation, or differentiation, and serve as specific 
highways for cell migration (Alberts et al., 2002). They are produced and 
assembled in co-operation by cells situated on both sides of the basement 
membrane.
The main BL components include type IV collagen, lam inin, 
entactin/nidogen, and heparan and chondroitin sulfate proteoglycans (PGs). PGs 
are present in all BL structures where they may function in charge-dependent 
molecular sieving and the immobilization of growth factors like FGF-2 and 
VEGF, which can bind to perlecan, the main BL heparan sulfate PG (Handler et 
al., 1997; Iozzo, 2001).
Type IV  collagens are trimeric proteins (~540 kDa) composed of three 
parallel a (IV ) chains, which form a partially triple-helical structure with 
numerous interruptions (Timpl, 1996). Six different chains have been cloned
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(a l(IV ) to a6(IV)). The a l(IV ) and a2(IV) chains are found in most basement 
membranes, whereas the expression of a3-6(IV ) chains is more restricted 
(Hudson et al., 1993; Yurchenco and O'Rear, 1994b). The most common trimer is 
a l(IV )2cc2(IV). Type IV collagen trimers can assemble into a three-dimensional 
network through three types of interactions (Timpl, 1996; Yurchenco and O'Rear, 
1994b). Four molecules can bind to each other at the N-terminal cysteine-rich 
domain (7S) to form tetramers, which are joined to a network structure by a 
dimeric interaction between C-terminal non-collagenous (N C I) domains. 
Additional lateral associations of collagen molecules lead to the formation of 
irregular three-dimensional networks, which are stabilized by disulfide bonds and 
covalent cross-links (see also Table 1.1).
Lam inins are a group of large heterotrimeric glycoproteins (~400-900 
kDa) consisting of three distinct polypeptide chains: a , (3,and y chains 
(Tryggvason, 1993). At least twelve different heterotrimeric laminin isoforms, 
assembled from five a , three (3, and three y chains, have been characterized with 
different tissue distributions and functions (Colognato and Yurchenco, 2000; 
Tryggvason, 1993; Yurchenco and Wadsworth, 2004). Like type IV collagen, 
laminins also self-assemble through calcium-dependent interactions involving the 
terminal domain of three chains to form a polymer network in vitro (Timpl, 1996; 
Yurchenco and O'Rear, 1994b).
The networks of type IV collagen and laminin are connected through 
various interactions. For example, nidogen is a sulfated glycoprotein (150 kDa), 
which bridges these molecules together (Colognato and Yurchenco, 2000). It has 
a C terminal binding site for the EGF repeat of laminin y chains that is located 
near the center of laminin trimer, and an N-terminal binding site for type IV 
collagen. In addition, perlecan contains binding sites for both type IV collagen 
and laminin (Kallunki and Tryggvason, 1992). The NCI domains of type XV and 
XVIII collagens also bind to perlecan and laminin/nidogen complexes (Sasaki et
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al., 1998b). Much of the information required for the assembly of complicated 
ECM structures including collagen fibrils and type IV collagen and laminin 
networks appears to be intrinsic to the molecules. Indeed, these components can 
be induced to self-assemble in vitro in cell-free systems to structures resembling 
those found in vivo (Yurchenco and O'Rear, 1994a). In contrast, fibronectin 
fibrillogenesis is controlled by cell surface integrins and cytoskeletal components 
(Magnusson and Mosher, 1998), and in tissues, basement membrane assembly 
may also be regulated through cell-cell interactions.
1.2 Cross-talk between the extracellular matrix and cells
A dynamic reciprocal interplay between cells and the ECM environment 
is the basis of a flow of information that regulates cell survival, proliferation, 
differentiation, and migration during different biological processes (i.e. embryonic 
development) (Zagris et al., 2004). The major players mediating and modulating 
this information not only include ECM components, growth factors, cytokines, 
integrins and intracellular signal transduction cascades but also extracellular 
matrix modifying enzymes (Streuli, 1999) (Fig. 1.2).
In normal adult tissues, ECM remodeling and cell proliferation are slow, 
the capacity for cell motility is generally repressed, and stable cell adhesion is 
essential for the maintenance and function of the tissues. For example, epithelial 
cells receive signals for quiescence through interactions with intact basement 
membrane and neighbouring cells (Radisky et al., 2001). In the absence of 
specific ECM interactions, cells fail to respond correctly to growth factors and 
maintain or achieve an appropriate phenotype (Streuli, 1999). Consequently, the 
cells function inappropriately or die. Indeed, changes in the ECM, adhesive 
interactions, and ECM remodeling machinery are the first to take place during 
malignant transformation and metastasis (Radisky and Bissell, 2004; Yap, 1998).
ECM can affect cell behavior by storing and mobilizing growth factors 
and cytokines.
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Fig. 1.2. Some ways in which ECM  remodeling can affect cellular 
differentiation (reproduced from Streuli C., 1999). (a) Remodelled ECM 
directly alters cell-ECM interactions, affecting integrin signalling and integrin- 
mediated crosstalk with growth factors, (b) ECM remodelling releases bound 
growth factors (GF). (c) Exposure o f cryptic sites (grey bands) within the ECM 
alters integrin signalling, (d) ECM remodelling releases bioactive ECM 
fragments (black bar), (e) Surface-bound ECM remodelling enzymes shed 
growth factor ectodomains. GFR, growth factor receptor.
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These signal to cells through receptor tyrosine (or serine/threonine) kinases and 
receptors coupled with either G-proteins or signaling complexes consisting of 
tyrosine or serine/threonine kinases and phosphatases. The remodeling of ECM 
components, and the release or activation of ECM-bound growth factors by 
proteolysis, both modulate transduced signals, which in turn control cell 
phenotype. Some of these changes participate in the modulation of proteolysis by 
feedback signaling (Taipale and Keski-Oja, 1997). Interestingly, a distinct 
subfamily of discoidin domain tyrosine kinase receptors (DDR1 and DDR2), 
which signal in response to collagens rather than growth factors, have also been 
identified (Alves et al., 1995; Vogel et al., 1997). These receptors can also 
establish a feedback loop between cells and pericellular proteolysis (Olaso et al., 
2002).
Cells attach and react to the surrounding ECM also through a large 
diversity of adhesion receptors including integrins, heterodimeric transmembrane 
glycoproteins composed of noncovalently associated a -  and (3-chains. The 
combination of a-  and (3-chains provides each integrin with a unique range of 
specificities for different ECM components and cell surface counter receptors 
(Ruoslahti and Obrink, 1996). Clustering of integrins by ligand-specific 
interactions induces cytoskeletal accumulation of multiprotein complexes 
composed of integrins associated with interacting adaptor proteins and signaling 
molecules. Intracellular events can then feed back on the expression and activity 
of the integrins and other gene products of the cell. The response that a particular 
cell makes depends on the composition and architecture of the ECM network as 
well as on the repertoire of cell receptors expressed.
1.3 Cell migration: an interplay between extracellular matrix and
pericellular proteolysis?
Binding of ECM components to specific cell surface integrins not only
27
modulates the integrin activity but also induces integrin clustering into focal 
contacts at the leading edges of migrating cells. The cytoplasmic tails of integrins 
interact with cytoskeletal multiprotein complexes that link the focal contacts to 
actin filaments and intracellular signaling pathways. These interactions regulate 
the migratory potential of cells.
Cell migration is a recurring phenomenon in all morphogenic processes 
during embryonic development (Zagris, 2001). In adults, physiological migration 
processes include trophoblast invasion and invasive migration by neutrophils and 
macrophages (Mignatti and Rifkin, 2000). In many other adult cells the capacity 
for cell movement can be activated by wounding or trauma or by malignant 
transformation. Cell migration is accomplished by propulsive forces transferred 
from the ECM to cytoskeleton through repeated cycles of adhesion, detachment 
and proteolysis. These cycles are regulated by the activity of Rho family of small 
GTPases such as Cdc42, Rac and Rho, which are critical for the assembly of actin 
cytoskeletal components to form membrane ruffles, filopodia, and lamellipodia 
(Lauffenburger and Horwitz, 1996; Mitchison and Cramer, 1996).
The direction of cell migration is mainly affected by chemoattractants 
and by the generation of preferred adhesive interactions. Chemoattractants include 
cytokines and growth factors such as TG F-a, EGF, FGF, and VEGF as well as 
ECM fragments, which are recognized by adhesion receptors.
Proteolytic enzymes and their inhibitors may thus modulate cell 
migration by: 1) clearing the restricting ECM, 2) remodeling ECM components or 
cell adhesion molecules to modify the affinity and dynamics of cell-ECM 
interaction, 3) mobilizing and activating or inactivating growth factors, cytokines, 
and chemokines (Fowlkes et al., 1994; Imai et al., 1997; McQuibban et al., 2001; 
Whitelock et al., 1996), 4) generating bioactive peptides such as endostatin 
(Sasaki et al., 1998a; Wickstrom and Carlstedt, 2001), angiostatin (Cornelius et 
al., 1998), and sites in laminin-5 a3  chain that may direct the migration front of 
invading cells (Giannelli et al., 1997; Koshikawa et al., 2000).
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1.4 Extracellular matrix remodeling
Coordinated degradation of ECM is involved in various physiological 
tissue remodeling processes such as tissue morphogenesis and growth, 
angiogenesis, trophoblast implantation, bone remodeling, wound healing, and 
involution of postpartum uterus or postlactation mammary gland (Mott and Werb, 
2004; Sternlicht and Werb, 2001; Vu and Werb, 2000; Zagris, 2001). Both 
excessive and deficient proteolysis are associated with a number of pathological 
conditions like arthritis, periodontitis, chronic wounds, and scleroderma 
(Birkedal-Hansen, 1995; Sternlicht and Werb, 2001; Mott and Werb, 2004). 
During tumor invasion, neoplastic cells utilize proteolytic and invasive 
mechanisms in a controlled but abnormally regulated fashion to allow cell 
attachment, localized degradation of the ECM, and cell migration through the 
digested barrier (Stetler-Stevenson and Yu, 2001). Rem odeling of the 
differentiated ECMs of various organs and the subepithelial or subendothelial 
basement membranes is dependent on the focal and concerted action of several 
proteinases from different proteinase families.
Focal proteolytic activity can be achieved when proteinases are 
compartmentalized and activated in the immediate pericellular environment where 
proteinase inhibitors, derived either from plasma or secreted by the tissue cells, 
have limited access (Sternlicht and Werb, 2001). Indeed, the localization of 
proteases and their activators to the plasma membrane and special membrane 
domains via a transmembrane domain or binding to cell surface receptors has 
emerged as an important mechanism for the generation of proteolytic activity 
which then mediates a variety of cellular functions (Sternlicht and Werb, 2001).
The cell surface enzymes characterized in pericellular proteolysis include 
matrix metalloproteinases (MMPs), adamalysin-related m etalloproteinases 
(ADAMs), and serine proteases including type II transmembrane serine 
proteinases (TTSPs), plasmin and the urokinase plasminogen activator (uPA) / 
uPA receptor system (Blobel, 1997; Hooper et al., 2001). All these proteinases
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have multidomain structures that provide them with capacity to interact with 
multiple partners in many cases on both sides of plasma membrane and in 
intracellular compartments. Therefore, they may be involved in multiple cellular 
pathways.
During cell invasive and morphogenic processes, cell surface association 
of proteolytic activity has several advantages. First, the proteinase-inhibitor 
balance can be finely tuned to favor pericellular proteolysis, while the 
surrounding tissue is protected by inhibitors. As a result, sufficient matrix can be 
degraded to allow forward movement while an attachment surface is left for 
propulsion. Secondly, cell surface-associated proteinases may specifically interact 
with cell surface signaling receptors or their pericellular ligands, as well as with 
the cytoplasmic signaling complexes, and in this manner function as key 
regulators of signaling events. Thirdly, proteolytic enzymes may interact and 
cooperate with adhesion receptors to control the continuous cell adhesion and 
detachment events required for cell movement (Werb, 1997; Hiraoka et al., 1998; 
Hotary et al., 2000).
For example, the ADAMs that are thought to be involved in fertilization, 
development, inflammation, and angiogenesis (Black et al., 1997; Blobel, 1997) 
have been implicated in the proteolysis of ECM components and cell surface 
proteins (including Notch and TN F-a), in RGD-dependent and -independent 
interactions with integrins, and in signaling via interactions of their cytoplasmic 
domains (Black et al., 1997).
The uPA/uPA receptor (uPAR) system, on the other hand, is an example 
of complex coordinated regulation of protease and adhesion systems to promote 
cell migration. While uPAR is the major binding site for uPA, the plasminogen 
activator generating active plasmin (Chapman, 1997), uPAR may also serve as a 
high affinity receptor for vitronectin (Wei et al., 1994). Based on the observation 
that macrophage adhesion is affected by uPA binding to uPAR independently of 
the proteolytic activity of uPA, uPAR has been suggested to transduce signals to
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cytoskeleton that regulate cell adhesion (Gyetko et al., 1994).
1.5 Matrix metalloproteinases
Proteases are classified into exo- or endopeptidases according to the 
terminal or internal cleavage site on the target proteins respectively (Woessner,
1998). Endopeptidases are divided into the major classes of serine, cysteine, 
aspartic, and metalloproteinases based on their amino acid sequences and the 
cofactors determ ining their catalytic activity and m echanism. M atrix 
metalloproteinases (MMPs) form one of the four subfamilies that belong to 
metzincins, which in turn is one of numerous metalloproteinase superfamilies 
(Sternlicht and Werb, 2001; Woessner, 1998).
MMPs have historically been categorized in four subgroups on the basis 
of their specificity for ECM components: collagenases, gelatinases, stromelysins 
and matrilysins (Sternlicht and Werb, 2001). As the list of MMPs is growing, a 
numbering system has been adopted and MMPs are now classified according to 
their structure. Eight structural classes are recognized, five of which are secreted 
MMPs, and three membrane-type MMPs (MT-MMPs) (reviewed in Mook et al., 
2004).
The MMP family currently consists of 28 distinct but structurally related 
vertebrate enzymes, with 24 characterized human homologues that have partially 
overlapping substrate specificities (Freije et al., 2003; Overall and Lopez-Otin, 
2002; Sternlicht and Werb, 2001) (Fig. 1.3). They are all zinc-dependent neutral 
endopeptidases, whose activation requires the removal of the N-terminal 
prodomain. MMPs function in the degradation and remodeling of different ECM 
proteins and proteoglycans, but recent studies also suggest various other roles for 
these enzymes. For example, MMPs can cleave membrane or ECM-bound 
cytokine precursors, chemokines, growth factors, hormone receptors, growth 
factor binding proteins, proteinase inhibitors, and thus modulate their assembly 
and activity (for a review, see Sato et al., 2005).
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Fig. 1.3. Schematic representation of the structure of the 24 human matrix 
metalloproteinases (MMPs), classified into different groups on the basis of 
domain organization (reproduced from Overall and Lopez-Otin, 2002).
Archetypal MMPs contain a signal peptide (necessaiy for secretion), 
propeptide, a catalytic domain that binds zinc (Zn2+) and a hemopexin carboxy 
(C)-terminal domain. Y, D, and G represent tyrosine, aspartic acid and glycine 
amino acids that are present in the catalytic domain o f all collagenases. 
Matrilysins contain the minimal domain organization that is required for 
secretion, latency and catalytic activity. Gelatinases contain fibronectin type II 
modules that improve collagen and gelatin degradation efficiency. Convertase- 
activatable MMPs contain a basic insert in the propeptide that is targeted by 
furin-like proteases (convertase cleavage site). MMPs that belong to this group 
can be secreted enzymes, or membrane-anchored via GPI 
(glycosylphosphatidylinositol), type I or type II transmembrane (TM) 
segments. MMP-23A and MMP-23B contain unique cysteine array (CA) and 
immunoglobulin (Ig)-like domains in their C-terminal region.
MMP activity is regulated by diverse mechanisms at the levels of gene 
transcription, mRNA stability, enzyme secretion and binding, zymogen activation, 
and inhibition by endogenous inhibitors to achieve precise proteolysis during 
normal tissue remodeling (Nagase and Woessner, 1999). Dysregulated MMP 
activity is typical of a number of pathological conditions such as chronic wounds, 
arthritis, periodontitis, cardiovascular disease, and cancer.
The vast majority of MMPs contain characteristic protein domains 
including from the N-terminal to the C-terminal extremities: a signal peptide, a 
propeptide, a catalytic domain with the zinc binding site, a hinge region and a C- 
terminal hemopexin-like domain - hemopexin is a serum glycoprotein that binds 
heme groups reversibly and delivers them to the liver where they are taken up by 
receptor-mediated endocytosis - that is thought to confer some degree of substrate 
specificity (Sternlicht and Werb, 2001).
MMPs can be divided into subgroups based on structural and functional 
criteria. They are either soluble proteins or membrane proteins anchored to 
cellular membranes by type I or type II transmembrane domains or by a glycosyl- 
phosphatidyl inositol (GPI)-anchor. The soluble secreted MMPs have been further 
classified in the subgroups of collagenases, which can degrade fibrillar collagens, 
g e la tin a se s , with high activity against gelatin and type IV collagen, and 
stromelysins, m atrilysins and o ther M M Ps, which degrade a variety of ECM 
components (see Table 1.2). The membrane-anchored MMPs form the group of 
the so-called m em brane-type m atrix  m etalloproteinases and they will be 
described in-depth in section 1.6.
Table 1.2. Secretory m atrix  m etalloproteinases
Enzyme name(s) ECM substrates Other substrates
Collagenases
MMP-l/Collagenase-1 Col I, II, III, VII, VIII, X, ProMMP-1, 2; casein, a2M ; a l-P I;
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XI; gelatin; entactin; 
aggrecan; tenascin; MBP; 
perlecan; IGF-BP-2, 3
a2AC; proTNFa
MMP-8/Collagenase-2 Col I, II, III, gelatin; 
e n t a c t i n ;  a g g r e c a n ;  
tenascin
ProMMP-8; a2M ; a l-P I
MMP-13/Collagenase-3 Col I, II, III, IV, IX, X, 
XIV; gelatin; entactin; 
aggrecan; tenascin; 
osteonectin; 
fibrinogen/fibrin
ProMMP-9; 13; a2M ; a2AC; PAI
Gelatinases (type IV collagenases)
MMP-2/Gelatinase A Gelatin; elastin; 
fibronectin; Col I, IV, V, 
VII, X, XI; laminin; 
aggrecan; vitronectin; 
decorin; MBP; IGF-BP- 
3/5
ProMMP-1, 2, 13; plasminogen; 
casein; a2M ; a l-P I; a2AC; 
proTNFa; proTGF(32; proILip; MCP3; 
FGFrl
MMP-9/Gelatinase B Gelatins; Col IV, V, VII, 
XI, XIV, XVII; elastin; 
fibrillin; fibronectin; 
aggrecan;
fibrinogen/fibrin; MBP
Plasminogen; casein; a2M ; a l-P I; 
proTNFa; proTGF(32; proILip
Stromelysins, matrilysins and others
MMP-3/Stromelysin-1 Fibronectin; laminin; 
gelatin; Col III, IV, V, 
VII, IX, X, XI; elastin; 
decorin; nidogen; 
perlecan; aggrecan; 
tenascin;
fibrin/fibrinogen; fibrillin; 
entactin; vitronectin; 
IGFBP-3
ProMMP-1, 3 ,7 , 8, 9, 13; 
plasminogen; casein; a2M ; a l-P I; 
a2AC; proTNFa; E-cadherin; proIL- 
lp; proHB-EGF
MMP-10/Stromelysin-2 Fibronectin; laminin; 
gelatin; Col III, IV, V, 
VII, IX, X, XI; decorin; 
elastin; nidogen; 
fibrin/fibrinogen; fibrillin; 
entactin; tenascin; 
vitronectin; aggrecan
ProMMP-1, 8, 10
MM P-ll/Stromelysin-3 Laminin; fibronectin; 
aggrecan; IGF-BP-1
a2M ; a l-P I
MMP-7/Matrilysin-l Fibronectin; laminin; Col 
IV; gelatin; aggrecan; 
decorin; nidogen; elastin; 
fibrillin; laminin; MBP; 
osteonectin; tenascin; 
vitronectin
ProMMP-2,7; casein; a l-P I; pro 
a  defensin; FasL; (34 integrin; E- 
cadherin; plasminogen; proTNFa
MMP-26/Matri lysin-2 Col IV; gelatin;
fibronectin;
fibrin/fibrinogen
ProMMP-9; casein; a l-P I
MMP-12/Macrophage 
metalloelastase |
Elastin; fibronectin; Plasminogen; casein
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fibrinogen/fibrin; laminin
M M P-19 Col IV; gelatin; 
fibronectin; tenascin; 
aggrecan; COMP
MMP-20/Enamelysin Amelogenin; aggrecan; 
COMP
MMP-28/Epilysin ND Casein
Modified from (Me Cawley and Matrisian, 2001: Sternlicht and Werb, 2001). Abbreviations: Col, 
collagen; COMP, cartilage oligomeric matrix protein; IGF-BP, insulin-like growth factor binding 
protein; Ln, laminin; MBP, myelin basic protein; PAI, plasminogen activator inhibitor; a2M, 
a2  macroglobulin;al-PI, a l  proteinase inhibitor; a2AC, a2  antichymotrypsin; ND, not 
determined.
1.5.1 Collagenases
Collagenases-1, -2, and -3 (now referred to MMP-1, MMP-8, and MMP- 
13, respectively) are the main secreted neutral proteinases, which can initiate the 
degradation of native helix of fibrillar collagens (Reynolds, 1996). The 
hemopexin domains of these MMPs are essential for specific binding and 
cleavage of this substrate (Allan et al., 1995; Clark and Cawston, 1989). All three 
collagenases can cleave a specific site (GIy775-IIe/Leu776) at each a-chain of the 
trimeric collagen molecule. The resulting N-terminal 3/4 and C-terminal 1/4 
fragments are spontaneously denatured at 37°C to gelatin, which can be further 
degraded by other proteinases (Ala-aho and Kahari, 2005) (Fig. 1.4). Three 
collagenases have overlapping activities on the fibrillar collagen types I, II, and 
III, but their substrate preferences differ (see Table 1.2).
MMP-1 was the first MMP to be discovered based on its activity in the 
metamorphosing tadpole tail (Gross and Lapiere, 1962). It was also the first MMP 
purified to homogeneity (Stricklin et al., 1977) and cloned as a cDNA (Goldberg 
et al., 1986). MMP-1 is secreted in vitro by fibroblasts of various origins, 
chondrocytes, osteoblasts, endothelial cells, keratinocytes, hepatocytes, 
macrophages and monocytes, eosinophils and tumor cells.
MMP-8 is synthesized by polymorphonuclear leukocytes during their
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Fig. 1.4. Degradation of fibrillar collagens (reproduced by Ala-aho R. et 
al., 2005). Fibrillar collagens are degraded by collagenases, MMP-1, MMP-8 
and MMP-13 at the specific site of the a  chain resulting in generation o f 3/4 N- 
terminal and 1/4 C-terminal fragments that are denaturated into gelatin at body 
temperature. Gelatin fragments are further degraded by gelatinases MMP-2 and 
MMP-9 but also by MMP-13. Furthermore MMP-13 cleaves type I  collagen in 
non-helical telopeptide. Membrane bound MT1-MMP (MMP-14) can also 
cleave fibrillar collagen and MMP-2 shows weak collagenolytic activity.
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maturation in bone marrow, stored in intracellular granules, and released in 
response to external stimuli (Hasty et al., 1990). It is also expressed by 
chondrocytes, rheumatoid synovial fibroblasts, gingival fibroblasts, bronchial 
epithelial cells and melanoma cells (Cole et al., 1996; Vernooy et al., 2004).
MMP-13 is expressed during fetal bone development, postnatal bone 
remodeling, and gingival wound repair (Ravanti et al., 1999). In addition, MMP- 
13 expression has been associated with pathological conditions such as severe 
chronic inflammation in osteoarthritic cartilage, rheumatoid synovium, and 
chronic wounds, as well as malignant tumor invasion (Airola et al., 1997; Balbin 
et al., 1999; Johansson et al., 1997; Vaalamo et al., 1997).
1.5.2 Gelatinases
MMP-2 (gelatinase A, 72-kDa gelatinase) and MMP-9 (gelatinase B, 92- 
kDa gelatinase) differ from the other MMPs in that they contain three head-to-tail 
repeats homologous to the type II repeat of the collagen-binding domain of 
fibronectin (Collier et al., 1988). These domains are required to bind and cleave 
collagen (Keski-Oja and Todaro, 1980; Keski-Oja and Vaheri, 1982; Murphy et 
al., 1994; Steffensen et al., 1995; Vartio, 1982; Vartio and Vaheri, 1981) and 
elastin (Shipley et al., 1996). The hemopexin domain does not affect MMP-2 
binding to collagen (Allan et al., 1995), but similarly to collagenases, it is critical 
for the initial cleavage of the triple helical type I collagen (Patterson et al., 2001). 
The hinge domain of MMP-9 contains an additional type V collagen-like insert 
(Wilhelm etal., 1989).
A wide range of normal and transformed cells of fibroblastic, endothelial, 
and epithelial origin constitutively express MMP-2 (Collier, 2001; Huhtala et al., 
1991; Salo et al., 1982; Tryggvason et al., 1990; Vartio and Vaheri, 1981). During 
development it is widely expressed by stromal cells (Reponen et al., 1992). 
Expression of MMP-9 is more restricted and is often low in normal tissues, but it 
can be induced when tissue remodeling occurs during development, wound
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healing and cancer invasion. MMP-9 is secreted by alveolar macrophages, 
polym orphonuclear leukocytes, osteoclasts, keratinocytes, and invading 
trophoblasts, and by several transformed cell lines, but not by fibroblastic cells 
(Hibbs, 1992; Reponen et al., 1995; Saarialho-Kere et al., 1993; Vartio et al., 
1983a).
Both gelatinases can degrade a variety of proteins in vitro, but the in vivo 
substrates are largely unknown (Sternlicht and Werb, 2001). Based on their ability 
to degrade type IV collagen and laminin (the main components of BM), the 
correlation between the levels of MMP-2 expression and activity, coupled with 
the invasive potential of certain cancer cells, gelatinases, especially MMP-2, have 
been suggested to degrade BM components in vivo (Tryggvason et al., 1987). 
Both gelatinases can also efficiently degrade partially denatured collagens of all 
types following the initial cleavage by collagenases (Overall et al., 1989). MMP- 
2, but not MMP-9, selectively cleaves the a2-chain of laminin 5 and promotes cell 
migration in a mammary epithelial cell model (Giannelli et al., 1997). MMP-9 has 
been suggested to affect angiogenesis by releasing ECM-bound VEGF (Vu et al.,
1998).
1.5.3 Stromelysins, matrilysins and other MMPs
Stromelysins include stromelysin-1, -2 and -3 (MMP-3, M M P-10, and 
MMP-11, respectively). The domain structures of stromelysins resemble those of 
collagenases. However, they are unable to cleave native fibrillar collagens. 
Stromelysin-3 is inactive against many ECM components; instead it can cleave 
proteinase inhibitors, a2-macroglobulin (a2M ) and a l-P I  (Pei et al., 1994), and 
insulin-like growth factor binding protein (IGF-BP) (Manes et al., 1997). It also 
differs from most secreted MMPs by having recognition sequence for proprotein 
convertases between the pro- and catalytic domains. This would suggest a 
possible mechanism of post-translational regulation in its activity. Some recently 
characterized soluble MMPs including MMP-21 and epilysin (MMP-28) also
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contain insertions with similar basic sequences (Pei, 1999; Velasco et al., 1999).
Matrilysins-1 and -2 (MMP-7 and MMP-26, respectively), macrophage 
metalloelastase (MMP-12), MMP-19 and enamelysin (MMP-20) are other MMPs 
with broad substrate specificities (see Table 1.2).
1.6 Membrane-type matrix metalloproteinases
The existence of membrane-bound MMPs was first suggested by the 
finding that plasma membranes from various tumor cells contained a proMMP-2 
activator sensitive to MMP inhibitors (Brown et al., 1993; Strongin et al., 1993). 
Eventually, Sato et al. (Sato et al., 1994) cloned the cDNA for the first MT-MMP 
(MMP-14), encoding a 63-kDa type I transmembrane protein that could activate 
proMMP-2 and promote cell invasion. To date, additional cDNAs for membrane- 
bound MMPs have been cloned. Their six protein products have been named MT- 
MMP-2, -3, -4, -5, and -6, and Cysteine Array-MMP (MMP-15, -16, -17, -24, -25, 
and -23, respectively) (Zucker et al., 2003).
MT-MMPs have recently gained considerable attention, basically 
because of the marked abnormalities associated with MT1-MMP knockout mice 
in contrast to the more subtle phenotypes of mice deficient in secretory MMPs 
(Holmbeck et al., 1999; Shapiro, 1998; Sounni and Noel, 2005; Zhou et al., 2000). 
MT1-MMP is also more active in ECM degradation and promoting cell 
invasiveness in experimental models than its soluble form or the secretory MMPs, 
highlighting the importance of cell surface localization and cellular regulation of 
these enzymes (Chun et al., 2004; Hiraoka et al., 1998; Holmbeck et al., 1999; 
Hotary et al., 2000; Hotary et al., 2003; Sabeh et al., 2004). For this reason, I will 
now describe the general structural and functional features of MT-MMPs, and I 
will then focus my introduction on MT1-MMP (see section 1.8), not only for its 
biological relevance but also because it is the main topic of my experimental 
work.
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1.6.1 Structure and activation of MT-MMPs
The MT-MMPs contain the protein domains characteristic of MMPs 
including from the N-terminal to the C-terminal extremities; a signal peptide, a 
propeptide, a catalytic domain with the zinc binding site, a hinge region and a C- 
terminal hemopexin domain (Figures 1.5 and 1.6). MMP-23 differs from all 
others, however, by having unique cysteine-rich, proline-rich, and IL-1 type II 
receptor-like domains instead of the C-terminal hemopexin-like domain (Pei, 
1999) It also has an atypical N-terminal prodomain that lacks the conserved 
“cysteine switch” sequence, but contains a potential membrane spanning region. 
This binds proMMP-23 to the cellular membranes as a type II transmembrane 
protein. A single proteolytic cleavage between the pro- and catalytic domains by 
furin both activates the proenzyme and releases the activated soluble enzyme from 
the cell membrane (Pei et al., 2000).
In any case, all MT-MMPs are produced as zymogens containing a 
secretory signal sequence and a propeptide whose proteolytic cleavage is required 
for MMP activation. The prodomain of MT-MMPs contains a conserved motif, 
Tyr42-Gly43-Tyr44-Leu45, that acts as an intramolecular chaperone. It appears 
essential for adequate protease folding and enzymatic activities, including 
proM M P-2 activation, substrate degradation and tissue inhib itor of 
metalloproteinases-2 (TIMP-2) binding (Pavlaki et al., 2002). A basic 
tetrapeptidic sequence A rg l0 8 -A rg l0 9 -L y s ll0 -A rg lll  (RRKR) is inserted 
between the propeptide and the catalytic domain. This furin recognition motif is 
cleaved by proprotein convertases during the trafficking of MT-MMPs from the 
endoplasmic reticulum to the plasma membrane, although the precise localization 
of this event is still unclear (Cao et al., 1998; Kang et al., 2002; Mayer et al., 
2003; Yana and Weiss, 2000). However, the activation of MT-MMPs by a furin- 
independent alternative pathway has been reported in some types of cells (Cao et 
al., 1996; Rozanov et al., 2001; Sato et al., 1996). This alternative activation 
pathway depends on an autoproteolytic activation or on the action of non-furin
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Fig. 1.5. Comparison of the amino acid sequences of human MT-MMPs 
(reproduced from Velasco et al., 2000). The amino acid sequences o f human 
MT-MMPs were extracted from the SwissProt database, and the multiple 
alignment was performed with the PILEUP program o f the GCG package. 
Conserved residues in all human MT-MMPs are shaded. MT6-MMP sequence 
is shown in bold.
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Transmcmbrane MT-MMPs
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peptide ^ | Catalytic domain I Hcmopcxiitc-Iike domain
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Fig. 1.6. The protein structure of MT-MMPs (reproduced from Sounni et 
al., 2005). Human membrane type matrix metalloproteinases (MT-MMPs) 
contain the basic common domains o f almost MMPs: signal, pro-, catalytic, 
and hinge domains. MT1-, MT2-, MT3-, and MT5-MMP belong to the 
transmembrane-anchored type and are characterized by a transmembrane and a 
cytoplasmic domain. MT4-MMP and MT6-MMP are anchored to the plasma 
membrane via glycosylphosphatidylinositol, and belong to the GPI group.
^  Hcmopcxinc-pcptidc^ ^  Catalytic dom- ■like domain
A
Furin-like m o tif
M T4.M M P(M M P-17) and MT6-MMP (MMP.26)
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proprotein convertases, or on other proteases located at the plasma membrane. In 
addition, an extracellular activation of proM Tl-M M P by plasmin has been 
reported (Okumura et al., 1997). This debated aspect will be described in-depth in 
section 1.8.3.2 regarding the activation of MT1-MMP because its characterization 
is one of the main topics of my thesis.
The propeptide is followed by the catalytic domain containing the zinc- 
binding consensus motif HEBXHXBGBXH, where X is a variable residue and B 
is a bulky hydrophobic amino acid. The catalytic domain of MT-MMPs contains a 
characteristic 8-amino acid insertion between strands |3II and p ill named the 
“MT-loop” (English et al., 2001a). The 3D structure of the complex between the 
catalytic domain of MT-MMPs and TIMP-2 shows that the MT-loop generates a 
pocket in the MMP catalytic domain fold that interacts with TIMP-2 (Lang et al., 
2004). Although mutations in or deletions of the MT-loop of MT-MMPs do not 
affect its catalytic activity towards synthetic substrates, it impairs the kinetic of 
proMMP-2 activation (English et al., 2001a), whose mechanism will be described 
in section 1.6.3.1. Consistently, divergences in MT-loop structure between MT- 
MMPs are translated into their ability to activate proMMP-2. For example, MT4- 
MMP and MT6-MMP which lack the MT-loop are either unable to activate or 
inefficient at activating proMMP-2 (English et al., 2001a). Furthermore, human 
MT2-MMP is somewhat defective in cell-mediated activation of proMMP-2, 
whereas mouse MT2-MMP is very efficient in this activity. Indeed, the 
replacement of two residues (Pro 183 and Glul85) in the MT-loop of the human 
enzyme by the corresponding ones (S eri83 and Asp 185) of mouse MT2-MMP 
endowed the human enzyme with efficient activation of proMMP-2 (Miyamori et 
al., 2000).
As is the case for most MMPs, MT-MMPs contain a C-terminal 
hemopexin-like domain that confers some degree of substrate specificity (Overall,
2002). However, MT-MMPs differ from the other MMPs by the presence of a C- 
terminal domain rich in hydrophobic residues that is involved in their association
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with the cell membrane. According to the structure of this C-terminal extension 
(Fig. 1.6), MT-MMPs can be classified into two sub-groups: (1) type I 
transmembrane proteins, including MT1-, MT2-, MT3- and MT5-MMP, 
characterized by a long hydrophobic sequence followed by a short cytoplasmic 
tail and (2) glycosylphosphatidylinositide (GPI)-anchored MT-MMPs (MT4- and 
MT6-MMP) containing a short hydrophobic signal anchoring to GPI; this 
sequence is not followed by a cytoplasmic tail. The cytoplasmic tail of type I 
transmembrane MT-MMPs appears to play an important role in numerous cellular 
events such as cell signaling, sub-cellular localization, MT-MMP trafficking and 
dimerization (Itoh and Seiki, 2005; Itoh et al., 2001; Sounni et al., 2004; Uekita et 
al., 2004; Wang et al., 2004b) (see also section 1.9).
1.6.2 Extracellular matrix substrates of MT-MMPs
The contribution of MT-MMPs to the degradation of a variety of ECM 
components results in the release of sequestered biologically active proteins and 
in the regulation of cell migration, growth, differentiation, and survival by 
controlling cell adhesion and the cytoskeletal organization (Egeblad and Werb, 
2002; Zucker et al., 2003). In addition to these matrix substrates, MT-MMPs are 
also able to cleave other signaling molecules such as cell surface receptors, 
growth factors, growth factor binding proteins, cytokines/chemokines (Table 1.3). 
The importance of such MT-MMP proteolytic events in the regulation of cell 
behavior is described below.
Table 1.3. Extracellular and non-extracellular substrates of MT-MMPs 
(reproduced from Sounni et a l,  2005)
MT-MMPs ECM  substrates Non-ECM  substrates
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M Tl-MMP Gelatin, collagens I, II, III, 
laminin-5, fibronectin, fibrin, 
proteoglycan
SDF1, MCP-3,
proTNFa, IL-8, CTGF, death 
receptor-6, secretory leukocyte 
protease inhibitor, CD44, 
integrin av  subunit, tissue 
Transglutaminase (tTG), 
gClqr, syndecan-1, p glycan, 
low density lipoprotein 
receptor related protein (LRP), 
proMMP-2
MT2-MMP Collagen I, fibronectin, 
gelatin, aggrecan, perlecan, 
laminin-1, tenascin, nidogen
tTG, LRP, proMMP-2
MT3-MMP Collagen II, III, fibronectin, 
laminin-1, vitronectin, 
aggrecan
tTG, CD44, syndecan, LRP, p 
glycan, a2-macroglobulin, a l -  
antiproteinase and proMMP-2
MT4-MMP Fibrinogen, fibrin, gelatin ProTNFa, aggrecanase-1, LRP
MT5-MMP Gelatin, fibronectin, 
chondroitine sulfate, dermatan 
sulfate
ProMMP-2
MT6-MMP Gelatin, fibronectin, 
chondroitine sulfate, dermatan 
sulfate, collagen type IV, 
fibrin, fibrinogen
al-antiproteinase, ProMMP-2
1.6.3 Non extracellular matrix substrates
As introduced above, although MT-MMPs can cleave ECM components, 
they can also cleave several soluble, cell surface and pericellular proteins (Table 
1.3), regulating cell behavior in tumor metastasis and angiogenesis. These 
regulatory mechanisms include (1) alteration of cell-cell interactions, cell-matrix 
interactions, (2) release, activation or inactivation of autocrine, or paracrine 
signaling molecules, (3) shedding or activation of surface receptors and (4) 
activation of intracellular signaling pathways (Fig. 1.7).
For example, cell surface-associated MMP-2, MMP-9 and MMP-13 can 
activate latent transforming growth factor-beta (TGF|3) (Egeblad and Werb, 2002)
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Fig. 1.7. Functions of M T-M MPs in cancer progression associated with 
their catalytic activities (reproduced from Sounni et al., 2005). The
membrane type-matrix metalloproteinases (MT-MMPs) promote cancer 
progression through different mechanisms: (1) by activating soluble proMMPs, 
(2) by shedding transmembrane precursors of growth factors, and growth factor 
binding proteins (GF-BP)), (3) by degrading the extracellular matrix (ECM), 
facilitating cell migration and the release o f growth factors and/or cytokines, 
(4) by interacting and/or activating receptors and cell surface molecules, (5) by 
inducing signal transduction and thereby regulating gene expression, (6) by 
interacting with intracellular molecules such as MTCBP-1. TIMPs and RECK 
inhibit the activity of MT-MMPs. RTK, receptor tyrosin Kinase; CCR2 and 
CXCR4, chemokines receptors for MCP-3 and SDF-1, respectively; ERK, 
extracellular regulated kinase; FAK, focal adhesion kinase; MTCBP-1, MTI-  
MMP cytoplasmic tail binding protein-1; tTG, tissue transglutaminase; GF-BP, 
growth factor binding proteins; RECK, Reversion inducing cystein-rich protein 
with Kasai motifs.
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and M TI-M M P modulates the bioavailability of TGFp through different 
mechanisms by: (1) activating MMP-13 and MMP-2, (2) releasing active TGFp 
from cell surface complexes involving a v p 8  integrin, and (3) releasing a 
membrane-anchored proteoglycan that binds TGFp (Velasco-Loyden et al., 2004).
Recently, the list of non-matrix substrates of MT-MMPs has been 
completed by cytokines and chemokines (Table 1.3). Monocyte chemoattractant 
protein-3 (MCP-3) is inactivated upon cleavage by MMP-2. Inactivated MCP-3 
molecules can also efficiently be generated by a recombinant M TI-MM P and 
other soluble MMPs such as MMP-1, MMP-3 and MMP-13 (McQuibban et al.,
2002). These data provide a new mechanism by which MT-MMPs could control 
inflammatory response in cancer and other diseases.
1.6.3.1 Role of MT-MMPs in activation of proMMPs
MT-MMPs also control the pericellular activation of proMMPs. The 
major physiological activators of proMMP-2 (gelatinase A) are members of the 
MT-MMP sub-group. The activation of proMMP-2 by MTI-MMP involves the 
action of TIMP-2 (Strongin et al., 1995). TIMP-2 belongs to the family of tissue 
inhibitors of metalloproteinases (TIMPs) that will be described in section 1.7.3. 
The currently accepted model involves the stoichiometric binding of TIMP-2 to 
the MTI-MMP catalytic domain on the cell surface, followed by the binding of C- 
terminal hemopexin-like domain of proMMP-2 to the C-terminus of TIMP-2 
(Seiki, 1999; Seiki et al., 2003) (for more details on MTl-MMP-dependent MMP- 
2 activation, see section 1.8.3.4).
MT2-, MT5- and MT6-MMP can also activate proMMP-2, but the 
involvement of TIMP-2 in the activation process is not clear (Morrison et al., 
2001). MMP-2 activation by MTI-MMP through a TIMP-2 independent process 
in endothelial cells can be promoted by av|33 integrin (Brooks et al., 1996) or 
claudin, a tight junction protein (Miyamori et al., 2001). It has recently been
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reported (Zhao et al., 2004) that proMMP-2 activation by MT3-MMP also 
involves formation of a ternary complex on the cell surface. ProMMP-2 can 
assemble trimolecular complexes with the catalytic domain of MT3-MMP and 
TIMP-2 or TIMP-3. Based on affinity chromatography experiments, it appears 
that TIMP-3 binds more efficiently to MT3-MMP than to M TI-M M P and 
enhances the activation of proMMP-2 by MT3-MMP but not by M TI-M M P 
(Zhao et al., 2004). Finally, comparison of the activation of proMMP-2 by cells 
expressing MT1-, MT2- or MT3-MMP, demonstrated that both MT2-MMP and 
MT3-MMP are less efficient than M TI-MM P (Sounni and Noel, 2005). The 
catalytic domain of MT6-MMP can activate proMMP-2 and generates a higher 
ratio of mature/intermediate forms of MMP-2 than MT5-MMP (Nie and Pei,
2003). At variance with the other MT-MMPs, MT4-MMP is an inefficient 
proMMP-2 activator (English et al., 2001a; English et al., 2000).
MTI-MMP also contributes to the activation of procollagenase-3 (MMP- 
13), directly, or indirectly via MMP-2 activation (Knauper et al., 1996). ProMMP- 
13 activation by MTI-MMP does not involve the establishment of a trimolecular 
complex between proMMP-13, MTI-MMP and TIMP-2 (Knauper et al., 2002). 
The role of MT-MMPs in proMMP activation was extended by recent studies 
(Toth et al., 2003) reporting that proMMP-9 activation is initiated by MTI-MMP 
and then mediated by MMP-2 or MMP-3. The activation of proMMP-9 by MT1- 
MMP/MMP-2 axis is regulated by the concentration of TIMP-2 (Toth et al.,
2003).
Altogether, these data demonstrate that MT-MMPs participate in a 
zymogen activation cascade leading to an amplification of proteolysis, in 
proximity to the cell surface. This pericellular activation of MMPs acts in a 
concerted manner with the cascade of protease activation involving the 
plasminogen/plasmin activator system leading also to proMMP activation.
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1.7 Regulation of MMP activity
The proteolytic activity of MMPs is regulated at two main levels: 1) 
transcription and 2) proenzyme activation. Additional mechanisms by which 
MMP activity is fine-tuned involve regulation of mRNA stability, translational 
efficiency, enzyme compartmentalization, secretion, cell-surface recruitment, 
shedding, oligomerization, cellular uptake and internalization, substrate targeting, 
autolysis and finally, enzyme inhibition (Fig. 1.8).
These mechanisms operate coordinately to ensure that MMP expression 
and activity are confined to those sites and conditions in which proteolytic activity 
is necessary. Malignant tumours, however, have developed strategies to 
circumvent these regulatory mechanisms, and to generate the uncontrolled 
proteolytic activity that accompanies cancer development and metastasis (Overall 
and Lopez-Otin, 2002).
1.7.1 Gene expression
Regulatory mechanisms of MMP gene transcription exist for cell-type 
and stimulus specificity (Birkedal-Hansen et al., 1993). Many of the MMPs are 
expressed only in a few cell types or tissues, suggesting the presence of cell or 
tissue-specific promoters, enhancers and/or silencers (Harendza et al., 1995). 
Most MMP genes are not expressed in normal adult tissues or by unstimulated 
cells in vitro, but their expression is markedly induced by growth factors, pro- 
inflammatory cytokines, and phorbol esters (Westermarck and Kahari, 1999). In 
contrast, MT1-MMP is constitutively expressed in vitro by different cell types 
including fibroblasts, endothelial cells, and smooth muscle cells, and its 
expression is only modestly enhanced by the tumor promotor PMA, TN F-a, and 
the lectin concanavalin A (ConA), not affected by TGF-P, and decreased by 
dexamethasone (Lohi and Keski-Oja, 1995). In addition, the mRNAs for all other 
MT-MMPs are detectable by Northern blot analysis in normal human tissues.
49
OOOC CXXXXXDC00003000C
mt-mmp
Koaxxxxjcooxi
MVP rPNA
MMP ge-e
Peguatcry a gras
Po3t-lrarscrp:»ya s'ccssarg
Trarscrpiior | .-gtivatton] 
iTrarspcrt |
Ce i 3-rac«
| ma:_re MMP FVe-pioMMP
Slap leaser] | Trarsation
| Scljpe aclsn |
|--------  AutCiySiS
I  rHiD-.cr
MMF roe; n carcsr
{ I
Ge-etc
inr.atnry
Ce crcv.:h .-rgoge^esis Invasion Apcptoos Jn—ire
rec
Fig. 1.8. Levels of regulation of M MP expression and activity (reproduced 
from Overall and Lopez-Otin, 2002). Diverse regulatory signals, such as 
soluble factors, extracellular-matrix-cell interactions (ECM) or cell-cell 
contacts (cells) interact with specific receptors at the cell surface and initiate a 
cascade o f events that lead to the generation o f functional matrix 
metalloproteinases (MMPs), which are localized to the cell surface (MT- 
MMPs) or secreted to the extracellular medium (proMMP). ProMMPs are 
activated by different events. These active MMPs are involved in a number of 
processes that promote cancer development (red boxes), including promoting 
genetic instability, cell growth, angiogenesis and invasion. They also interfere 
with apoptosis induction and the host antitumour immune response. MMP 
autolysis or inhibitors can interfere with the induction of these cellular effects. 
The levels of MMP regulation that might be therapeutically targeted are shown 
in orange boxes, and include cell responses to regulatory signals, signal 
transduction, transcription induction, post-transcriptional processing, MMP 
activation and transport, and secretion.
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MMP-2 is also constitutively expressed in most fibroblastic cells, and its 
expression is enhanced by TGF-p but not by phorbol esters (Collier et al., 1988). 
Both MT1-MMP and MMP-2 promoters have Spl (transcription factor specificity 
protein 1) binding sites that are important for basal promoter activity.
In endothelial cells cultured in a collagen matrix, enhanced MT1-MMP 
transcription is driven by increased binding of Egr-1 (early growth response 
transcription factor-1) - a zinc finger transcription factor critical for coupling 
extracellular signals to changes in cellular gene expression - to the MT1-MMP 
promoter (Haas et al., 1999). The MT1-MMP promoter features consensus 
binding sites for Spl and Egr-1, whereas the MMP-2 promoter does not contain 
Egr-1 binding sites, thus allowing cells to specifically upregulate MT1-MMP. 
Interestingly, the induction of Egr-1 expression occurs in response to potential 
angiogenesis initiators such as wound formation, mechanical stress, and fluid 
shear stress (Khachigian et al., 1996; Silverman and Collins, 1999). Other details 
about transcriptional regulation of MT1-MMP gene expression will be described 
in section 1.8.3.1.
1.7.2 Zymogen activation
All MMPs are synthesized as latent zymogens containing about 10-kDa 
amino terminal globular prodomain that protrudes into the active site of the 
enzyme and maintains its latency. The propeptide serves to maintain proMMPs in 
an inactive state (Becker et al., 1995; Morgunova et al., 1999). A cysteine-zinc 
bond links the unpaired cysteine residue in the prodomain to the catalytic zinc ion 
preventing the access of a water molecule that is necessary for catalysis (Bode et 
al., 1999b). The sequence surrounding the cysteine in the prodomain, 
(K)PRCGV/NPD(V), and the zinc binding sequence in the catalytic domain, 
HEXGHXXGXXH, are the two best-conserved sequences in MMPs (Bode et al., 
1999a). Activation of the soluble proMMPs can be accomplished in vitro by 
detergents, oxidants, mercurial compounds, sulfhydryl reagents, and acidic pH, all
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of which expose the prodomain cysteine by conformational change, and cause the 
disruption of Cys-Zinc bond, also called “cysteine switch” (Springman et al.,
1990). In addition, cleavage of the prodomain by various serine-, cysteine-, and 
metalloproteinases leads to unfolding and exposure of the remaining portion of 
the propeptide and disruption of the cysteine-zinc bond. The initial cleavages 
usually occur usually in the flexible, exposed a l-a l l  loop and is followed by a 
series of (autocatalytic) cleavages leading to the generation of the mature enzyme.
In most cases the proteolytic activation of proM M P occurs 
extracellularly because several soluble enzymes can activate most secreted MMPs 
(Mignatti and Rifkin, 1993; Mignatti and Rifkin, 2000). For instance, the lack of 
activation of many MMPs (MMP-3, MMP-9, M M P-12, and M M P-13) in 
macrophages of uPA-deficient mice suggests an important role of the cell surface 
plasminogen activator/plasmin system on the activation of some secreted MMPs 
in vivo (Carmeliet et al., 1997).
The characterization of constitutive intracellular activation of 
prostromelysin-3 (MMP-11) by the Golgi-associated endopeptidase furin unveiled 
a novel mechanism for the activation of MMPs (Pei and Weiss, 1995). A basic 
sequence RXRXKR present in the prodomain was found to signal the cleavage as 
shown by site-directed mutagenesis. All MT-MMPs contain similar basic 
recognition sequences (RXK/RR) at the C-terminal end of the prodomain, and 
these MMPs also appear to be activated during transport to the cell surface. This 
aspect will be described in-depth in section 1.8.3.2 regarding the activation of 
MT1-MMP because its characterization is one of the main topics of my thesis.
1.7.3 Metalloproteinase inhibitors
Endogenous inhibitors such as the tissue inhibitors of metalloproteinases 
(TIMPs) and serum a2-macroglobulin (a2M ) can inhibit the activated MMPs in 
vivo. a2M  is an abundant serum inhibitor effective on many types of proteinases
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(Birkedal-Hansen et al., 1989; Sottrup-Jensen et al., 1989). In addition, 
thrombospondins can inhibit MMP-2 and -9 activation and induce their clearance 
through scavenger receptor-mediated endocytosis (Bein and Simons, 2000). New 
insight into the regulation of cell surface proteolysis was provided by the 
characterization of a GPI-anchored membrane glycoprotein, RECK (revision- 
inducing cysteine-rich protein with kazal motifs), which was shown to down 
regulate MT1-MMP, MMP-2 and MMP-9 function and tumor angiogenesis and 
metastasis (Oh et al., 2001; Takahashi et al., 1998).
The TIMPs are considered to be the key local MMP regulators in tissues. 
The TIMP family consists of four human TIMPs, TIMP-1, -2, -3, and -4, which 
share 30-50% sequence identity (Docherty et al., 1985; Greene et al., 1996; 
Silbiger et al., 1994; Stetler-Stevenson et al., 1989). They are composed of N- and 
C-terminal domains both of which are stabilized by three disulfide bonds between 
six conserved cysteine residues (Bode et al., 1999a; Fernandez-Catalan et al., 
1998; Tuuttila et al., 1998). TIMPs also have differential abilities to form 
complexes with progelatinases through interactions between their C-terminal 
domains and the C-terminal hemopexin domains of progelatinases (Henriet et al., 
1999).
All TIMPs can inhibit most MMPs by tight non-covalent binding to their 
active site in a 1:1 stoichiometric ratio (Gomez et al., 1997; Howard and Banda,
1991). MT-MMPs are an exception as TIMP-1 is a poor inhibitor of MT1-, MT2-, 
MT3-, and MT-5-MMP (Shimada et al., 1999). In contrast, MT4- and MT6-MMP 
are effectively inhibited by TIMP-1 (English et al., 2001b; Kolkenbrock et al.,
1999).
TIMPs have been thought to be mainly regulated at the level of gene 
expression. Various cultured cells constitutively express TIMP-2, whereas several 
growth factors/cytokines and chemicals upregulate the expression of TIMP-1 
(Gomez et al., 1997). TIMP-3 expression is induced in cultured cells by 
stimulation with serum, EGF, and TGF-p. Unlike other TIMPs, TIMP-3 is
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insoluble and binds to ECM both in vitro and in vivo. TIMPs are generally very 
stable, although they may be inactivated by limited proteolysis by serine 
proteinases such as trypsin and elastase (Itoh and Nagase, 1995; Okada et al., 
1988). Maquoi et al. demonstrated that internalization through an MT1-MMP 
dependent mechanism and subsequent degradation downregulate TIMP-2 in 
tumor cell cultures (Maquoi et al., 2000).
Due to their ability to inhibit proteolytic degradation required for cell 
invasion, TIMPs have been indicated as negative regulators of processes like 
angiogenesis and cancer invasion (Gomez et al., 1997). Indeed, TIMP-1 and 
TIMP-2 inhibit endothelial and vascular smooth muscle cell migration (Cheng et 
al., 1998; Fernandez et al., 1999), while TIMP-2 reduces melanoma cell invasion, 
tumor growth and angiogenesis in vivo (Valente et al., 1998). Adenovirus- 
mediated gene delivery of TIMP-3 inhibits melanoma cell invasion (Ahonen et 
al., 1998) and overexpression of TIMP-4 inhibits invasion of breast cancer cells in 
vitro and tumor growth and metastasis in vivo (Wang et al., 1997). On the other 
hand, TIMP-1, -2, and -3 stimulate the growth of several cell types (Henriet et al.,
1999). TIMP-2 can suppress EGF-mediated mitogenic signaling (Hoegy et al., 
2001), and TIMP-3 can induce apoptosis of normal and malignant cells (Ahonen 
et al., 1998; Baker et al., 1998). Recent data also suggest the involvement of 
TIMPs in other invasive processes such as implantation (Henriet et al., 1999).
1.8 MT1-MMP
1.8.1 Background
MT1-MMP was initially observed as a membrane-associated MMP-2 
activator (Overall et al., 1989). Subsequently, in 1994, Sato et al. discovered the 
first membrane-type MMP, now known as MT1-MMP, and identified it as a cell- 
surface proMMP-2 activator (Sato et al., 1994). Since its discovery, MT1-MMP
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has been extensively investigated and is now one of the best characterized MMPs. 
MT1-MMP has been implicated in various physiological and pathological 
processes such as wound healing, bone development, angiogenesis, inflammation, 
rheumatoid arthritis, atherosclerosis, and cancer invasion and metastasis (Itoh and 
Seiki, 2005).
Ablation of the gene encoding MT1-MMP causes craniofacial 
dysmorphism, arthritis, osteopenia, dwarfism and fibrosis of soft tissues in mice 
(Holmbeck et al., 1999). This is the most significant phenotype among the MMP 
knockout mice, and suggests that the activity of MT1-MMP, differently from 
other MMPs, cannot be substituted by any of the other members of the family. 
MT1-MMP is highly expressed in different cancers, and its overexpression 
promotes migration, invasion and metastasis of cancer cells in vitro as well as in 
vivo (Seiki, 2003). The enzyme has also been shown to be essential for 
angiogenesis (Hiraoka et al., 1998; Zhou et al., 2000). Furthermore, Hotary et al. 
recently reported that expression of MT1-MMP is crucial for cancer-cell growth 
in a 3D collagen-based matrix, suggesting that MT1-MMP has important roles not 
only in cancer invasion but in tumor progression overall (Hotary et al., 2003).
M T1-M M P degrades various ex trace llu la r m atrix  (ECM ) 
macromolecules including collagen I, II and III, fibronectin, laminin 1 and 5, 
fibrin, and aggrecan (Itoh and Seiki, 2004). On the cell surface, MT1-MMP also 
activates other members of the MMP family, for example, proMMP-2 and 
proMMP-13, creating a wider proteolytic repertoire on the cell surface. MT1- 
MMP cleaves CD44, which promotes cell migration; it processes a v  integrin to 
the mature form; it degrades transglutaminase, modifying the attachment of the 
cells to fibronectin (for a review, Itoh and Seiki, 2005); and also cleaves low- 
density lipoprotein receptor-related protein (LRP), which is a scavenger receptor 
for proteinases in the extracellular milieu (Rozanov et al., 2004b). In addition, 
cleavage of the laminin 5y chain by MT1-MMP also stimulates epithelial-cell 
motility (Koshikawa et al., 2000). Because MT1-MMP acts on the cell surface, it
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modifies the immediate environment of the cell resulting in alteration of signaling 
from the ECM or adhesion molecules, thereby influencing cellular functions. For 
MT1-MMP to undertake these activities effectively, negative and positive 
regulation of the enzyme at different levels is essential.
Considering the biological relevance of this enzyme and the fact that it is 
the main topic of my thesis, the remaining part of the introduction will describe 
how MT1-MMP affects cellular function by changing the microenvironment, and 
the many ways in which cells can regulate the activity of this enzyme.
1.8.2 Modulation of cell functions by M T1 -MMP
Expression of MT1-MMP on the cell surface, together with the MMPs it 
activates, creates wide proteolytic repertoire in the pericellular space, and allows 
for efficient proteolytic changes to the cellular microenvironment which can result 
in modification of different cellular functions (Fig. 1.9).
1.8.2.1 MT1-MMP promotes cell invasion
When a cell migrates in tissue, the ECM is a physical barrier and needs 
to be degraded to clear a path (Murphy and Gavrilovic, 1999). MMP-2 degrades 
type IV collagen, a major component of the basement membrane. As cancer cells 
need to traverse the basement membrane to achieve invasion and metastasis, the 
activation of proMMP-2 by MT1-MMP is considered to be a critical step (Seiki, 
2003; Stetler-Stevenson et al., 1993). Overexpression of MT1-MMP enhances 
cellular invasiveness in in vitro invasion experiments with M atrigel, a 
reconstituted basement membrane (Sato et al., 1994) and in an in vivo lung 
metastasis assay, which requires degradation of real basement membrane 
(Tsunezuka et al., 1996). Furthermore, MT1-MMP gene silencing using double
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Fig. 1.9. Biological functions of MT1-M M P which promote cell m igration 
and invasion (reproduced from Itoh and Seiki, 2005). MT1-MMP sheds 
CD44 and syndecan-1, degrades collagens and other matrix components, 
releases EGF-like repeats from laminin 5, activates proMMP-2 and proMMP- 
13, upregulates ERK, and upregulates VEGF-A expression through Src. All o f 
these activities result in increased cell migration and invasion in tissue.
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stranded RNA interference in cancer cells also showed that downregulation of 
MT1-MMP only is sufficient to inhibit Matrigel invasion of cancer cells 
significantly (Ueda et al., 2003). These findings strongly suggest that MT1-MMP 
is indeed a critical part of the invasion machinery.
1.8.2.2 MT1-MMP is a critical collagen environment modulator
An important function of MT1-MMP is its collagen degrading activity. 
All collagenolytic MMPs cleave interstitial collagen at a specific site, 3/4 away 
from the N-terminus (see Fig. 1.4), which then initiates denaturation of triple 
helical collagen into gelatin, rendering it susceptible to many different proteinases 
(Visse and Nagase, 2003). Among the collagenases, MT1-MMP is unique in that 
it is a membrane-tethered collagenase (Holmbeck et al., 2004). The importance of 
MT1-MMP as a collagenase is particularly highlighted by the phenotype of MT1- 
MMP gene knockout (KO) mice (Holmbeck et al., 1999; Zhou et al., 2000). The 
neonatal KO mice are indistinguishable from heterozygous and wild-type 
littermates, but at 5 days of age growth impairment becomes apparent (Holmbeck 
et al., 1999; Zhou et al., 2000). KO mice develop severe fibrosis in periskeletal 
soft tissue, and show delayed ossification of bone, and die around 7-12 weeks of 
age (Holmbeck et al., 1999; Zhou et al., 2000). Fibroblasts derived from KO mice 
lack the ability to degrade type I collagen (Holmbeck et al., 1999).
Detailed analyses suggest that the bone phenotype of the KO mice may 
in part result from the lack of cellular collagen degradation by osteocytes 
(Holmbeck et al., 2005). This suggests that osteocytes were not able to create the 
right ECM environment for osteocytogenesis. No other MMP gene KO mice have 
shown such drastic phenotypes and many events including long bone growth, soft 
tissue organization, molar root formation and eruption, and cartilage remodeling 
in the skull are found to be MTl-MMP-dependent (Holmbeck et al., 2004). These 
findings strongly suggest that MT1-MMP is an essential cellular collagenase 
important for organizing the ECM microenvironment, which cannot be substituted
58
for by any other MMP during development.
MT1-MMP is also an important collagenase during migration of cells in 
a collagen matrix; only MT1-MMP can promote cellular invasiveness into 
collagen I matrix in epithelial cells and fibroblasts (Hotary et al., 2000; Sabeh et 
al., 2004). Other soluble collagenase MMPs, such as MMP-1, MMP-2, MMP-8, 
and MMP-13, fail to promote invasion even though they are secreted as an active 
form under the experimental conditions used (Hotary et al., 2000; Sabeh et al., 
2004). For MT1-MMP to promote collagen invasion, the enzyme needs to be 
membrane-bound since a soluble form of MT1-MMP lacking the transmembrane 
and cytoplasmic domains was not able to do so (Hotary et al., 2000; Sabeh et al., 
2004). Thus, MT1-MMP as a membrane-tethered collagenase plays a unique role.
Interestingly, pericellular collagen degradation is essential not only for 
invasion, but also for tumor cells to grow within a collagen-based 3D matrix 
(Hotary et al., 2003). Again, MT1-MMP was found to play a critical role. The 
effect of MT1-MMP is specific to 3D cultures, suggesting that it is acting 
although pericellular degradation of collagen matrix. Soluble collagenase MMPs 
(MMP-1, MMP-2, and MMP-13) cannot substitute for MT1-MMP, and without 
MT1-MMP tumor cells cannot proliferate (Hotary et al., 2003). Though the role 
of MT1-MMP in metastasis was originally ascribed to the cancer cell invasion 
step, these findings suggest that MT1-MMP may also play a role in promoting 
tumor growth.
1.8.2.3 MT1-MMP stimulates cell motility
Initially, the enhanced invasiveness caused by MT1-MMP expression 
was thought to be due to enhanced pericellular ECM degradation. It has now 
become evident that path clearance is not the only mechanism. It was found that 
shedding of CD44from the cell surface by MT1-MMP enhances cell migration on 
a hyaluronan-based 2D matrix (Kajita et al., 2001). CD44 is a widely expressed 
major hyaluronan receptor, which interacts with the cytoskeleton though its
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cytoplasmic domain. The exact mechanism behind the MT1-MMP/CD44- 
mediated promotion of cell migration is not clear. MT1-MMP may regulate the 
adhesion properties of lamellipodia through CD44 shedding or it may modulate 
signals mediated by CD44. A similar observation was made with syndecan-1 
(Endo et al., 2003). MT1-MMP causes release of syndecan-1 and this shedding is 
required for efficient cell migration on collagen. Again the underlying mechanism 
is not clear. Syndecan-1 is known to associate with, and stabilize, av|33 integrin, 
promoting cell spreading (Beauvais et al., 2004). It is possible that shedding of 
syndecan-1 associated with avp3 affects integrin signaling. Expression of MT1- 
MMP is reported to activate extracellular signal-regulated protein kinase (ERK) 
and ERK activation is shown to be essential for M Tl-M M P-dependent cell 
migration (Gingras et al., 2001; Takino et al., 2004). It is not clear how MT1- 
MMP activates ERK, but this may be a part of the mechanism(s) of CD44- 
mediated cell migration. Elucidating this mechanism may be one of the keys to 
understanding how MT1-MMP promotes cell migration (see Chapter 5).
Another mechanism for MTl-MMP-mediated stimulation of cell motility 
is through the cleavage of laminin 5 (Koshikawa et al., 2005), a major component 
of basement membrane. Indeed, MT1-MMP cleaves the y2 chain of laminin 5, 
releasing EGF-like domains, which bind the EGF receptor and stimulate epithelial 
cell motility (Schenk and Quaranta, 2003). Cleavage of the y2 chain of laminin 5 
by MT1-MMP may be tissue-specific as in keratinocytes astacin-like 
metalloproteinases, bone morphogenic protein-1 (BMP-1), and its variant forms 
(tolloid metalloproteinases), but not MT1-MMP, are reportedly responsible for y2 
chain cleavage (Veitch et al., 2003). However, it is not clear if this cleavage of 
laminin y2 chain by BMP-1 affects keratinocyte migration. It has also been shown 
that the p3 chain of human laminin 5 is cleaved by MT1-MMP (Udayakumar et 
al., 2003). Interestingly, the cleavage product is shown to stimulate prostate 
cancer cell motility (Udayakumar et al., 2003), but the mechanism remains to be
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determined.
1.8.2.4 MT1-MMP promotes angiogenesis
Angiogenesis is a formation of new vessels from existing vessel and 
provides a mechanism to establish a blood supply. It is fundamental for wound 
healing, tumor growth, and progression of rheumatoid arthritis (Sivakumar et al., 
2004). Angiogenesis itself is a process of cellular invasion by endothelial cells: 
they need to detach from neighboring cells, invade into stromal tissue, proliferate, 
and generate a tube structure. During this process, endothelial cells need to 
degrade basal lamina, fibrin, and collagen enriched stromal tissue. Previous 
reports have shown that MMP-2 (Brooks et al., 1998), MMP-9 (Bergers et al., 
2000), and their cognate cell surface receptors such as avp3 integrin (Brooks et 
al., 1998; Silletti et al., 2001) and CD44 (Yu and Stamenkovic, 1999) play a 
critical role in this process, but Chun et al. recently reported that although 
plasmin, MMP-2, MMP-9, a v p 3  integrin, and CD44 are not essential for 
angiogenesis, MT1-MMP is (Chun et al., 2004). Tissues from mice lacking the 
former genes generated normal neovessels in type I collagen in an ex vivo model, 
but MTl-MMP-less tissue failed to support angiogenesis (Chun et al., 2004). This 
observation is specific for collagen matrix; in fact, in a fibrin matrix, MT1-MMP 
KO mice tissue supported normal neovessel formation. The fact that neovessel 
formation in fibrin gel is inhibited by TIMP-2 but not by TIMP-1, and the 
observation that MT2-MMP and MT3-MMP gene expression was upregulated 
during tube formation by human umbilical vein endothelial cells in fibrin gels 
(Lafleur et al., 2002) suggests that these MT-MMPs may compensate for MT1- 
MMP. MT1-MMP also promotes angiogenesis by means other than stimulation of 
endothelial cell invasion. Expression of MT1-MMP in tumors stimulates 
angiogenesis in vivo by stimulating VEGF synthesis by the tumor cells 
(Deryugina et al., 2002; Sounni et al., 2002). MT1-MMP specifically upregulates 
VEGF-A gene expression, and this is mediated by src tyrosine kinase (Sounni et
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al., 2004). This event requires proteolytic activity of MT1-MMP and is dependent 
on the cytoplasmic domain (Sounni et al., 2004). The mechanism behind this is 
not clear, but MT1-MMP activity on the cell surface presumably modifies the 
immediate microenvironment, which triggers a cell-signaling pathway to produce 
VEGF-A.
Taken together, M T1-M M P is an im portan t perice llu la r 
microenvironment modifier which affects cell functions and promotes invasion in 
tissue.
1.8.3 Regulation of MT1-MMP
1.8.3.1 Transcriptional regulation of MT1-MMP gene expression
As already mentioned in section 1.7.1, MT1-MMP gene expression can 
be regulated by cytoskeleton-ECM interactions. It is induced in fibroblasts and 
endothelial cells by culture in three dimensional collagen matrixes, by mechanical 
stretching, and by treatment of the cells with the cytoskeleton disrupting agent 
cytochalasin D (reviewed in Overall and Lopez-Otin, 2002). Therefore, signaling 
pathways initiated through collagen binding |31 integrins may regulate MT1-MMP 
expression (Haas and Madri, 1999). Interestingly, the induction of MT1-MMP 
occurs when the cells are cultured on or within a type I collagen gel, but does not 
occur when cells are grown on a thin coating of type I collagen (Azzam and 
Thompson, 1992; Haas et al., 1998; Tomasek et al., 1997). Recently, it was also 
demonstrated that collagen matrix provides cells with various signals for growth, 
survival, differentiation, migration and so on. Extra-cellular signal-regulated 
kinase (ERK) is activated in cells cultured either with a type I collagen matrix or 
on a collagen sheet, through interaction with integrins. ERK activated by collagen 
culture of cells in turn stimulates MT1-MMP expression (Takino et al., 2004). 
Activation of ERK is not maintained in the presence of MMP inhibitors, however.
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Thus, MT1-MMP functions in a positive feedback loop to induce sustained ERK 
activation and subsequent MT1-MMP accumulation, which collectively promotes 
cell migration on collagen (Sato et al., 2005).
MT1-MMP expression levels are also higher in fibroblasts cultured on a 
floating or stress-relaxed collagen lattice compared with the expression levels in 
actin stress-fiber containing fibroblasts cultured in stabilized lattices (Tomasek et 
al., 1997). Therefore, the induction of MT1-MMP expression could involve, in 
addition to ligand-specific integrin interactions, alterations in mechanical force 
and in the assembly of the actin cytoskeleton.
Cytokines also appear to regulate MT1-MMP expression during 
inflammation. Although TN F-a alone has little effect on MT1-MMP gene 
expression in cultured fibroblasts (Han et al., 2001), activation of NF-kB 
signaling synergistically by TNF-aand type I collagen induces MT1-MMP 
expression in skin fibroblasts (Han et al., 2001). TNF-a, IL -la , and IL-1 (3 also up 
regulate MT1-MMP gene expression in vascular endothelial cells (Rajavashisth et 
al., 1999). In human monocytes MT1-MMP expression is induced by 
lipopolysaccharide through the prostaglandin-cAM P dependent pathway 
(Shankavaram et al., 2001).
1.8.3.2 MT1-MMP modular domain structure and its proteolytic processing
MT1-MMP is produced as a 63 kDa protein (also referred to as proM Tl- 
MMP) and shares a common domain structure with other MMP family members, 
including a signal peptide (M1-S33), a propeptide domain (P34-R111), a catalytic 
domain (Y112-G285), a hinge region (E286-I318), a hemopexin domain (C319- 
C508), a linker region (P509-S538), a transmembrane domain (A539-F562), and a 
cytoplasmic tail (R563-V583) (Fig. 1.10). Three peculiar insertions, not found in 
most secreted MMPs, may determine the many distinct features of MT1-MMP:
63
NII2
Signal Propeptide Catalytic domain Hinge Hemopexin-like domain Linker TM CT 
1 34 112 286 319 509 539 563
M S P I Y
[3i b  n -COOH
GE IC CP S A
RRKR
108 ^  111
furin cleavage site RRHGTPPRRLLY CQRSLLDKV
563 ^  583
p2 binding site
Fig. 1.10. MT1-MMP modular domain structure. MT1-MMP is produced as 
a 63 kDa protein and shares a common domain structure with other MMP 
family members, including a signal peptide, a propeptide domain, a catalytic 
domain, a hinge region, a hemopexin-like domain, a linker region, a 
transmembrane domain (TM) and a cytoplasmic tail (CT).
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1) an 11-aa insertion between the propeptide and the catalytic domain that 
contains an RRKR sequence, a recognition motif for cleavage by subtilisin-like 
Golgi associated proteinases (present also in MMP-11, MMP-23 and MMP-28);
2) an 8-aa insertion in the N-terminal part of the catalytic domain (MT-loop); and
3) a C-terminal insertion containing a stretch of 24-aa hydrophobic sequence (a 
transmembrane domain) followed by a 20-aa cytoplasmic domain. The crystal 
structure of MT1-MMP catalytic domain in complex with TIMP-2 has been 
characterized (Fernandez-Catalan et al., 1998): it consists of a five-stranded |3 
sheet and three a  helixes characteristic for the MMP fold. The structure differs 
from a classical MMP fold mostly by the presence of two large insertions distals 
to the active site cleft: the long flexible loop between pil and (3III strands known 
as the “MT-MMP loop” and the elongated loop between p v  strand and aB  helix.
As mentioned, the 63 kDa proM Tl-MM P contains a basic recognition 
sequence (RRKR) at the C-terminal end of the prodomain that appears to be 
processed during its transport to the cell surface to produce a 60 kDa MT1-MMP 
form. It has been shown that co-expressed furin, a subtilisin-like proteinase, 
activates a truncated MT1-MMP mutant lacking the transmembrane and 
cytoplasmic domains; furthermore, an irreversible inhibitor of furin, the 
Pittsburgh mutant of a  1-antitrypsin, prevents MT1-MMP activation (Pei and 
Weiss, 1996; Sato et al., 1996). The N-terminus of the furin-activated MT1-MMP 
mutant is identical to the endogenous MT1-MMP purified from HT-1080 
fibrosarcoma cells (Strongin et al., 1995). In addition, treatment of human 
fibroblasts, fibrosarcoma cells as well as several melanoma cells with the 
synthetic furin inhibitor Dec-RVKR-CH2C1 inhibits full-length MT1-MMP 
processing and MMP-2 activation (Kurschat et al., 1999; Maquoi et al., 1998; 
Sato et al., 1999). This evidence would support the idea that furin is the most 
likely candidate for MT1-MMP activation.
Yana and Weiss (Yana and Weiss, 2000), on the other hand, described 
furin-independent pathways for full-length MT1-MMP processing that are
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affected by the membrane tethering of the enzyme. These alternative pathways 
were described by using cell types expressing different furin-like proprotein 
convertases.
Conversely, Cao and Zucker (Cao et al., 1998; Cao et al., 2000; Cao et 
al., 1996) have questioned the requirement for the proteolytic removal of the 
prodomain, suggesting that the prodomain is required for binding of TIMP-2 to 
the catalytic domain as well as for the catalytic activity of MT1-MMP (Cao et al.,
2000). A possible explanation for this requirement for the prodomain may be 
related to a chaperone-like function essential for folding and trafficking of the 
enzyme (Cao et al., 2000). This function is dependent on the conserved Y42GYL45 
sequence within the propeptide domain (Pavlaki et al., 2002). The degree of 
catalytic MMP activity obtained by conformational changes without removal of 
the prodomain is currently unclear (Bannikov et al., 2002).
The role of furin in MT1-MMP activation as well as the role of the MT1- 
MMP prodomain in MT1-MMP catalytic activity are still completely debated and 
for this reason I decided to investigate these issues in my experimental work (see 
Chapter 3).
It has been also shown that its 60 kDa active form undergoes further 
processing to a 44-45 kDa species by MMP-2 or MT1-MMP itself (Lehti et al., 
1998; Stanton et al., 1998; Toth et al., 2002). This step inactives MT1-MMP by 
removal of its catalytic domain, and is a downregulatory mechanism. The 
proteolytic processing of MT1-MMP may be an indication of how active the 
enzyme is on the cell surface. A high level of 45 kDa form coincides with high 
proMMP-2 activation whereas no proMMP-2 activation appears to occur when 
the 45 kDa form is not detected (Lehti et al., 1998; Stanton et al., 1998). Thus, 
MT1-MMP can either be functionally active, undergoing further processing, or 
functionally inactive, remaining as an intact mature form. This suggests that there 
may be a step which regulates its functional activity after expression of the mature 
enzyme on the cell surface.
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In some cells, the whole ectodomain of MT1-MMP was shown to be 
shed (Harayama et al., 1999; Toth et al., 2002; Toth et al., 2004). Cleavage occurs 
at the VaI524-IIe bond in the linker-2 region and releases functional MT1-MMP 
from the cell surface (Toth et al., 2004). Although shed MT1-MMP may act as a 
soluble proteinase in the extracellular milieu, the biological activity of MT1-MMP 
on cell function would effectively be lost since the enzyme needs to be 
membrane-tethered to exert these effects (Cao et al., 1995; Hotary et al., 2000; 
Sabeh et al., 2004). Thus, this can be another aspect of the downregulatory 
mechanism, although it is not clear how frequently and widely this shedding event 
actually occurs.
1.8.3.3 Inhibition of MT1-MMP activity
On the cell surface, active MT1-MMP is one of the main factors that 
influence the cellular microenvironment; its inhibition is thus one of the critical 
steps to regulate its activity (Fig. 1.11).
MT1-MMP is inhibited by endogenous inhibitors TIMP-2, -3, and -4, but 
not by TIMP-1 (Bigg et al., 2001; Will et al., 1996). This TIMP-1 insensitive 
nature is common to all transmembrane type MT-MMPs (e.g., MT2-, MT3-, and 
MT5-MMPs) and allows them to work under conditions where high levels of 
TIMP-1 are present. Another inhibitor for MT1-MMP is RECK (reversion- 
inducing-cysteine rich protein with Kazal motifs), a GPI-anchored glycoprotein 
(Oh et al., 2001). RECK was originally discovered as a tumor invasion suppressor 
gene with dual functionality: suppressing MMP-9 expression and inhibiting its 
enzyme activity (Takahashi et al., 1998). Later, it was also found to inhibit the 
proteolytic activity of MT1-MMP and MMP-2 (Oh et al., 2001). Mice with a 
disrupted RECK gene do not survive and show defects in collagen fibrils, the 
basal lamina, and vascular development, a phenotype that may be the result of 
excess MMP activities. Interestingly, this phenotype was partially suppressed by 
an MMP-2 null mutation (Oh et al., 2001).
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Fig. 1.11. Cellular regulation of MT1-MMP (reproduced from Itoh and 
Seiki, 2005). MT1-MMP is regulated in a number o f ways including: 
transcription, trafficking to cell surface, homophilic complex formation, 
association with CD44 followed by localization to migration front, 
autodegradation, and inhibition by inhibitors such as TIMPs, N-Tes, and 
RECK. The enzyme is also internalized by caveolae-dependent and clathrin- 
dependent pathways. The internalized enzyme can be recycled back to the cell 
surface or degraded in CD63-positive lysosomes. MT1-MMP at the migration 
front can colocalize with 1 integrin, and MTCBP-1 can bind to the cytoplasmic 
domain of MT1-MMP, suppressing its pro migratory effects.
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Part of the phenotype could be due to excess MT1-MMP or MMP-9, but RECK 
may also have other important biological roles besides MMP inhibition. 
Chondroitin/heparan sulfate proteoglycans, Testican 1 and 3 and a splicing variant 
of Testican 3, N-Tes, have also been shown to inhibit MT1-MMP (Nakada et al.,
2001), although the mechanisms of inhibition are not known.
1.8.3.4 Regulation of MMP-2 activation by MT1-MMP
Since proMMP-2 activation is an important step for cancer cells to 
invade into basal lamina, the mechanism of activation has thus been extensively 
studied. This process is not based on a simple interaction of proMMP-2 and MT1- 
MMP but directly involves, as a third player, its endogenous inhibitor TIMP-2 
(Strongin et al., 1995). The catalytic domain of MT1-MMP expressed on the cell 
surface forms a complex with the N-terminal inhibitory domain of TIMP-2 to 
form an enzyme-inhibitor complex (Fig. 1.12).
The exposed C-terminal domain of TIMP-2 has a high affinity for the 
hemopexin domain of proMMP-2, leading to the formation of an MT1- 
MMP/TIMP-2/proMMP-2 ternary complex (Strongin et al., 1995). Formation of 
this complex is absolutely essential and proMMP-2 activation can not occur 
without TIMP-2 (Butler et al., 1998; Kinoshita et al., 1998; Wang and Keiser, 
2000). Since MT1-MMP in this complex is inhibited by TIMP-2, another MT1- 
MMP free from TIMP-2 is required to carry out the activation of proMMP-2. To 
promote molecular interaction between a free MT1-MMP molecule and the 
ternary complex of MTl-MMP/TIMP-2/proMMP-2, MT1-MMP forms a homo­
o lig o m er com plex  th ro u g h  its  hem opex in  do m ain s  an d /o r 
transmembrane/cytoplasmic domains (Itoh et al., 2001; Lehti et al., 2002). Within 
this complex, one MT1-MMP acts as a receptor and the other as an activator, 
forming a proMMP-2 activation complex. Formation of this homo-oligomer 
complex is important in the activation process on the cell surface: in fact, when a 
catalytic domain deletion mutant of MT1-MMP is overexpressed,
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Fig. 1.12. C urren t model of proM M P-2 activation by M T1-M M P 
(reproduced from Itoh and Seiki, 2004). (a) In the current model, MT1- 
MMP (blue) forms a homodimer complex through the hemopexin (Hpx) 
domains (Step 1). One of the enzymes binds its endogenous inhibitor -  tissue 
inhibitor o f metalloproteinase 2 (TIMP-2; purple) -  through the catalytic site o f 
the enzyme and the inhibitory site of TIMP-2 (Step 2). The Hpx domain of 
proMMP-2 (red) has an affinity for the exposed C-terminal domain of TIMP-2 
in the complex, resulting in formation o f a (MTl-MMP)2-TIMP-2-proMMP-2 
complex, which places proMMP-2 in an optimal position for activation by 
TIMP-2-Ifee MT1-MMP in the complex (Steps 3 and 4). MT1-MMP is O- 
glycosylated at linker-1 region. When the enzyme forms a homodimer complex 
(Step 1), the sugar moiety might sterically enable one of the catalytic domains 
o f MT1-MMP to be accessible for TIMP-2 binding (Step 2). It is also possible 
that the sugar inhibits the interaction of a molecule, which inhibits the binding 
of the enzyme to TIMP-2. This permits further interaction o f proMMP-2 with 
the TIMP-2 (Step 3) and subsequent activation of proMMP-2 (Step 4). The 
proteolytic action of MT1-MMP on proMMP-2 is represented by a red 
lightening bolt, (b) Glycosylation-defective mutant MT1-MMP enzymes form 
homophilic complexes (Stepl), but the steric arrangement o f catalytic domains 
does not allow TIMP-2 to bind (Step 2). Alternatively, unglycosylated MT1- 
MMP might interact with a molecule that sterically inhibits TIMP-2 binding to 
the enzyme. As a result, the mutant enzyme cannot activate proMMP-2.
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proMMP-2 activation is effectively inhibited (Itoh et al., 2001). Also, replacement 
of the hemopexin domain with one derived from another MMP, such as MT4- 
MMP (Itoh et al., 2001) or MMP-2 (Cao et al., 2004) significantly inhibits 
activation, presumably because it blocks formation of the homo-oligomer 
complex.
The trimolecular complex facilitates the first cleavage of proMMP-2 
prodomain by a neighboring TIMP-2-free active MT1-MMP, thereby generating a 
64 kDa intermediate MMP-2 form. Full activation of the intermediate MMP-2 
species is achieved by an intermolecular autocatalytic process (Atkinson et al., 
1995; Murphy et al., 1999) or by the action of the plaminogen/plasmin system 
(Baramova et al., 1997; Sounni et al., 2002). This activation is completely 
inhibited at high concentrations of TIMP-2, TIMP-3, TIMP-4, but not TIMP-1 
(Butler et al., 1999; Lafleur et al., 2001). Therefore, proMMP-2 activation occurs 
in a TIMP-2-dependent two-step cleavage mechanism. TIMP-2 can be substituted 
by TIMP-3 in this process, but not by TIMP-1 (Lafleur et al., 2001). TIMP-4, 
however, which is considered a better MT1-MMP inhibitor, is not able to 
substitute for TIMP-2 in proMMP-2 activation (Toth et al., 2000). Whereas 
TIMP-2 acts as a positive regulator of MT1-MMP activity at low concentrations, 
it blocks proMMP-2 activation at higher concentrations (Hernandez-Barrantes et 
al., 2000; Murphy et al., 2003; Worley et al., 2003).
The formation of this M Tl-M M P/TIM P-2/proM M P-2 trimolecular 
complex is post-translationally regulated by the O-glycosylation pattern of MT1- 
MMP and is abolished in cells transfected with MT1-MMP mutants and/or treated 
with inhibitors of O-glycolysation; the O-glycosylation of MT1-MMP is 
associated with the recruitment of TIMP-2 to the cell surface (Wu et al., 2004) 
(for more details, see also Fig. 1.12).
Interestingly, homo-oligomer complex formation can be also upregulated 
by the expression of a constitutively active form of Racl, a small GTPase which 
generates extensive lamellipodia (Itoh et al., 2001). Under these conditions, MT1-
71
MMP exclusively localizes at the lamellipodia edge, and this is accompanied by 
enhanced proMMP-2 activation (Itoh et al., 2001).
This suggests that homo-oligomer complex formation is a regulated 
process and may be one of the mechanisms that determines the functional activity 
of M TI-M M P. In cell-free systems, proMMP-2 can be activated by the 
recombinant catalytic domain of MTI-MMP (Will et al., 1996), a domain which 
does not form a homo-oligomer complex. It is plausible that homo-oligomer 
complex formation is needed to facilitate the activation process on the cell 
surface, and the ancillary domains, including hemopexin, transmembrane, and 
cytoplasmic domains, play a role in this event. It is also possible that other 
proteins, which interact with MTI-MMP mediate clustering of the enzyme, as 
suggested by a report showing that a hemopexin domain-deleted mutant of M TI- 
MMP activates proMMP-2 (Wang et al., 2004a). This may be attributed to 
transmembrane/cytoplasmic domain-mediated homo-oligomer complex formation 
(Lehti et al., 2002). It may be important to evaluate the contribution of each 
domain to homo-oligomer formation for proMMP-2 activation.
1.8.3.5 Cell surface localization of MTI-MMP
When cells migrate in tissue, degradation of ECM barrier is essential, but 
only in the direction of migration, because ECM is also important for mechanical 
support. To achieve such focal degradation, cells localize their M TI-M M P at 
lamellipodia, the migration front of the cells (Itoh et al., 2001; Mori et al., 2002; 
Sato et al., 1997). This localization is achieved by interaction of M TI-MM P with 
CD44 through the hemopexin domain of the enzyme and stem region of CD44 
(Mori et al., 2002). CD44 in turn is associated with F-actin through its 
cytoplasmic domain by interacting with Ezrin/Radixin/Moesin proteins. This 
associates MTI-MMP indirectly with F-actin. Overexpression of the cytoplasmic 
domain deletion mutant of CD44 abrogated MTI-MMP association with F-actin 
presumably by competing for the interaction of MTI-MMP with full-length CD44
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(Mori et al., 2002). This completely abolishes localization of MTI-MMP to the 
lamellipodia (Mori et al., 2002), suggesting that association with F-actin is critical 
for localization of both CD44 and MTI-MMP to the cell front. The interaction of 
MTI-MMP with CD44 through the hemopexin domain of the molecule is also 
required for CD44 shedding by the enzyme (Suenaga et al., 2005).
It has been also shown that M TI-MM P can be co-localized with |31 
integrin (Ellerbroek et al., 2001; Wolf et al., 2003). It is not clear whether this is 
due to a direct/indirect interaction, but these reports suggest that MTI-MMP and 
(31 integrin are functioning in the same area on the cell surface.
1.9 Trafficking and intracellular regulation of MTI-MMP
MTI-MMP has been shown to be internalized by clathrin-dependent and 
caveolae-dependent pathways (Jiang et al., 2001; Remade et al., 2003; Uekita et 
al., 2001) (Fig. 1.13). Because internalization removes MTI-MMP from the cell 
surface, this can be a mechanism of downregulation. However, almost 
paradoxically, the internalization process appears to be essential for the enzyme to 
promote cell migration (Uekita et al., 2001). Clathrin-dependent internalization of 
MTI-MMP is mediated through the C-terminal cytoplasmic tail. The \k2 subunit 
of adaptor protein 2 (AP-2), which mediates incorporation of membrane proteins 
into clathrin cages, interacts with the LLY573 sequence in the cytoplasmic tail of 
MTI-MMP (Uekita et al., 2001).
When LLY573 was mutated to alanines or deleted, the internalization of 
MTI-MMP was inhibited, and the mutant M Tl-MMPs could not promote cell 
migration (Uekita et al., 2001). MTI-MMP is also internalized through caveolae 
(Rem ade et al., 2003). Structural or sequence requirements for this type of 
internalization are not known, but it is generally thought that localization to the 
membrane lipid rafts is essential since caveolae are lipid rafts containing caveolin
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Fig. 1.13. Internalization and recycling pathways of M T1-M M P 
(reproduced from Itoh and Seiki, 2004). MT1-MMP (blue) is internalized 
via the clathrin-mediated pathway. The cytoplasmic domain of MT1-MMP 
contains the motif o f Leu-Leu-Tyr573, which binds to the 2 subunit of adaptor 
protein 2 (AP2; purple), facilitating a formation o f clathrin-coated pit. The 
cytoplasmic domain of MT1-MMP also contains the Asp-Lys-Val582 motif, 
which is essential for the enzyme to be recycled to the cell surface through 
endosomes. MT1-MMP is also internalized via caveolae-mediated pathway, 
but the fate of MT1-MMP in the caveosome is not clear.
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(Varma and Mayor, 1998). Galvez et al. have demonstrated that caveolae- 
mediated internalization of MT1-MMP also plays an important role in MT1- 
MMP-mediated endothelial cell migration on a collagen substratum (Galvez et al., 
2004).
A part of internalized MT1-MMP was shown to be transported to the 
CD63 positive lysosomes for degradation (Takino et al., 2003). Interestingly, 
CD63 tetraspanin, a well established component of late endosomal and lysosomal 
membranes, interacts with MT1-MMP directly through the N-terminus of CD63 
and the hemopexin domain of MT1-MMP (Takino et al., 2003). Expression of 
CD63 accelerates internalization and lysosomal degradation of MT1-MMP, and it 
requires both the hemopexin and the cytoplasmic domains of MT1-MMP (Takino 
et al., 2003). Therefore, CD63 is one of the regulators of MT1-MMP trafficking.
MT1-MMP is also recycled back to the cell surface after internalization. 
Wang et al. have shown that the DKV583 motif in the C-terminus of the 
cytoplasmic domain is a critical sequence (Wang et al., 2004b). Deletion of 
DKV583 inhibits recycling of MT1-MMP. A similar motif, EWV is present at the 
C-terminus of MT2-, MT3- and MT5-MMP, and MT3-MMP is shown to be able 
to co-recycle with MT1-MMP in MDCK cells (Wang et al., 2004b). Mint-3 has 
been identified as a protein that interacts with the EWY motif of MT5-MMP 
(Wang et al., 2004b). Mint-3 upregulates surface levels of MT5-MMP, 
presumably by increasing the recycling frequency. It would be interesting to know 
if Mint-3 can also regulate trafficking of MT1-MMP.
Another protein which interacts with the cytoplasmic domain of MT1- 
MMP has been named MT1-MMP cytoplasmic-binding protein-1 (MTCBP-1) 
(Uekita et al., 2004). MTCBP-1 does not affect proMMP-2 activation by MT1- 
MMP but suppresses MTl-MMP-mediated cell migration. Interestingly many 
cancer cell lines, which express high levels of MT1-MMP express low level of 
MTCBP-1 and normal fibroblasts which express low levels of MT1-MMP express 
a high levels of MTCBP-1 (Uekita et al., 2004). This inverse correlation suggests
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that MTCBP-1 may act as an invasion suppressor.
1.10 Main findings of this thesis
In order to understand the role of intracellular trafficking, membrane 
sorting and cell surface release of matrix metalloproteinases in tumor invasion and 
metastatic dissemination, as the main topic of my PhD project, I decided to focus 
my attention mainly on MT-MMPs since they represent a restricted subset of 
MMPs, which may also cleave cell surface proteins and serve as receptors and 
activators for secreted MMPs. In addition, the severe connective tissue disorders 
of MT1-MMP knockout mice, and the efficacy of MT1-MMP to promote, both 
directly and indirectly, migratory and invasive phenotype of normal and 
neoplastic cells, prompted me not only to characterize the molecular mechanisms 
of MT1-MMP activation but also to define its subcellular activation compartment.
In chapter 3 I report that MT1-MMP is mainly associated with detergent- 
resistant membranes and that MT1-MMP undergoes proteolytic processing only if 
associated with detergent-soluble membranes. In chapter 4 I report that MT1- 
MMP activation occurs intracellularly in a post-Golgi, pre-plasma membrane 
compartment. In chapter 5 I discuss the biological meaning of these data in the 
regulation of MTl-MMP-dependent activities.
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CHAPTER 2
Materials and Experimental Procedures
2.1 General Materials
Sodium dodecyl sulphate (SDS), glycine, DL-dithiothreitol (DTT), 
p o ta s s iu m  a c e ta te ,  T R IZ M A  b a se , m a g n e s iu m  a c e ta te ,  
Tris[Hydroxymethyl]aminomethane (Tris), ethidium bromide, ethylene glycol-bis 
(2 -a m in o e th y le th e r) -N ,N ,N ',N '- te tra a c e tic  acid  (E G T A ), e th y l- 
enediaminetetraacetic acid (EDTA), KH2P04, Na2H P04, NaH2P04 , M gS04, 
bovine serum albumine (BSA), aprotinin, benzamidine, leupeptin, pepstatin, 1,10- 
phenanthroline, phenylmethylsulphonyl fluoride (PMSF), brefeldin A (BFA), 
kanamycin, gelatin, methylcellulose, uranyl acetate, sucrose, tunicamycin, 
lysozyme, sodium azide, sodium deoxycholate, tannic acid, methyl-p- 
cyclodextrin, lovastatin, mevalonate, rhodamine and fluorescein 5-isothiocyanate 
(FITC) were from Sigma-Aldrich (WI, USA). NaCl, Na2B40 7, HC1, NaOH, KOH, 
NH4C1, (NH4)S 04, glacial acetic acid, ethanol, trichloroacetic acid (TCA) were 
from Carlo Erba (Italy). Piperazine-l,4-bis(2-ethanesulfonic acid) (PIPES), 4-(2- 
Hydroxy-ethyl)-piperazine-l-ethane-sulfonic acid (HEPES), glycerol, KC1, 
MgCl2, and CaCl2 were from Merck (Germany). Triton X-100 and Nonidet P-40 
(NP-40) were from Fluka (Sigma-Aldrich, WI, USA). The broad-range MMP 
inhibitor BB-94 was from British Biotechnology (UK). Other materials will be 
specified for each procedure.
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2.2 Cell culture and transfection
2.2.1 Materials
A375MM cells (hereafter referred to as A375 cells), an established 
human melanoma cell line (Kozlowski et al., 1984), were kindly provided by Dr. 
G. Egea (University of Barcelona, Spain). Human fibrosarcoma HT1080 cells 
were purchased from American Tissue Type Collection (VA, USA). Modified 
Eagles Medium (MEM), Dulbecco’s Modified Eagles Medium (DMEM), F12 
Medium, Fetal Calf Serum (FCS), non essential amino acids (NEA), penicillin, 
streptomycin, trypsin/EDTA, and L-glutamine were from Gibco (NY, USA). All 
the plastic materials were from Corning (NY, USA). Filters (0.45 and 0.2 jim) 
were from Amicon (MA, USA).
2.2.2 Growth media
A375 cells were maintained in DMEM/F12 (1:1) nutrient mixture 
supplemented with 10% FCS, 4 mM L-glutamine, 100 U/ml penicillin and 100 
mg/ml streptomycin. HT1080 cells were grown in MEM supplemented with 10% 
FCS, 4 mM L-glutamine, 0.1 mM NEA, 100 U/ml penicillin and 100 fxg/ml 
streptomycin.
2.2.3 Growth conditions
All cell lines were grown under a controlled atmosphere in the presence 
of 5% C 02 at 37°C. Cells were grown in a flask until 80-100% confluence. The 
medium was removed and trypsin/EDTA solution (0.05% trypsin, 0.02% EDTA) 
added for 2-5 minutes. The medium was then added back to block protease action 
and the cells were collected in a plastic tube. After centrifugation for 5 min at 300 
x g, the pellet was resuspended in fresh medium.
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2.2.4 Cell transfection
For transfection, cells were plated at 50% confluence, and the next day 
were incubated 1 hour at 37°C with 0.45 ^g/cm2 DNA of interest and 2 jAljig 
DNA TransFast (Promega, WI, USA). Complete medium was then added. 
Experiments involving overexpression of exogenous proteins were usually 
performed the day after transfection.
2.3 cDNA Constructs
MT1-MMP cDNA encoding an open reading frame from amino acid 
residues Me^-Val583, GFP-tagged-MTl-MMP and the catalitically inactive MT1- 
MMP mutant (E240A) were cloned in a pcDNA3.0 expression vector (Gibco, NY, 
USA), (as described in Cao et al., 1996), and kindly provided by Dr. S. Zucker 
(Stony Brook University, NY, USA). The FLAG-tagged-M Tl-M M P (FI 12) 
cDNA was cloned in a pcDNA3.0 expression vector (Gibco, NY, USA), (as 
described in Wu et al., 2004), and kindly provided by Dr. M.S. Stack 
(Northwestern University, Chicago, IL, USA). The FLAG-tagged al-PD X  cDNA, 
(described in Jean et al., 1998), was kindly provided by Dr. G. Thomas (Oregon 
Health Sciences University, Portland, OR, USA) and subcloned in pcDNA3.0, as 
described below. GFP-tagged furin cDNA was kindly provided by Dr. J. 
Bonifacino (NIH, Bethesda, MD, USA). GFP-tagged Rab4, Rab5, Rab7, R ab ll 
were kindly provided by Dr. M. Zerial (Max-Planck, Dresden, Germany). The 
ts045 temperature-sensitive Vesicular Stomatitis Virus G glycoprotein mutant 
(VSV-G)-GFP chimera was a generous gift of Dr. J. Lippincott-Schwartz (NIH, 
Bethesda, MD, USA).
79
2.4 General subcloning procedures
2.4.1 Materials
Restriction enzymes were from Amersham Pharmacia Biotech (NJ, 
USA). T4 DNA ligase, DNA molecular size standards were from Gibco (NY, 
USA). “QIAprep Spin Miniprep Kit” and “Qiagen Plasmid Maxi Kit” were from 
Qiagen (CA, USA). Tryptone Peptone, Yeast extract and agar were from Difco 
(Becton Dickinson, MD, USA). 3-Morpholino-propane-sulfonic acid (MOPS), 
RbCl and MnCl2 were from Sigma Aldrich (WI, USA).
2.4.2 Solutions and media
Luria Broth (LB): 1% (w/v) Tryptone Peptone, 0.5% (w/v) Yeast extract, 
1% (w/v) NaCl; autoclaved 15 min at 121°C. LB-agar: LB plus 1.5% (w/v) agar: 
autoclaved 15 min at 121°C. Tfbl: 30 mM potassium acetate, 100 mM RbCl, 10 
mM CaCl2, 50 mM MnCl2, 15% (v/v) glycerol pH 5.8. Tfb2: 10 mM MOPS, 75 
mM CaCl2, 10 mM RbCl, 15% (v/v) glycerol pH 7.0. TE buffer: 10 mM Tris-HCl 
pH 8.0, 1 mM EDTA. 50X TAE buffer (1 litre): 242 gr. TRIZMA base, 57.1 ml 
glacial acetic acid, 100 ml 0.5 M EDTA.
2.4.3 DNA agarose gel
Agarose gels were prepared by dissolving agarose (Bio-Rad 
Laboratories, UK) in IX TAE buffer and heating with a microwave oven. 0.5 
pig/ml of ethidium bromide were added and the gel was poured and run on an 
agarose gel apparatus from Bio-Rad Laboratories (UK). 0.3-0.5 jig of DNA 
standards were loaded and often used as a reference to give an approximate 
estimation of the amounts of DNA samples.
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2.4.4 PCR amplification of DNA inserts
To amplify specific regions of DNA inserts, PCR was performed 
incubating 10 ng DNA-plasmid as template in 50 ji\ of 20 mM Tris-HCl pH 8.8, 
10 mM KC1, 2 mM M gS04, 10 mM (NH4)S 04, 0.1% Triton X-100, 0.1 mg/ml 
nuclease free BSA, 1 piM each oligonucleotide, 200 pM  each dNTP, 2.5 U Pfu 
Turbo DNA Polymerase. All reagents, except DNA and oligonucleotides, were 
from Stratagene (CA, USA). Oligonucleotides were purchased from Gibco (NY, 
USA) or from Sigma-Aldrich (WI, USA). The PCR reaction mixtures were 
subjected to 35 temperature cycles in a programmable thermal cycler 
(PerkinElmer, MA, USA). Melting-, annealing-, and elongation-temperatures 
were adjusted according to the features of template and primers. To facilitate the 
subsequent subcloning of PCR products, the forward and the reverse primers were 
provided with restriction sites at their 5 ’ ends (see specific sections).
2.4.5 Restriction and ligation
DNA (vectors and inserts) were cut with 5 U/^g of appropriate restriction 
enzymes in the buffer supplied with each enzyme by Amersham Pharmacia 
Biotech (NJ, USA). After restriction, enzymes were usually inactivated by 
incubating at 65-75°C for 10-20 min, according to the manufacturer’s instructions, 
and loaded on 1% agarose gel. The bands of interest were cut out of the gel with a 
sterile scalpel, and DNA was extracted from the gel with Qiaex II extraction kit 
(Qiagen, CA, USA), according to the manufacturer’s instructions. DNA was 
eluted in 10 mM Tris-HCl pH 8.0. To ligate vector and insert, about 100 ng of 
vector and about 3-fold molar amounts of insert were incubated with 1U T4 DNA 
ligase in T4-DNA-ligase buffer (Gibco, NY, USA) 10 min at room temparature 
(RT).
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2.4.6 Preparation of competent bacteria
A single colony of X L-1 Blue E. Coli bacteria (Stratagene, CA, USA) 
was picked from a LB-agar plate and used to inoculate 10 ml of LB. Bacteria were 
grown O.N., the culture was diluted in 190 ml of fresh LB and incubated at 37 °C 
until the optical density reached 0.5 (at 600 nm). Bacteria were harvested by 
centrifugation at 4,000 x g for 10 min at 4 °C. The bacterial pellet was 
resuspended in 64 ml of Tfbl and left on ice for 1 to 2 hours. After centrifugation 
and resuspension of the pellet in 8 ml of Tfb2 cells were frozen in liquid nitrogen 
and stored at -80°C in 400 ]A aliquots.
2.4.7 Transformation of bacteria
The DNA plasmid of interest (10 ng of uncut plasmid or half of a ligation 
reaction) was added to 200 ji\ of competent bacteria (see previous section) 
previously thawed on ice. After gentle mixing, the cells were left on ice for 30 
min, heat shocked for 45 sec at 42°C, and after addition of 800 pi\ LB, incubated 
under shaking (200 rpm) at 37°C for 45 min. Bacteria were plated on LB agar 
containing the appropriate selective antibiotic and incubated O.N., at 37 °C. The 
next day, an isolated bacterial colony was picked and used to inoculate 2ml of LB 
containing the appropriate antibiotic. The culture was incubated at 37 °C O.N. 300 
]A of 50% (v/v) sterile glycerol were added to 700 ]A of the bacterial culture and 
stored at -80 °C.
2.4.8 Small-scale preparations of plasmid DNA (miniprep)
The clones obtained after transformation of ligation reaction were usually 
screened by miniprep and subsequent restriction analysis. Isolated bacterial 
colonies were picked and inoculated in 5 ml of LB containing the appropriate 
antibiotic. After O.N. growing at 37°C under continuous shacking (200 rpm), 700 
\i\ of the culture was mixed with 300 ]A 50% (v/v) sterile glycerol and stored at
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-80°C, while the rest of the culture was chilled on ice and centrifuged 10 min at 
4,000 x g. The DNA was extracted using the “QIAprep Spin Miniprep Kit” 
(Qiagen, CA, USA), according to the manufacturer’s instructions and analysed by 
restriction analysis and separation on agarose gel.
2.4.9 Large-scale preparation of plasmid DNA fmaxiprep)
A small amount of bacteria transformed with the plasmid of interest, 
were scraped from the glycerol stock, inoculated in 2 ml of LB containing the 
appropriate selective antibiotic and grown at 37°C under continuous shacking 
(200 rpm) for 6-8 hours. This pre-culture was used to inoculate 200 ml of LB 
containing selective antibiotic. After an O.N. incubation, bacteria were collected 
by centrifugation at 6000 x g in a JA14 rotor for 10 min at 4 °C and processed 
according to the maxi-plasmid purification protocol of the “Qiagen Plasmid Maxi 
Kit”. The DNA obtained was resuspended in TE buffer and stored at -20 °C.
2.5 General biochemical procedures
All the experiments involving the following procedures were performed at 
least three times, in duplicate.
2.5.1 Materials
Ponceau red, bromophenol blue, coomassie brilliant blue R250, 
ammonium persulphate (APS), N,N,N’,N’-tetramethylethylenediamine (TEMED) 
were from Sigma-Aldrich (WI, USA). |3-mercaptoethanol was from Fluka (Sigma- 
Aldrich, WI, USA). Methanol, butanol, and glacial acetic acid were from Carlo 
Erba (Italy). Secondary antibodies conjugated with Horse-Radish Peroxidase 
(HRP) and directed against mouse or rabbit IgGs were from Calbiochem (CA, 
USA).
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2.5.2 Solutions
Acrylamide stock solution: 40% (w/v) acrylamide-bisacrylamide (37.5:1) 
(Eurobio, France). Running buffer: 25 mM TRIZMA base, 0.2 M glycine, 0.1% 
(w/v) SDS. SDS-sample buffer: 62.5 mM Tris-HCl pH 6.8, 2% (w/v) SDS, 10% 
(v/v) glycerol, 5% (v/v) P-mercaptoethanol and 0.1% (w/v) bromophenol blue. 
Transfer buffer: 25 mM TRIZMA base, 0.2 M glycine, 20% (v/v) methanol. 
Phosphate buffered saline (PBS): 1.5 mM KH2P04, 8 mM Na2HP04, 2.7 mM 
KC1, 137 mM NaCl. T-PBS: 0.05% (w/v) Triton X-100 in T-PBS. Blocking 
solution: 1% (w/v) BSA in T-PBS.
2.5.3 Sodium dodecvl sulphate -  polyacrylamide gel electrophoresis 
(SDS-PAGE)
2.5.3.1 Assembly of polyacrylamide gels
Two 16 x 18 cm plates were used for assembling a regular gel, while 32 
x 18 glasses were used for assembling longer gels. The plates were assembled to 
form a chamber using two 1.5 mm plastic spacers aligned on the lateral edges of 
the plates. The plates were then fixed using two clamps and mounted on a plastic 
base which sealed the bottom. All equipment was from Hoefer Scientific 
Instruments (Germany). The ‘running’ polyacrylamide gel was prepared by 
mixing H20 , 40% (w/v) acrylamide-bisacrylamide solution, 1.5 M Tris-HCl pH
8.8, 10% (w/v) SDS, in order to have 4% (w/v) acrylamide, 375 mM Tris-HCl, 
0.1% (w/v) SDS. Then, 0.06% (w/v) of ammonium persulphate and 0.06% (v/v) 
TEMED were added, the solution was pipetted and poured into the gap between 
the plates, leaving about 5 cm for the stacking gel. Immediately after pouring, the 
gel was covered with a layer of butanol and left at RT for about 1 hour. The 
butanol layer was removed. The ‘stacking’ polyacrylamide gel was prepared by
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mixing H20 , 40% (w/v) acrylamidebisacrylamide solution, 0.5 M Tris-HCl pH
6.8, 10% (w/v) SDS, to have 4% (w/v) acrylamide, 125 mM Tris-HCl, 0.1% (w/v) 
SDS. Then, 0.1% (w/v) ammonium persulphate and 0.07% (v/v) TEMED were 
added, the solution pipetted and poured on the ‘running’ gel. Immediately, a 15- 
well comb was inserted between the glasses and left fori hour at RT.
2.5.3.2 Sample preparation and run
Samples were prepared by adding SDS-sample buffer, incubating at 
100°C for 5-15 min in a Multi-Block Heater (Lab-Line, IL, USA), cooled at RT, 
briefly centrifuged and loaded on the gel. One or two wells were loaded with 3 pi\ 
of Rainbow recombinant protein molecular mass markers (Amersham Pharmacia 
Biotech, NJ, USA). The gel was then transferred into the electrophoresis 
apparatus (Hoefer Scientific Instruments, NJ, USA) and the electrophoresis was 
carried out under a constant current of 8 mA (for O.N. runs) or 40 mA (for short 
4-hour runs).
2.5.3.3 Evaluation of protein concentration
When required, protein concentration was evaluated using a 
commercially available protein assay kit (Bio-Rad Laboratories, UK) according to 
the manufacturer's instructions.
2.5.3.4 TCA-based protein precipitation
10% TCA and 0.4 mg/ml sodium deoxycholate were added from a 5X 
TCA/deoxycholate stock to 500 ja\ of the third elution fractions. The mixture was 
vortexed and incubated on ice for 1 hour. After a 10 min centrifugation at 13,000 
x g at 4°C, the supernatant was collected and the pellet was washed twice, by 
adding cold acetone, centrifuging as indicated above and removing the 
supernatant. At the end, the pellet was dried under gentle aspiration, resuspended
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in SDS-sample buffer, incubated at 100°C for 15 min vortexing every 5 min and 
subjected to SDS-PAGE.
2.5.3.5 Coomassie brilliant blue Staining
Gels were incubated in staining solution (methanol, H20 , acetic acid 
5:5:2, and 0.1 % coomassie brilliant blue) for 2 hours, washed and then destained 
with 30% methanol 10 % acetic acid.
2.5.3.6 Gel drying
When required, the gels were washed with H20  and 10% polyacrylamide, 
briefly incubated with 4% (v/v) glycerol and dried with a gel dryer (Hoefer 
Scientific Instruments, Germany) at 80°C under vacuum for 4 hours.
2.5.4 Western Blotting
2.5.4.1 Protein transfer onto nitrocellulose
The polyacrylamide gel was soaked for 15 min in transfer buffer, placed 
on a sheet of 3MM paper (Whatman, NJ, USA) and covered by a nitrocellulose 
filter (Schleicher & Schuell, Germany). The filter was covered by a second sheet 
of 3MM paper, to form a "sandwich" which was subsequently assembled into the 
blotting apparatus (Hoefer Scientific Instruments, NJ, USA). Protein transfer 
occurred at 500 mA for 4 hours or at 125 mA O.N. At the end of the run, the 
sandwich was disassembled and the nitrocellulose filter was soaked in 0.2% (w/v) 
ponceau red and 5% (v/v) acetic acid for 5 min to visualize the protein bands, and 
then rinsed with 5% acetic acid to remove the excess of unbound dye.
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2.5.4.2 Probing nitrocellulose with specific antibodies
The nitrocellulose filters were cut into strips with a razor blade. Strips 
containing the proteins of interest were incubated in T-PBS containing 5% skim 
milk powder (Fluka, Sigma-Aldrich, WI, USA) for 1 hour at RT, and then with 
the primary antibody at the appropriate working concentration in blocking 
solution (see Table 2.1 for the working diluitions of antibodies used in this thesis). 
After 2-3 hour incubation at RT, or O.N. incubation at 4°C, the antibody was 
removed and the strips washed in T-PBS twice for 10 min. The strips were next 
incubated for 1 hour with the appropriate HRP-conjugated secondary antibody 
diluted 1:2000 in blocking solution and washed twice in T-PBS for 10 min and 
once in PBS for 3 min. After washing, the strips were incubated with ECL 
reagents from Amersham Pharmacia Biotech (NJ, USA), according to the 
manufacturer’s instructions, for electrochemiluminescence-based detection. The 
strips were incubated with the ECL developing solution for 1 min at RT and 
directly exposed to BioMax Films (Kodak, NY, USA).
Table 2.1. List of antibodies used in Western blot experiments
Specificity Owner (Company or Animal source Dilution
(antibody name) Group’s Head)
MT1-MMP
(MMR2)
Our laboratory Rabbit 1:10,000
MT1-MMP
(M3927)
Sigma-Aldrich 
(WI, USA)
Rabbit 1:1,000
a  1-Antitrypsin 
(A0012)
DAKO A/S 
(Denmark)
Rabbit 1:500
Caveolin-1
(SC-894)
Santa Cruz 
(CA, USA)
Rabbit 1:1,000
FLAG
(F7425)
Sigma-Aldrich 
(WI, USA)
Rabbit 1:200
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FLAG (M l) 
(F3040)
Sigma-Aldrich 
(WI, USA)
Mouse 1:100
FLAG (M2) 
(F3165)
Sigma-Aldrich 
(WI, USA)
Mouse 1:100
2.6 Preparation of antibodies
2.6.1 Materials
Glutathione, lysozyme, isopropyl-|3-D-l-thiogalactopyranoside (IPTG), 
sodium azide, Freund’s adjuvant, borate, ethanolamine and triethanolamine were 
from Sigma-Aldrich (WI, USA). The glutathione-Sepharose resin was from 
Amersham Pharmacia (Italy).
2.6.2 Generation of MT1-MMP antibodies
In all experiments and unless indicated otherwise, MT1-MMP was 
immunodetected or immunoprecipitated with rabbit polyclonal antisera (MMRs) 
raised against recombinant GST-fused polypeptides corresponding to: a) the 
MT1-MMP propeptide domain (amino acids 34-112) (for MMR3 antibody) and b) 
the propeptide-deleted extracellular portion of MT1-MMP (amino acids 113-538) 
(for MMR1 and MMR2 antibodies).
The cDNA coding for the MT1-MMP propeptide domain was amplified 
by PCR (see  ab o v e) w ith  the  fo llo w in g  p rim ers : 5 ’-
CCGGAATTCCCCGAAGCCTGGCTACAGCAA-3’ (forward primer), and 5 ’- 
G AGT CG ACCT A GCGCTT CCTTCG A AC ATT G-3 ’ (reverse primer). The PCR 
reaction mixture was subjected to 35 temperature cycles (30 sec melting at 95°C, 
30 sec annealing at 55°C and 1 min elongation at 72°C). The PCR product was 
digested with EcoRI and Sail and subcloned in EcoRI/Sall-digested pGEX-4Tl
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(Amersham Pharmacia Biotech, NJ, USA; see also section for general subcloning 
procedures) generating the pGEX-4Tl+(MTl-MMP)propeptide plasmid. Glycerol 
stocks were established and stored at -80°C . The cDNA coding for the 
propeptide-deleted extracellular portion of MT1-MMP was kindly provided by 
Dr. S. Zucker (Stony Brook University, NY, USA).
These cDNAs were used to transform competent BL21(DE3) E. Coli 
strain (Stratagene, CA, USA). These bacteria were grown in LB plus kanamycin 
(50 mg/ml) until the optical density (600 nm) was about 0.7-0.9. At this point, the 
fusion protein was induced for 3 h at 37°C with 1 mM IPTG. The cells were 
harvested by centrifugation (6000 x g, JA 10 rotor) for 10 min at 4°C and 
resuspended in 25 ml of 20 mM Tris-HCl (pH 8.0), 100 mM NaCl, 1 mM EDTA, 
1 mg/ml lysozyme in the presence of a mixture of protease inhibitors (2.0 pg/ml 
aprotinin, 0.5 pg/ml leupeptin, 2 pM pepstatin, 0.5 mM 1,10-phenantroline, 1 mM 
PMSF). 1% Triton X-100 was added, the suspension was stirred for 30 min, and 
then sonicated for 2 min on ice. The lysed cells were centrifuged for 20 min 
(1,800 rpm, JA 20 rotor). 2.5 ml of a glutathione-Sepharose resin (Amersham 
Pharmacia, Italy) was diluted up to 40 ml in PBS to remove the preservative and 
centrifuged (2,000 x g) for 5 min. The supernatant was discarded and the resin 
was resuspended again in PBS. This procedure was repeated twice. Supernatant 
from bacterial lysates were added to the glutathione-Sepharose resin and 
incubated for 30 min at 4°C with occasional agitation. The beads were washed 
with 3 x 50 ml PBS, and assembled into a column. Protein elution was started by 
the addition of 1 ml of 100 mM Tris-HCl, 20 mM glutathione, 5 mM DTT. 1 ml 
was collected and termed fraction 1. This procedure was repeated six times. Each 
step of the protein purification was analysed by SDS-PAGE (Fig. 2.1).
The remaining part of this preparation was performed with the help of 
Mr. G. Di Tullio (Protein analysis facility, Department of Cell Biology and 
Oncology, Consorzio Mario Negri Sud).
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Fig. 2.1. Purification of GST+(M Tl)propeptide. The cDNA coding for the 
MT1-MMP propeptide (amino acids 34-112) was amplified by PCR, as 
described in materials and methods section, and cloned in the pGEX-4Tl 
vector to be expressed as a GST-fused chimera from BL21(DE3) E.Coli. The 
expressed protein was then purified by using a glutathione-Sepharose resin. 
Small amounts of the recombinant protein during different purification steps 
were analysed by 12% SDS-PAGE, transferred to nitrocellulose membrane and 
visualized by Ponceau red. Fractions: (-) IPTG-unstimulated bacteria; (+) 
IPTG-stimulated bacteria; (T) total crude lysates; (S) supernatant; (P) pellet 
and (E) eluted purified protein. The position of molecular weight standards are 
indicated on the left.
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Purified fusion protein (lm g) was mixed with an equal volume of 
complete Freund’s adjuvant (Sigma Aldrich, WI, USA) and used to immunise 
New Zealand rabbits. The rabbits were boosted after 15 and 30 days with 500 pig 
of antigen in incomplete Freund’s adjuvant. The rabbits were bled and the 
presence of anti-MTl-MMP antibody tested by Western blotting.
2.6.3 Affinity purification of MMR2 antiserum
This purification was performed by Mr. G. Di Tullio (Protein analysis 
facility, Department of Cell Biology and Oncology, Consorzio Mario Negri Sud, 
Italy). The polyclonal anti-MTl-MMP antibody (MMR2) was affinity-purified on 
an affinity column prepared by coupling purified GST-fused propeptide-deleted 
extracellular MT1-MMP portion (5 mg) with glutathione-Sepharose beads (2 ml). 
To cross-link this fusion construct convalently to Sepharose beads, the beads were 
first washed twice with 10 ml of 0.2 M borate-NaOH, pH 8.6. After centrifugation 
(500 x g, 2 min at 4°C), recovered beads were incubated with 20 mM dimethyl 
pimelimidate-HCl (Pierce, IL, USA) in 0.2 M triethanolamine (2 ml). After 30 
min of continuous mixing at RT, the beads were centrifuged and the supernatant 
discarded. The cross-linking reaction was stopped by adding 10 ml 0.2 M 
ethanolamine-HCl, pH 8.2, for 60 min. The beads were washed twice with 5 ml of 
0.1 M glycine-HCl, pH 2.5 to remove non-covalently-linked molecules. The resin, 
now ready for the affinity purification, was washed twice with PBS and stored 
with 0.02% sodium azide at 4 °C until use. The crude rabbit serum raised against 
the GST-fused polypeptide (2 ml) was loaded onto the resin and, after extensive 
washing with PBS, the antibodies specifically bound to the column were eluted 
with 0.1 M glycine, pH 2.5 (5 ml). The pH of the eluted fractions (1 ml each) was 
adjusted to 7.0 with 1 M Tris, pH 10. The pooled eluate fractions, as well as the 
flow-though fraction, were dialysed 12-15 hours against PBS plus 0.02% sodium 
azide and concentrated by ultrafiltration (Centriprep 30; Amicon, MA, USA) to 
the original serum volume. Purified antibodies were stored at -20°C.
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2.7 Preparation of detergent-resistant membranes
2.7.1 Solutions
Phosphate buffered saline (PBS): 1.5 mM KH2P04, 8 mM Na2HP04, 2.7 
mM KC1, 137 mM NaCl. TNE buffer: 50 mM Tris-HCl, 150 mM NaCl, 2 mM 
EDTA, pH 8.0. Lysis buffer: 1% (v/v) Triton X-100 in TNE buffer containing a 
cocktail of protease inhibitors: 2.0 [xg/ml aprotinin, 0.5 p,g/ml leupeptin, 2 p,M 
pepstatin, 0.5 mM 1,10-phenantroline, 1 mM PMSF. Solubilization buffer: 0.2% 
(w/v) SDS in Lysis buffer.
2.7.2 Isolation of Triton X-100-insoluble membranes
TX-100-insoluble membranes were prepared as originally described by 
Brown and Rose (Brown and Rose, 1992) with the following modifications. Cells 
at confluence in 35 mm dishes were washed twice with ice-cold PBS containing 1 
mM CaCl2 and 1 mM MgCl2 and then lysed for 20 min on ice in 0.5 ml of TNE 
buffer (pH 7.4) containing 1% Triton X-100. Lysates were then collected and 
ultracentrifuged at 120,000 x g in TL100.1 rotor (Beckman, CA, USA) for 60 min 
at 4°C. Supernatants, representing the soluble material, were collected in 1.5 ml 
tubes and prepared for SDS-PAGE with 4X SDS-sample buffer. The pellets, 
representing the insoluble material, were directly resuspended in SDS-sample 
buffer. Small amounts of each samples were loaded on gel.
2.7.3 Immunoprecipitation of Triton X-100-insoluble membranes
Cells were seeded on 6-well plates and transfected as described above. 
Twenty-four hours after transfection confluent cells were washed twice with ice- 
cold PBS and then incubated with 0.5 ml Lysis buffer on a shaker for 60 min at
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4°C. Cell lysates were scraped, collected and ultracentrifuged at 120,000 x g in 
TL100.1 rotor (Beckman, CA, USA) for 60 min at 4°C. Meanwhile, protein A- 
Sepharose beads (Amersham Pharmacia, Italy) were washed twice with ice-cold 
PBS and resuspended in TNE buffer at a final concentration of 42 mg/ml, 
corresponding to a mixture containing 10% (v/v) beads.
After ultracentrifugation, cleared lysates were collected in 1.5 ml tubes 
and stored at 4°C. When required, the Triton X-100 insoluble material was also 
suspended in 0.5 ml solubilization buffer, incubated for 60 min at 37°C and then 
rapidly cooled at 4°C. Lysates were then incubated on a rolling wheel with 5 pi of 
polyclonal sera or 1 pi of affinity-purified antibodies for 60 min at 4°C. 50 pi of a 
10% protein A-Sepharose beads mixture were added to collect immune complexes 
for 60 min at 4°C. After a quick spin (13,000 x g for 2 min at 4°C), the 
supernatant was removed by aspiration and the pellet was washed three times in 
lysis buffer. The last wash was removed as completely as possible, reaching a 
final volume of approximately 50 pi. For SDS-PAGE analysis, 50 pi of SDS- 
sample buffer were added. Samples were heated to 90 °C for 10 min and then 
loaded onto gel. Samples were also stored at -20°C.
2.7.4 Flotation assay of Triton X-100-insoluble membranes
Flotation assay of Triton X-100-insoluble material was performed using 
previously published protocols (Arreaza et al., 1994) with the following 
modifications. Cells were grown to confluence in 100 mm dishes and then washed 
in ice-cold PBS and lysed with 1% Triton X-100 in TNE buffer (50 mM Tris-HCl, 
150 mM NaCl, 2 mM EDTA, pH 8.0) for 10 minutes on ice. Lysates were scraped 
from dishes, adjusted with OptiPrep density gradient medium, a 60% (w/v) 
solution of iodixanol in water (Sigma-Aldrich, Germany), to a final 35%, and then 
placed at the bottom of a centrifuge tube. A discontinuous Optiprep gradient (5- 
30% in TNE) was layered on the top of the lysates and the samples were
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ultracentrifuged at 120,000 x g for 16 hours in a swinging-bucket rotor (model 
SW41, Beckman, CA, USA). One-milliliter fractions were harvested from the top 
of the gradient. MT1-MMP immunoprecipitation was performed, as described 
above, with 5 pi of MMR2 antiserum after adding Triton X-100 to the samples to 
reach the final concentration of 1%. Immunoprecipitates were recovered with 
protein A-Sepharose (Amersham Pharmacia, Italy), washed twice in TNE, 
resuspended with SDS-sample buffer and separated by SDS-PAGE; proteins were 
then electro-transferred to nitrocellulose filters and detected by autoradiography 
with the Fujifilm bioimaging analyzer system BAS 1800 II (Fuji, Japan) and 
relative software.
2.8 Pulse-chase analysis
Twenty-four hours after transfection, confluent cells were washed twice 
with DMEM and then labeled for different times with an amino acid mixture for 
in vitro protein radiolabeling containing L-[35S]Methionine and L-[35S]Cysteine 
(Redivue, Amersham Pharmacia, Italy) at a final concentration of 0.1 mCi/ml, in 
DMEM lacking L-Methionine and L-Cysteine (Gibco, NY, USA). Depending on 
the experiment, cells were then chased for different times in complete growth 
medium. Cells were thus cooled on ice and washed twice with ice-cold PBS. After 
extraction with 1% Triton X-100 in TNE, soluble and insoluble fractions were 
separated by ultracentrifugation at 4°C (120,000 x g, 1 hour). The pellet, 
containing Triton X-100-insoluble material, was further incubated with 0.2% 
SDS, 1% Triton X-100 in TNE at 37°C for 1 hour. M T1-M M P 
immunoprecipitation was performed with MMR2 antiserum. Immunoprecipitates 
were recovered with protein A-Sepharose (Amersham Pharmacia, Italy), washed 
twice in TNE, resuspended with sample buffer and separated by SDS-PAGE; 
proteins were then transferred to nitrocellulose filters and detected by 
autoradiography. Quantitative analysis was performed with the Fuji BAS 1800 II 
software (Fuji, Japan).
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2.9 Biotinylation assay of cell surface proteins
Twenty-four hours after transfection, confluent cells were cooled on ice, 
washed twice with ice-cold PBS and incubated twice for 20 minutes each with 1 
mg/ml NHS-biotin (Pierce, IL, USA) in PBS at 4°C. Next, cells were washed with 
PBS and excess NHS-biotin was quenched for 20 minutes with 50 mM NH4C1 in 
PBS. After extraction with 1% Triton X-100 in TNE buffer (pH 7.4) at 4°C, 
soluble and insoluble material was separated by ultracentrifugation at 4°C 
(120,000 x g, 60 min). The pellet, containing Triton X-100-insoluble material, 
was further incubated with 0.2% (w/v) SDS, 1% (v/v) Triton X-100 in TNE (pH 
7.4), containing a standard antiprotease mix at 37°C for 1 hour.
Biotinylated proteins were captured by an overnight incubation at 4°C 
with streptavidin-agarose beads (Sigma-Aldrich, Germany). Supernatants, 
containing non-biotinylated proteins, were recovered, precipitated in 10% (w/v) 
TCA for 30 minutes on ice, washed twice with ice-cold acetone and resuspended 
in SDS-sample buffer. The pellets containing biotinylated proteins, were washed 
twice in TNE (pH 7.4), resuspended in sample buffer and subjected to SDS- 
PAGE. Proteins were then electro-transferred to nitrocellulose filters and probed 
with specific antibodies.
2.10 Co-immunoprecipitation
Transfected confluent cells were pulse-labeled as described above, and 
then cooled on ice, washed twice with ice-cold PBS and lysed on ice with RIPA 
buffer (150 mM NaCl, 1% (v/v) NP-40, 0.5% (w/v) sodium deoxycholate, 0.1% 
(w/v) SDS, 50 mM Tris, pH 8.0), containing a standard antiprotease mix (Sigma- 
Aldrich, WI, USA). Cleared supernatants were recovered after centrifugation at 
4°C (13,000 x g, 5 min) and incubated with different antibodies, as indicated in 
figure legends, at 4°C for 2 hours and then O.N. incubated with protein A-
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Sepharose beads (Amersham Pharmacia, Italy). Immunoprecipitates were then 
collected, washed twice with ice-cold RIPA buffer (pH 8.0), resuspended with 
SDS-sample buffer and separated by SDS-PAGE; proteins were then electro­
transferred to nitrocellulose filters and directly detected by autoradiography.
2.11 Cell treatments
2.11.1 A-glvcosidase F treatment
Cells were seeded on 6-well plates and transfected as described above. 
Twenty-four hours after transfection, confluent cells were washed twice with ice- 
cold PBS and then incubated with 200 pi A-glycosidase F buffer (20 mM sodium 
phosphate buffer, pH 8.0, 30 mM EDTA, 0.5% (w/v) NP-40, 0.1% (v/v) SDS, 
0.5% (v/v) |3-mercaptoethanol) on a shaker for 20 min at 4°C. Cell lysates were 
scraped, collected and centrifuged at 13,000 rpm for 5 min at 4°C. After 
centrifugation, cleared lysates were denatured for 10 min at 90°C and then rapidly 
incubated O.N. at 37°C. Where indicated, samples were treated with 0.5 U N- 
glycosidase F (Sigma-Aldrich, WI, USA) during the incubation time. For SDS- 
PAGE analysis, 200 pi of 2X SDS-sample buffer was added. Samples were heated 
to 90 °C for 10 min and then loaded onto gel. Proteins were then electro­
transferred to nitrocellulose filters and probed with specific antibodies.
2.11.2 Cholesterol depletion
Cells were seeded on 6-well plates and transfected as described above. 
Four hours after transfection, new complete medium was added in the presence or 
absence of 4 pM  lovastatin and 0.25 mM mevalonate (Keller and Simons, 1998). 
After an overnight incubation at 37°C, cells treated with lOmM methyl-|3- 
cyclodextrin for 60 min. Cells were then lysed for 20 min on ice in 0.5 ml of TNE
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buffer (50 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA, pH 7.5) containing 1% 
Triton X-100. Lysates were then collected and ultracentrifuged at 120,000 x g in 
TL100.1 rotor (Beckman, CA, USA) for 60 min at 4°C. Supernatants, 
representing the soluble material, were collected in 1.5 ml tubes and prepared for 
SDS-PAGE with 4X SDS-sample buffer. The pellets, representing the insoluble 
material, were directly resuspended in IX SDS-sample buffer. Representative 
amounts of each samples were loaded on gel.
2.12 Immunofluorescence microscopy procedures
2.12.1 Materials
Alexa 488-, Alexa 546- and Alexa 633-conjugated goat anti-rabbit, 
antimouse, and anti-sheep antibodies, Alexa 488, Alexa 546- and Alexa 633- 
conjugated chicken anti-mouse and anti-rabbit antibodies were from Molecular 
Probes (OR, USA). Paraformaldehyde, and saponin were from Sigma-Aldrich 
(WI, USA). Mowiol was from Calbiochem (CA, USA).
2.12.2 List of antibodies used for morphological studies in this thesis
See Table 2.2 for the working diluitions of antibodies used in 
immunofluorescence experiments. In all experiments and unless indicated 
otherwise, MT1-MMP was immunodetected with an immuno-purified rabbit 
polyclonal antibody (MMR2) raised against a recom binant GST-fused 
polypeptide corresponding to amino acids 113-538. In all the colocalization 
experiments, cells were sectioned optically with z-series on a Zeiss LSM510 
confocal system. Extensive overlap was observed in the perinuclear area only 
between MT1-MMP and furin.
97
Table 2.2. List of antibodies used in immunofluorescence experiments
Specificity Owner (Company or Animal Dilution
(antibody name) Group’s Head) source
MT1-MMP
(MMR2)
Our laboratory Rabbit 1:1,000
PDI
(SPA-891)
StressGen
(Canada)
Mouse 1:500
Giantin M.A. De Matteis 
(CMNS, Italy)
Mouse 1:1,000
TGN46 S. Ponnambalam 
(Leeds, UK)
Sheep 1:500
Transferrin receptor 
(6890)
Zymed Lab. 
(CA, USA)
Mouse 1:250
Mannose-6-P
receptor
Affinity Bio. 
(CO, USA)
Mouse 1:200
VSV-G 
(luminal domain)
M.A. De Matteis 
(CMNS, Italy)
Mouse 1:1,000
FLAG
(F7425)
Sigma-Aldrich 
(WI, USA)
Rabbit 1:200
FLAG (M l) 
(F3040)
Sigma-Aldrich 
(WI, USA)
Mouse 1:100
FLAG (M2) 
(F3165)
Sigma-Aldrich 
(WI, USA)
Mouse 1:100
2.12.3 Solutions
Paraformaldehyde: 4% (w/v) paraformaldehyde were dissolved in 65°C- 
heated PBS by adding a few drops of concentrated NaOH and brought to pH 7.4 
with 1 M HCI. Blocking solution: 0.05 % saponin, 0.5 % BSA, 50 mM NH4C1 in 
PBS. Mowiol: 20 mg of mowiol were dissolved in 80 ml of PBS, stirred O.N. and 
centrifuged for 30 min at 12,000 x g.
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2.12.4 Procedure
Cells were fixed by adding 1 volume of 4% paraformaldehyde for 15 min 
at RT, and incubated in blocking solution for 60 min at RT. The cells were 
subsequently incubated with the specified antibodies diluted in blocking solution 
(see Table 2.2 for the list and dilutions of antibodies) for 2-3 hours at RT or O.N. 
at 4°C. After incubation with the primary antibody, cells were washed three times 
in PBS and incubated with a fluorescent-probe conjugated secondary antibody 
directed against the constant region of the primary IgG molecule for 1 hour at RT. 
Secondary antibodies were diluted 1:300 in blocking solution. Usually, Alexa 
488- and Alexa 546- or 633- conjugated antibodies were used in double-labelling 
(rabbit/mouse) experiments in all possible combinations. In triple-labelling 
(rabbit/mouse/sheep) experiments, Alexa 488-conjugated anti-rabbit or anti­
mouse antibodies raised in chicken rather than in goat were used to avoid possible 
crossreactions between secondary anti-sheep antibodies and secondary antibodies 
raised in goat. Coverslips were mounted in mowiol on microscope slides. 
Immunofluorescence samples were observed by a multiphoton microscope (Till 
photonics, Germany) or a LSM 510 confocal microscope equipped with 63X 
objectives (Zeiss, Germany). Optical confocal sections were taken at 1 Airy unit 
with resolution of 512 x 512 pixels and exported as JPEG files.
2.13 VSV-G transport assay
This assay was performed with the help of Dr. Massimiliano Baldassarre 
(Department of Cell Biology and Oncology, Consorzio Mario Negri Sud). A375 
melanoma cells were plated on 12 mm glass coverslips, transfected with VSV-G- 
GFP and incubated overnight at 40°C to allow for expression while blocking exit 
from the endoplasmic reticulum. The following day, cells were washed 3 times 
with complete medium containing 20 mM HEPES and incubated at 20°C for 30 
min in the same medium and chased at 32°C in the presence or absence of 0.5 %
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tannic acid (Sigma-Aldrich, WI, USA). Cells were then fixed and processed for 
immunofluorescence as described above, with the difference that cells were not 
permeabilized prior to incubation with antibodies. A combination of an antibody 
directed against the lumenal/extracellular domain of VSV-G and a fluorophore- 
conjugated secondary antibody was used to detect plasma membrane staining as 
compared to total VSV-G measured as GFP fluorescence. For each treatment at 
least 20 cells were quantified. Plasma membrane staining was measured using the 
LSM 510 software (Zeiss, Germany) together with an electronic spreadsheet. The 
quantification was then normalized for cell number and expressed as a percentage 
of control. Experiments were repeated at least three times.
2.14 Immuno-electron microscopy procedures
These procedures were mainly performed by Dr. Galina Beznoussenko 
(Department of Cell Biology and Oncology -  Consorzio Mario Negri Sud, Italy).
2.14.1 Ultrathin cryosectioning and immunogold labeling
Cells were fixed with 2% formaldehyde and 0.2% glutaraldehyde in 0.2 
M PHEM buffer (60 mM PIPES, 25 mM HEPES, 2 mM MgCl2, 10 mM EGTA, 
pH 7.4) washed in the same buffer and collected by centrifugation. Pellets were 
embedded in 10% gelatin, cooled in ice, and cut into 1 mm3 blocks in the cold 
room. The blocks were infused with 2.3 M sucrose at 4°C for at least 2 hours, and 
frozen in liquid nitrogen. 50-60 nm-thick sections were cut at -120°C using an 
Ultracut R/FCS (Leica, Italy) equipped with an antistatic device and a diamond 
knife (Diatome, PA, USA). Ultrathin sections were picked up in a mix of 1.8 % 
methylcellulose and 2.3 M sucrose (1:1), used as a cryoprotectant as described 
(Liou et al., 1996). Cryosections were collected on formvar/carbon-coated slot 
copper grids and then incubated with different combinations of rabbit polyclonal 
antibodies followed by protein A-conjugated gold particles of different sizes (Slot
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and Geuze, 1985). Double immunolabeling was performed as described before 
(Slot and Geuze, 1985; Webster, 1999) with optimal combinations of gold particle 
sizes. To reduce crossreactivity and specificity problems in double labeling 
experiments (when two rabbit polyclonal antibodies were used), following 
treatment with the first secondary antibody and protein A, sections were 
additionally fixed with 1% glutaraldehyde (Fluka, Sigma-Aldrich, WI, USA) for 5 
min, washed with 0.12% glycine and incubated in blocking solution (0.05% 
saponin, 0.5% BSA, 50 mM NH4C1 in PBS) containing 0.01% BSA-c (Aurion, 
The Netherlands), as previously recommended (Webster, 1999). Additionally, all 
sequences of primary antibody addition and combinations of protein A-conjugated 
gold particles of different sizes were tested. After labeling, sections were treated 
with 1% glutaraldehyde, counterstained with uranyl acetate, and embedded in 
methylcellulose/uranyl acetate as described (Slot et al., 1991). Automated data 
acquisition was carried out on a Tecnai 20 electron microscope at 200 kV 
(FEI/Philips Electron Optics, Japan) equipped with a slow-scan CCD camera.
2.14.2 Quantitative immuno-electron microscopy
To determine the distribution of MT1-MMP throughout the secretory 
pathway in transfected A375 cells, quantification was performed on over 30 cross- 
sections of cells expressing average levels of MT1-MMP. In detail, labeling 
density of MT1-MMP protein in different compartments was calculated as 
previously described (Mayhew et al., 2003), micrographs were taken at a 46,000 
X magnification for each marker. Fields were taken randomly with the only 
criterion being a well-preserved morphology. Labeling densities in Table 4.1 were 
expressed as the number of gold particles per intersections of the morphometrical 
grid. Estimation of colocalization on EM cryosections was performed according 
to (Martinez-Menarguez et al., 2001).
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2.15 Gelatin degradation assay
2.15.1 Preparation of fluorescent-labeled gelatin
This preparation was performed according to (Mueller and Chen, 1991), 
with the following modifications. Two mg/ml of gelatin were dissolved in a buffer 
containing 61 mM NaCl and 50mM Na2B40 7 (pH 9.3) and then incubated at 37°C 
for 1 hour. After this incubation time, 1.8 mg/ml of FITC (or rhodamine) were 
added and mixed for 2 hours in complete darkness. This preparation was then 
dialysed O.N. at RT in PBS IX in complete darkness. Dialysis was usually 
repeated for 2 day with 2-3 buffer changes per day. After a quick spin to remove 
insoluble material, small aliquots, containing 2% (w/v) sucrose, were stored in the 
dark at4°C.
2.15.2 Preparation of fluorescent-labeled gelatin coated coverslips
Fluorescent gelatin coated coverslips were prepared and the assay carried 
out as described (Baldassarre et al., 2003; Bowden et al., 2001; Mueller and Chen, 
1991). Briefly, glass coverslips were sterilized in 70% ethanol for 15 minutes at 
RT. Air-dried coverslips were then coated with pre-warmed fluorescent-labeled 
gelatin, using enough to cover the surface. Each coverslip was inverted onto a 200 
ml drop of 0.5% ice-cold gluteraldehyde in PBS IX and incubated at 4°C for 15 
minutes. Each coverslip was then transferred to each well of a standard 12-well 
plate with coated gelatin side up, gently washed three times with PBS IX and 
finally incubated with sodium borohydride (5 mg/ml) in PBS IX for 3 minutes at 
RT. Washed coverslips were sterilized again in 70% ethanol for 5 minutes, dried 
for 20 minutes under sterile hood and then quenched in DMEM for 1 hour at 
37°C. Coverslips were then ready for seeding cells.
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2.15.3 Procedure
Cells were cultured on gelatin-coated coverslips for 16 hours and then 
fixed and processed for immunofluorescence as described above. Most 
experiments were analyzed with a Zeiss LSM 510 laser scanning confocal 
microscope (Zeiss, Germany). Immunofluorescence images were acquired at high 
confocality (pin hole=l Airy unit) to achieve the thinnest possible optical slices at 
the substrate-cell interface. To determine the number of degrading cells for each 
experiment we analyzed 100 random fields (containing at least 50 transfected 
cells) at a 63X magnification as previously described (Baldassarre et al., 2003). In 
some experiments involving multi-color labeling, fluorescence was acquired by 
wide-field fluorescence microscopy in each channel along the z-axis. To remove 
blurring caused by the objective lens and reduce the background caused by 
fluorescence from out-of-focus regions, images were subjected to mathematical 
deconvolution with an acquired point spread function (Delta Vision, WA, USA). 
Images were thresholded to remove noise and enhance the contrast of structures of 
interest, and were superimposed and saved.
2.15.4 Quantification of gelatin degradation areas
To determine the number of degrading cells for each experiment 
100 random fields (containing at least 50 transfected cells) were analyzed using a 
63X objective. Values were then expressed as the percentage of transfected cells 
that presented at least one degradation patch (irrespective of degradation area 
extension) relative to the total number of cells analyzed. To determine, instead, 
areas of degradation, using the same criteria to select cells, the area of each 
degradation patch was measured using the LSM 510 software (Zeiss, Germany) 
together with an electronic spreadsheet. The total area for each condition was then 
normalized for cell number and expressed as a percentage of control. Experiments 
were repeated at least three times.
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2.15.5 Analysis of the dynamics of gelatin degradation
This analysis was performed with the help of Dr. M assimiliano 
Baldassarre (Department of Cell Biology and Oncology, Consorzio Mario Negri 
Sud, Italy). Cells expressing MT1-MMP+GFP chimera were placed in a glass- 
bottom Petri dish coated with rhodamine-cojugated gelatin and containing culture 
medium buffered with 20 mM HEPES (pH 7.4). The Petri dish was placed on the 
stage of a multiphoton microscope (Till photonics, Germany) equipped with a 
thermoregulation device set to 37 °C. Movies were produced under a 63X oil- 
immersion objective, at a definition of 512x512 pixels, with the pinhole diameter 
set at its maximum value. The scan speed was at 1 frame/minute and, for double 
imaging of the same sample, the multi-track configuration was applied. Movie 
files were converted to TIFF format by Graphic Converter 4.0, edited by NIH 
Image 1.6.2, and again converted into QuickTime format.
2.16 Gelatin zymography
This method was perfomed according to (Birkedal-Hansen and Taylor, 
1982), with the following modifications. Aliquots of HT1080 conditioned serum 
starved medium were dissolved in non-reducing SDS-sample buffer and separated 
by SDS-PAGE using 10% polyacrylamide gels containing 1 mg/ml of gelatin 
(Sigma-Aldrich, WI, USA). After electrophoresis the gels were washed twice with 
50 mM Tris-HCl, pH 7.5, containing 5 mM CaCLj, 1 pM ZnCl2, 2.5% Triton X- 
100 for 15 min to remove SDS, followed by a brief rinsing in washing buffer 
without Triton X-100. The gels were then incubated at 37°C for 12-24 h in 50 mM 
Tris-HCl buffer containing 5 mM CaCL2, 1 pM ZnCl2, pH 7.5. The gels were then 
stained with coomassie brilliant blue R250 followed by destaining with 10% 
acetic acid, 5% methanol, as described above.
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CHAPTER 3
Intracellular Trafficking and Activation of 
MT1-MMP
3.1 Introduction
MT1-MMP, similarly to most MMPs, is synthesized as a pro-enzyme. It 
is generally thought that the propeptide needs to be removed for the protein to 
function properly and that this occurs through cleavage at a short amino acid 
stretch at the C-terminus of the propeptide by the action of a prohormone 
convertase (furin or similar, Sato et al., 1996; Yana and Weiss, 2000). It has also 
been proposed, however, that MT1-MMP does not require the cleavage of its 
propeptide to enable it to activate MMP-2 in certain cell types (Cao et al., 1996). 
In addition, activation of MT1-MMP might also occur by plasmin at the cell 
surface (Okumura et al., 1997). A further layer of complexity derives from the 
fact that mechanisms as diverse as autocatalytic processing, ectodomain shedding, 
homodimerization and internalization might all contribute to the modulation of 
MT1-MMP activity on the cell surface (for a review, Osenkowski et al., 2004). 
Indeed, MT1-MMP has also been found to be partially located in detergent- 
resistant membrane (DRM) fractions (Annabi et al., 2001), and recent results have 
addressed the role of DRM in M Tl-M M P/CD44/caveolin interaction and 
hyaluronan cell surface binding (Annabi et al., 2004). Hence, MT1-MMP 
membrane partitioning could represent a mechanism for the regulation of its 
activities. At variance with these findings, it has been recently proposed that only 
a deletion mutant of MT1-MMP lacking the cytosolic C-terminal tail is 
partitioned into DRM (Rozanov et al., 2004a).
The intracellular processing and activation of MT1-MMP, and their
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dependence on partitioning within different membrane subdomains are the subject 
of this results chapter.
3.2 Results
3.2.1 MT1-MMP processing and membrane partitioning
To analyze MT1-MMP, I produced two new rabbit polyclonal antisera 
(MMR1, MMR2) raised against the same GST-fused polypeptide corresponding 
to amino acids 113-538 of MT1-MMP (see section 2.6 in Chapter 2). These were 
tested and compared to the commercially available affinity-purified polyclonal 
antibody M3927 by immunoprecipitation from untransfected and MT1-MMP- 
transfected A375 melanoma cells (Fig. 3.1 A). The three different antibodies 
displayed uneven efficiency in the detection of a lower molecular mass (60 kDa) 
MT1-MMP band, presumably the fully processed mature form. To better 
characterize the 60 kDa MT1-MMP band, I produced another rabbit polyclonal 
antiserum (MMR3), raised against a GST-fused polypeptide corresponding to the 
propeptide domain of MT1-MMP (amino acids 35-112), as a tool for the specific 
detection of unprocessed immature MT1-MMP forms. MMR2 and MMR3 
antibodies were tested by immunoprecipitation from M Tl-M M P-transfected 
A375 melanoma cells (Fig. 3.1 B). By comparing the molecular patterns of MT1- 
MMP detected with these two different antibodies, I could definitively concluded 
that the 60 kDa band corresponds to the propeptide-deleted MT1-MMP form.
This set of data is of great practical importance because: 1) it suggests 
that detection of mature MT1-MMP is generally quite problematic as exemplified 
comparing the antisera generated in different animals but raised against the same 
polypeptide (MMR1 and MMR2); 2) the interpretation of experimental data on 
the maturation of MT1-MMP obtained with different antibodies (MMR2 and 
MMR3) becomes a critical issue for the interpretation of these results.
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Fig. 3.1. M olecular characterization of M T1-M M P processing in A375 
melanoma cells using different anti-M Tl-M M P antibodies. Untransfected 
(NT) and MTl-MMP-transfected (MT1-MMP) A375 cells were pulse-labeled 
with pSjmethionine/cysteine for 2 hours and their cleared lysates were 
immunoprecipitated with different antibodies: (A) MMR1 and MMR2, rabbit 
polyclonal antisera raised against the same GST-fused polypeptide 
corresponding to amino acids 113-538 of MT1-MMP; M3927, affinity-purified 
polyclonal antibody. (B) MMR3, rabbit polyclonal antiserum raised against a 
GST-fused polypeptide corresponding to amino acids 34-112 of MT1-MMP. 
MT1-MMP immunoprecipitates in A and B were subjected to SDS-PAGE, 
transferred to nitrocellulose membrane and visualized by autoradiography. The 
black arrowheads mark the positions of the MT1-MMP forms detected: the 
calculated molecular weights are, respectively, 65, 63 and 60 kDa. The 
positions of molecular weight standards are indicated on the left. The white 
arrowhead marks an unspecific band visible in all lanes which should not be 
confused with the 43 kDa form shown to be a MT1-MMP degradation product 
in some reports (see Introduction).
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Since MMR2 appeared to be by far the most sensitive antibody, it was 
used in all subsequent immunoprecipitation experiments. To study MT1-MMP 
processing, M Tl-M M P-transfected A375 cells were pulse-labeled with 
[35S]methionine/cysteine for 5 minutes and, after different chase times, processed 
for immunoprecipitation with MMR2. Three molecular forms of MT1-MMP 
could be detected of 65, 63 and 60 kDa (Fig. 3.2).
The 63 kDa form (also called proMTl-MMP) had a slow turnover rate 
over a time frame of 2 hours; only a minor fraction was converted to the mature 
lower molecular mass 60 kDa form, which instead appeared to turn over much 
more rapidly (Fig. 3.2). When BB94, a broad-range metalloprotease inhibitor 
(Davies et al., 1993), was included during preincubation and chase, MT1-MMP 
maturation occurred normally (see last lane in Fig. 3.2) excluding that, at least in 
my experimental conditions, MT1-MMP was functioning as a self-convertase, as 
proposed by one group (Rozanov and Strongin, 2003).
When treatments affecting transport or processing are applied such as the 
fungal toxin Brefeldin A (BFA), the 65 kDa form becomes dominant (Fig. 3.3). 
BFA treatment leads to intermixing between the endoplasmic reticulum and the 
Golgi apparatus and blocks exit from the Golgi apparatus itself (Fujiwara et al., 
1988; Lippincott-Schwartz et al., 1989). Proteins normally in transit through the 
endoplasmic reticulum and the Golgi apparatus would thus be over modified by 
different enzymes enriched in those compartments (e.g. glycosyltransferases), due 
to an increased exposure. For this reason, the 65 kDa form, previously observed 
(Maquoi et al., 1998; Yana and Weiss, 2000), has been proposed to be a post- 
translationally highly modified unprocessed immature form (Maquoi et al., 1998). 
To test this directly, I performed a deglycosylation assay using A-glycosidase F, 
which removes glycosylations aspecifically. After a 20 hours treatment of the cell 
lysates at 37°C in a sodium phosphate buffer, I verified no changes in the steady- 
state biochemical pattern of MT1-MMP if compared to the hyper-glycosylated 
human a  1-antitrypsin mutant, al-PD X , used here only as
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Fig. 3.2. Tim e-course analysis of MT1-MMP processing. MT1-MMP- 
transfected A375 cells were pulse-labeled with [3:>S]methionine/cysteine for 5 
minutes and chased for the indicated times. Where indicated, transfected cells 
were preincubated with 5 pM BB94 overnight and throughout the chase and 
immunoprecipitated with anti-MTl-MMP antiserum MMR2. 
Immunoprecipitates in A and B were subjected to SDS-PAGE, transferred to 
nitrocellulose membrane and visualized by autoradiography. The black 
arrowheads mark the positions of the MT1-MMP forms detected: calculated 
molecular weights are, respectively, 65, 63 and 60 kDa. The white arrowhead 
marks an unspecific band visible in all lanes. The positions of molecular 
weight standards are indicated on the right.
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Fig. 3.3. Biochemical characterization of the 65 kDa M T1-M MP form.
Untransfected (NT), MTl-MMP-transfected (MT1) and al-PDX-transfected 
(al-PD X ) A375 cells were lysed in a sodium phosphate buffer and processed, 
where indicated, with TV-glycosidase F at 37°C for an overnight incubation, as 
described in Materials and Methods. Cell lysates were then subjected to SDS- 
PAGE, transferred to nitrocellulose membrane and visualized by Western 
blotting with an immuno-purified rabbit polyclonal anti-MTl-MMP antibody 
(M3927) or with a rabbit polyclonal antiserum raised against human a l- 
antitrypsin (Dako, Denmark). Where indicated, MTl-MMP-transfected cells 
were treated with 2.5 pg/ml BFA for 2 hours before lysis. The black arrowhead 
marks the positions of the 65 kDa MT1-MMP form detected upon BFA 
treatment. The asterisks mark differently glycosilated specific bands detected 
for al-PD X . The positions of molecular weight standards are indicated on the 
right.
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a positive control. This is taken to indicate that the BFA-sensitive upper band is 
not hyper-glycosylated (Fig. 3.3). I have not further characterized this protein 
band as it is beyond the scope of my thesis.
Both endogenous and overexpressed MT1-MMP has been recently 
described to be partially located in detergent-resistant membranes (Annabi et al., 
2001). Insolubility in detergents is typical of glycolipid-rich domains, also 
referred to as “lipid rafts” (Simons and Ehehalt, 2002). It was thus possible that 
two populations of MT1-MMP, one associated with insoluble and the other with 
soluble membrane fractions, could coexist in transfected A375 cells and explain 
its peculiar processing pattern. I tested the Triton X-100 solubility of MT1-MMP 
in total membrane preparations from M Tl-MMP-transfected A375 melanoma 
cells and found that the majority of MT1-MMP (at least 70-80%) was Triton X- 
100-insoluble (P) and unprocessed (see 63 kDa band; Fig. 3.4). To exclude the 
possibility that insolubility was due to association with cytoskeletal elements or to 
the formation of non-specific protein aggregates, I further verified the distribution 
of MT1-MMP on an Optiprep-density gradient as described in Materials and 
Methods. I found that the majority of the 63 kDa proMTl-MMP floated towards 
the top of the gradient (Fig. 3.5 A), confirming that this population of proM Tl- 
MMP was associated with authentic detergent-insoluble membranes. The assay 
was validated by testing the distribution of caveolin-1, a bona-fide marker for raft- 
type membrane domains, and which co-fractionated with proMTl-MMP (Fig. 3.5 
B). Again, only the unprocessed 63 kDa proMTl-MMP was detected in the DRM- 
enriched fraction (lane 5 in Fig. 3.5 A).
3.2.2 Divergent processing of MT1-MMP depending on its
partitioning in different membrane subdomains
The above data suggested the possibility that differential MT1-MMP 
processing was connected to its partitioning in different membrane subdomains.
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Fig. 3.4. M T1-M MP localization in detergent-resistant m em branes 
(DRM). MT1-MMP transfected A375 cells were lysed with 1% Triton X-100- 
containing TNE buffer, as described in Materials and Methods. Insoluble (P) 
and soluble (S) fractions were separated by ultracentrifugation at 4°C (120,000 
x g, 1 hour), resuspended in sample buffer and subjected to SDS-PAGE, 
transferred to nitrocellulose membrane and visualized by Western blotting with 
the MMR2 antibody. The amount of 63 kDa form in each fraction was 
determined with Fuji BAS software and plotted in the bar chart.
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Fig. 3.5. M T1-M M P localization in low-density O ptiprep-gradient 
fractions from A375 melanoma cells. (A) MTl-MMP-transfected A375 cells 
were labeled with [35S]methionine/cysteine for 2 hours and lysed with a 1% 
Triton X -100-containing buffer, as described in Materials and Methods. 
Lysates were fractionated on a discontinuous Optiprep-density gradient, as 
reported in the scheme on the bottom. MT1-MMP immunoprecipitates from 
each fraction and a sample of the initial preparation (Inp) were subjected to 
SDS-PAGE, transferred to nitrocellulose membrane and visualized by 
autoradiography. The amount of 63 kDa form in each fraction was determined 
with Fuji BAS software and plotted graphically. (B) A small sample o f each 
fraction was tested by Western blotting with a polyclonal anti-caveolin-1 
antibody as a bona-fide marker for the DRM preparation.
113
To test this hypothesis, MTl-MMP-transfected cells were pulse-labeled 
with [35S]methionine/cysteine for 5 minutes and, after different chase times, lysed 
with 1% Triton X-100. Soluble (S) and insoluble (P) fractions were separated by 
ultracentrifugation and immunoprecipitated with polyclonal antibody MMR2 (Fig. 
3.6). The detergent-soluble 63 kDa proMTl-MMP fraction is rapidly processed to 
the mature form within 20 minutes and, after 60 minutes, is greatly reduced (see 
lanes S in Fig. 3.6). As a whole, the soluble MT1-MMP pool undergoes a rapid 
turnover (Fig. 3.6) and the mature MT1-MMP pool is degraded starting from 2 
hours (Fig. 3.2); DRM-associated proMTl-MMP, instead, is stable and remains 
unprocessed even after a 2 hour-long chase (Fig. 3.2). This indicates that only the 
detergent-soluble pool of MT1-MMP undergoes m aturation and rapid 
degradation; DRM-associated proM Tl-MM P is, on the other hand, completely 
excluded from processing and is quite stable over time.
3.2.3 Characterization of MT1-MMP association with detergent-
resistant membranes
Cholesterol is a crucial structural component of lipid rafts and is enriched 
in DRM (Brown, 1993; Simons and Ikonen, 1997). To directly demonstrate the 
involvement of cholesterol, I decided to analyse Triton X-100 insolubility of 
MT1-MMP in cholesterol-depleted membranes by using methyl-(3-cyclodextrin 
(mCD), previously described as a powerful tool for extracting cholesterol from 
biological membranes (Klein et al., 1995). At least in my experimental conditions, 
however, mCD does not seem to affect MT1-MMP partitioning in different 
membrane fractions extracted from MTl-MMP-transfected A375 cells (Fig. 3.7). 
It must be noted that mCD treatment was performed acutely on M Tl-M M P- 
transfected A375 cells and then MT1-MMP was analysed by performing 
immunoblotting analysis at steady-state. This is neither the most sensitive nor the 
sole approach to detect possible changes in the partitioning of a protein in
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Fig. 3.6. Time-course analysis of M T1-M M P processing in A375 melanoma 
cells and association with different m em brane fractions. Untransfected (NT) 
and MTl-MMP-transfected A375 cells were pulse-labeled with 
pS]methionine/cysteine for 5 minutes and, after the indicated chase times, 
incubated with TNE containing 1% Triton X-100 on ice. Soluble (S) and insoluble 
(P) fractions were separated by ultracentrifugation, immunoprecipitated with 
polyclonal anti-MTl-MMP antiserum MMR2, subjected to SDS-PAGE, 
transferred to nitrocellulose membrane and visualized by autoradiography. The 
bar chart shows the distribution in time of immature and mature MT1-MMP and 
association with different membrane fractions as determined with the Fuji BAS 
software.
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Fig. 3.7. Cyclo-p-methyldextrin does not affect M T1-M MP partitioning 
within different m em brane fractions. Untransfected (NT) and MTl-MMP- 
transfected A375 cells were treated, where indicated, with 10 mM cyclo-p- 
methyldextrin (mCD) for 60 min at 37°C, as described in Materials and 
Methods. Cells were then lysed with 1% Triton X-100-containing TNE buffer, 
as described in Materials and Methods. Insoluble (P) and soluble (S) fractions 
were separated by ultracentrifugation at 4°C (120,000 x g, 1 hour), 
resuspended in sample buffer and subjected to SDS-PAGE, transferred to 
nitrocellulose membrane and visualized by Western blotting with the MMR2 
antibody. A small amount of total lysates (T) were also loaded. The effect of 
cyclo-P-methyldextrin on A375 cells was monitored by phase-contrast 
microscopy.
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cholesterol-rich membranes; other biophysical conditions might confer detergent 
insolubility to MT1-MMP; for instance, oligomerization of MT1-MMP itself 
(Lehti et al., 2002) or MT1-MMP recruitment by other proteins, such as caveolin- 
1, that can bind tightly to cholesterol (Murata et al., 1995). In this context, the 
question of whether or not the MT1-MMP pool associated with detergent-resistant 
membranes is indeed located within “canonical” lipid rafts might have important 
implications with regard to the mechanisms involved in the regulation of its 
activity. For this reason, I pulsed M Tl-M M P-transfected A375 cells with 
[35S]methionine/cysteine for 5 minutes (instead of 2 hours as in Fig. 3.5), and I 
placed the membrane extracts at the bottom of a discontinuous Optiprep gradient 
to verify whether this newly synthesized MT1-MMP floats to the top of the 
gradient. Figure 3.8 shows that, in this case, the snap-pulsed proM Tl-MM P pool 
is mainly associated with the high-density fractions, although a small proportion is 
already associated with detergent-insoluble membranes (see Fig. 3.6).
Insolubility in Triton X-100 is a characteristic of “detergent-resistant 
membranes” (DRM), of which “lipid rafts”, defined as low-density structures 
enriched in cholesterol and sphingolipids, can be considered only a subclass 
(Helms and Zurzolo, 2004). In the specific case of MT1-MMP, DRM association 
seems to occur early and soon after protein synthesis within the endoplasmic 
reticulum and prior to the enrichment in esterified lipids within the Golgi stacks, a 
general indicator for lipid raft maturation (Khelef et al., 2000). Subsequent lipid 
enrichment would be correlated with MT1-MMP flotation within low-density 
Optiprep fractions. These data would be consistent with recent evidence that 
association of glycosylphosphatidylinositol (GPI)-anchored proteins with “lipid- 
enriched” DRM occurs concomitantly with their oligomerization within the trans- 
Golgi network (Paladino et al., 2004). This speculation is discussed with details 
later (see section 3.3.2).
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Fig. 3.8. Biochemical characterization of proM Tl-M M P association with
DRM. MTl-MMP-transfected A375 cells were labeled with 
[33S]methionine/cysteine for 5 min and 2 hrs, as indicated, and lysed with a 1% 
Triton X-100-containing buffer, as described in Materials and Methods. 
Lysates were fractionated on a discontinuous Optiprep-density gradient, as in 
Fig. 3.5. MT1-MMP described immunoprecipitates from each fraction and a 
sample of the initial preparation (Inp) were subjected to SDS-PAGE, 
transferred to nitrocellulose membrane and visualized by autoradiography. The 
normalized amount of 63 kDa form in each fraction was determined with Fuji 
BAS software, expressed as arbritary units (A.U.) and plotted graphically in 
grey (5 min) and black (2 hrs).
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3.2.4 Functional role o f different MT1-MMP forms in ECM
degradation
Overexpression of MT1-MMP in A375 cells led to, as expected, a 
massive degradation of cross-linked fluorescent gelatin. When monitored in vivo 
through the use of a GFP-tagged MT1-MMP chimera (which produces the same 
phenotype as wild-type MT1-MMP), this appeared to be an extremely rapid 
process (see time-lapse series in Fig. 3.9). The question thus arises as to which 
molecular forms and populations of MT1-MMP are responsible for this biological 
activity. A number of experiments were thus performed to better understand the 
processing of MT1-MMP and define the molecular form(s) responsible for the 
biological activity, a controversial issue in the field.
To interfere with proMTl-MMP processing, I decided to use the serpin- 
like protein a l-P D X , a bioengineered a  1-antitrypsin characterized as an 
extremely specific endocellular inhibitor of the pro-protein convertases furin and 
PC6 (Jean et al., 1998): expression of al-PD X  completely abated MT1-MMP- 
induced gelatin degradation by A375 cells (Fig. 3.10). Gelatin degradation relies 
on cell surface presentation of enzymatically active MT1-MMP; I thus verified 
the presence and membrane partitioning of MT1-MMP at the plasma membrane 
whether or not proMTl-MMP processing is inhibited by al-PD X . To this end, I 
performed biotinylation of surface proteins, as described in the material and 
methods section. Surface proteins were biotinylated on ice (to block all membrane 
trafficking events) and then probed by Western blotting analysis of the different 
membrane fractions (detergent-resistant vs. detergent-soluble) and cellular 
locations (intracellular vs. surface). I observed that, at steady state, the vast 
majority of MT1-MMP was intracellular, immature and associated with DRM 
(Fig. 3.11). Although total plasma membrane MT1-MMP levels were relatively 
low, probably because surface biotinylation is not very efficient, DRM-associated 
proMTl-MMP remained the dominant fraction over non-DRM proMTl-MMP.
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Fig. 3.9. Time-lapse series of gelatin degradation by A375 melanoma cells 
transfected with GFP-tagged MT1-MMP. Cells were cultured in glass 
bottom microwell dishes (Mattek, Ashland, MA, USA) coated with 
rhodamine-conjugated gelatin in the presence of 5 pM BB94 to block MMP 
activity. After 16 hours, cells were washed 3 times to remove BB94 and 
incubated in DMEM/F12 containing 20 mM HEPES pH 7.4 on a multiphoton 
microscope (Till photonics, Germany) fitted with a CCD camera. Images were 
acquired at 1 frame/minute for 1.5 hours. Representative images are shown 
here with indicated times. This experiment was performed in collaboration 
with Massimiliano Baldassarre (Consorzio Mario Negri Sud).
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Fig. 3.10. a l-P D X  blocks gelatin degradation in M Tl-M M P-transfected 
A375 melanoma cells. A375 cells transfected with MT1-MMP and pcDNA 
3.0 (MT1) or MT1-MMP and FLAG-tagged al-PD X  (M Tl/al-PD X ) were 
cultured on surfaces coated with rhodamine-conjugated gelatin. After 16 hours 
of incubation, cells were fixed and labeled with specific primary antibodies: 
polyclonal immunopurified anti-MTl-MMP antibody MMR2 (MT1) and 
monoclonal anti-FLAG antibody M2 (al-PDX). Degradation of the underlying 
fluorescent gelatin by the MTl-MMP/pcDNA3.0 and M Tl-M M P/al-PDX 
cotransfectants is shown (Gelatin). Merged staining (MTl-MMP/Gelatin) for 
the MTl-MMP/pcDNA3.0 cotransfectants is also shown. Transfected cells 
were visualized by wide-field fluorescence microscopy and acquired images 
were deconvoluted as described in Materials and Methods. The graph is a 
quantification of the average degradation area per single cell as determined 
using with NIH ImageJ 1.32 software and expressed in arbitrary units. Scale 
bars: 20 pm.
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Fig. 3.11. a l-P D X  blocks proM Tl-M M P processing bu t does not affect 
cell surface presentation of DRM-associated proM Tl-M M P. (A) Steady- 
state distribution profile of MT1-MMP in A375 melanoma cells: A375 cells 
transfected with MT1-MMP and pcDNA3.0 or MT1-MMP and al-P D X  were 
biotinylated and incubated with TNE containing 1% Triton X-100 on ice. 
Soluble (S) and insoluble (P) fractions were separated by ultracentrifugation. 
Intracellular fractions (Int) were separated from plasma membrane fractions 
(PM) by capturing the biotinylated proteins with streptavidin-conjugated 
agarose beads. Each fraction was subjected to SDS-PAGE and transferred on 
nitrocellulose membrane. The MT1-MMP distribution profile was analyzed 
with immunopurified polyclonal anti-MTl-MMP antibody MMR2. The empty 
arrowheads mark the positions of the pro- and mature (63 and 60 kDa) forms 
in the MTl-MMP/pcDNA cotransfectants, the black arrowheads indicate the 
65 and 63 kDa immature forms in the M Tl-M M P/al-PDX cotransfectants. 
Staining for caveolin-1 in the same experiment is reported as a bona-fide 
marker for the DRM preparation. (B) The graph shows the steady-state 
distribution profile of proMTl-MMP within different membrane fractions: 
soluble (S), insoluble (P), intracellular (Int) and plasma membrane fractions 
(PM). The values were determined with the NIH image software.
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This evidence also implies that mature 60 kDa MT1-MMP, shown here 
to be associated with the detergent-soluble membranes, is rapidly removed from 
the cell surface after presentation. This is in good agreement with the rapid 
turnover of MT1-MMP as verified in our pulse-chase analysis (see Fig. 3.6).
I then proceeded to analyze the effect of furin inhibition on MT1-MMP 
partitioning at the plasma membrane: although co-expression with al-PD X  totally 
inhibited the proteolytic processing of detergent-soluble MT1-MMP (Fig. 3.10), 
proMTl-MMP was still present at the plasma membrane (Fig. 3.11). Interestingly, 
in these conditions an increase of the 65 kDa unprocessed form of MT1-MMP 
was observed. As noted above, this has been previously reported (Maquoi et al., 
1998; Yana and Weiss, 2000) and also occurs when treatments affecting transport 
or processing are applied such as Brefeldin A (see Fig. 3.3).
In conclusion, these results clearly indicate that: 1) only the detergent 
soluble proM Tl-MM P fraction is processed to the mature 60 kDa form; 2) this 
fully processed MT1-MMP alone is responsible for gelatinolytic activity; 3) the 
processing enzyme is most likely furin or a furin-like convertase as previously 
suggested and 4) removal of the propeptide domain is not a prerequisite for arrival 
of M T1 -MMP at the plasma membrane.
3.2.5 Furin is excluded from DRM
My data indicates that furin, the MT1-MMP activating enzyme, is unable 
to process DRM-associated MT1-MMP which, as a result, reaches the plasma 
membrane in its 63 kDa immature form. A possible explanation for the inability 
of furin to activate the large fraction of DRM-associated MT1-MMP could be that 
they are physically segregated during transport and thus unable to interact. To test 
this, I examined the membrane partitioning of a GFP-tagged furin chimera by 
transient co-transfection with MT1-MMP. As shown in Fig. 3.12 A, despite the 
increased cellular burden due to overexpression, furinGFP, in contrast to MT1- 
MMP, was exclusively associated with the detergent-soluble membrane fraction.
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Fig. 3.12. Furin is excluded from detergent-resistant mem branes. (A)
Untransfected (NT) and Furin-GFP-transfected (FUR) A375 cells were 
labeled with [35S]methionine/cysteine for 2 hours and lysed with TNE buffer 
containing 1% Triton X-100 on ice. Soluble (S) and insoluble (P) fractions 
were separated by ultracentrifugation, immunoprecipitated with a polyclonal 
anti-GFP antibody and analyzed by SDS-PAGE/autoradiography. (B) A3 75 
cells transfected with MT1-MMP (MT1-MMP) or with MT1-MMP and 
Furin-GFP (MT1+FUR) were labeled with [35S]methionine/cysteine for 2 
hours and lysed with TNE containing 1% Triton X-100 on ice. Soluble 
fractions were collected after ultracentrifugation, immunoprecipitated with 
polyclonal anti-MTl-MMP antiserum MMR2 and analyzed by SDS- 
PAGE/autoradiography. The processing ratio of MT1-MMP (MT1- 
MMP/MTl-MMP+proMTl-MMP) was determined with the Fuji BAS 
software and plotted graphically.
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GFP chimeras have been extensively used to study membrane partitioning of 
diverse proteins with no reported alterations in normal profiles (Rodgers, 2002). 
Furtherm ore, in my experimental system, the furin-G FP chim era was 
enzymatically active as its expression clearly increased the extent of MT1-MMP 
maturation (Fig. 3.12 B).
Taken together, these results further confirm that partitioning of MT1- 
MMP into different membrane sub-domains regulates its processing and 
biological activities. This also supports the notion that differential partitioning 
into DRM reflects an intrinsic property of MT1-MMP similarly to the Alzheimer 
precursor protein (Ehehalt et al., 2003).
3.2.6 Functional role of different MT1-MMP forms in MMP-2 
activation
3.2.6.1 Background
I have thus far described experiments in A375 melanoma cells revealing 
that MT1-MMP undergoes biochemical processing only if associated with non­
detergent-resistant membrane fractions. I was also able to confer a functional 
meaning to this soluble processed MT1-MMP form: it is catalytically active and 
responsible for gelatin degradation.
A375 melanoma cells, selected as a model cell system, normally present 
a basal MMP-dependent degradation only in complete medium; this is probably 
dependent on the basal activation of soluble MMPs (e.g. MMP-2) present in the 
serum. Overexpression of MT1-MMP directly confers to these cells an extremely 
aggressive gelatin degradation ability with or without serum, as verified by in 
vitro gelatin degradation assays (see introduction). This activity can be totally 
inhibited upon overexpression of a l-P D X , a selective furin inhibitor, as a 
consequence of the total inhibition of proM Tl-MM P processing (see Fig. 3.10).
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Therefore, my data bring further evidence that furin is a key factor in the 
maturation of MMPs associated with the invasive and metastatic potential of 
tumor cells, as reported in literature (Maquoi et al., 1998; Yana and Weiss, 2000). 
This scenario, however, could be more complicated depending on both the 
specific protein expression profiles of the tumor cells used and the extracellular 
environment tested.
MT1-MMP was initially reported to be expressed in carcinoma cells in 
addition to the adjacent fibroblasts, and to act as a specific activator of immature 
MMP-2 (also called proMMP-2) (Sato et al., 1994). The M T1-MMP/MMP-2 
system is important for tumor cells to invade the basement membrane by 
degrading type IV collagen, a preferred MMP-2 substrate, and then the stroma by 
degrading type I collagen, a preferred MT1-MMP substrate (Stetler-Stevenson et 
al., 1993). To activate proMMP-2 on the cell surface, at least two molecules of 
MT1-MMP must be in close proximity. This is achieved by the formation of a 
homophilic MT1-MMP complex through interactions between their haemopexin- 
like domains (see Fig. 1.10, Introduction). One of the enzymes in the complex 
binds to TIMP-2 to form an enzyme-inhibitor complex. The exposed TIMP-2 C- 
terminal domain then binds to the proMMP-2 haemopexin-like domain, 
positioning proMMP-2 optimally for activation by the other active MT1-MMP 
molecule. This activation is thought to be a two-step process: the first one, 
involving MT1-MMP catalytic activity, generates the intermediate form (64 kDa), 
and the second one, due to an intermolecular autocatalytic reaction or to 
extracellular factors (e.g. plasmin), results in the formation to the mature form (62 
kDa) (Baramova et al., 1997).
High levels of MT1-MMP expression and MMP-2 activation in tumors 
correlate with a highly invasive phenotype. However, carcinoma cells in tissue 
and cancer cell lines, such as A375 melanoma cells, rarely express MMP-2 at high 
levels, even though they can activate MMP-2 derived from the surrounding 
fibroblasts by using cell-surface MT1-MMP. This implies that, unless one uses
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co-culture systems, experimental conditions can be very different depending on 
MMP levels expressed by the cells analyzed. HT1080 fibrosarcoma cells are a 
good model cell system to study the regulation of MTl-MMP-dependent MMP-2 
activation because they express high levels of both MT1-MMP and MMP-2.
In this context, I decided to understand the role of different MT1-MMP 
forms on activation of MMP-2 by promoting or inhibiting MT1-MMP processing 
and activity in HT1080 fibrosarcoma cells. MT1-MMP overexpression on the cell 
surface of HT1080 promotes activation of proMMP-2 in vitro and enhances 
cellular invasion of the reconstituted basement membrane (Sato et al., 1994). For 
this purpose, I set up and used gelatin zymographic methods. These are designed 
to analyze the proteolytic capacity of latent and active soluble MMPs (Heussen 
and Dowdle, 1980), as described in Materials and Methods.
3.2.6.2 Effect of MT1-MMP overexpression on MMP-2 activation in HT1080 
fibrosarcoma cells
Fig. 3.13 A shows an immunoprecipitation assay from MT1-MMP- 
transfected HT1080 cells, pulse-labelled with [35S]methionine/cysteine for 2h. 
Upon these experimental conditions, the total amount of the 60 kDa form of MT1- 
MMP is reduced compared to non-transfected HT1080 cells, and the 63 kDa form 
is accumulated in both Triton X-100-soluble (S) and insoluble (P) membrane 
fraction.
This evidence was unexpected because I have verified that, although 
basal degradation of gelatin is somewhat increased, MT1-MMP overexpression 
nevertheless confers a destructive gelatin degradation phenotype in HT1080 
similarly to A375 cells (Fig. 3.14). In addition, previous data in MT1-MMP- 
transfected A375 cells showed that gelatin degradation is only due the 60 kDa 
form (see Fig. 3.10). On the other hand, HT1080 fibrosarcoma cells do show 
different biological features from A375 melanoma cells; in HT1080, the basal 
expression of MT1-MMP and MMP-2 is relatively higher. Hence, a possible
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Fig. 3.13. Effect of M T1-M M P overexpression in HT1080 fibrosarcom a 
cells on M T1-M MP processing and MMP2 activation. (A) Non-transfected 
(NT) and MTl-MMP-trasfected (MT1) HT1080 cells were pulsed for 2 hours 
with [35S]methionine/cysteine and incubated with 1% Triton-X-100 at 4°C. 
Soluble (S) and insoluble (P) fractions were separated by ultracentrifugation, 
immunoprecipitated with MMR2 antibody and analyzed by SDS-PAGE, as 
described in Materials and Methods. (B) ProMMP2 activation analysis of 
conditioned media from non-transfected (NT), pcDNA3.0-transfected (Mock) 
and MTl-MMP-transfected (MT1) HT1080 cells. A small amount o f 
recombinant proMMP2 (purchased from Sigma-Aldrich, WI, USA) was also 
loaded as a molecular weight marker (r-proMMP2). Zymogram analysis was 
performed as described in Materials and Methods. Samples were resuspended 
in sample buffer without reducing agent and applied without boiling to 10% 
SDS-PAGE gels containing 1 mg/ml gelatin. The black arrows mark the 
positions of the MMP2 forms detected: calculated molecular weights are, 
respectively, 72, 64 and 62 kDa.
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Fig. 3.14. M T1-M MP overexpression in HT1080 fibrosarcom a cells is 
responsible for a widespread gelatin degradation. Non-transfected (a) and 
MTl-MMP-transfected (d) HT1080 fibrosarcoma cells were cultured on 
coverslips coated with FITC-labeled gelatin (b, e). After 16 h of incubation, 
cells were fixed, labeled with polyclonal immunopurifled anti-MTl-MMP 
antibody MMR2 and visualized by wide-field fluorescence microscopy. A 
merge section is also shown (c, f).
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explanation for this unexpected phenotype could be the contribution of active 
MMP-2 to gelatin degradation. In fact, when I performed a zymographic analysis 
from MTl-MMP-transfected HT1080 conditioned media, I found that a very high 
fraction of MMP-2 is present in its 62 kDa active form (Fig. 3. 13 B).
The possible interpretation of this set of data is that, in HT1080 
fibrosarcoma cells, MT1-MMP overexpression is responsible for an unexpected 
accumulation of its immature 63 kDa form in different membrane fractions. This 
accumulation might be due to the saturation of the molecular machineries 
involved with MT1-MMP processing and seems to be correlated with a stronger 
gelatinolytic activity as well as higher MMP-2 activation levels.
3.2.6.3 Effect of furin inhibitor ai-PDX and catalitically inactive MT1-MMP 
mutant (E240A) on MMP-2 activation in MT1-MMP overexpressing HT1080 
cells
As discussed above, the accumulation of proM Tl-M M P in HT1080 is 
associated with increased MMP-2 activation. To understand how this activation is 
related to the catalytic activities of MT1-MMP, I analysed activation pattern of 
MMP-2 from HT1080 cells co-transfected with MT1-MMP and a l-P D X . Fig. 
3.15 shows that a l-P D X  overexpression interferes only with the second step of 
proMMP-2 activation: the conversion of the intermediate 64 kDa form, generated 
upon proMTl-MMP accumulation, into a 62 kDa form. This result is at variance 
with previously published evidence that in HT1080 cells MT1-MMP catalytic 
activity involved only in the first step of proMMP-2 activation, while the second 
step relies on the extracellular plasminogen activator/plasmin system (Baramova 
et al., 1997). O f note, a similar phenotype was also produced when I 
overexpressed the catalytically inactive MT1-MMP mutant (E240A): proMMP-2 
was converted to its intermediate 64 kDa form without a significant maturation to 
its 62 kDa form (Fig. 3.15).
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Fig. 3.15. M olecular characterization of MMP2 processing in HT1080 
fibrosarcom a cells. Media conditioned by HT1080 cells transfected with 
MT1-MMP (MTI), cotransfected with MT1-MMP and a l-P D X  (MT1/PDX) 
or catalitically inactive MT1-MMP mutant (E240A) were collected and 
concentrated by centrifugation. Samples were resuspended in sample buffer 
without reducing agent and applied without boiling to 10% SDS-PAGE gels 
containing 1 mg/ml gelatin. The black arrows mark the positions of the MMP2 
forms detected: calculated molecular weights are, respectively, 72, 64 and 62 
kDa.
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As reported above, plasma membrane proMMP-2 activation is generally 
thought to be a two-step process: the first one, involving MT1-MMP catalytic 
activity, generates the intermediate form (64 kDa), and the second one, due to an 
intermolecular autocatalytic reaction or to extracellular factors (e.g. plasmin), 
results in the formation of mature MMP-2 (Baramova et al., 1997).
I have shown here that only this second step seems to be partially 
inhibited when the catalitically inactive mutant (E240A) is overexpressed and 
fully blocked when MT1-MMP is cotransfected with a l-PD X . Taken together, 
these results suggest that the immature MT1-MMP form (63 kDa) would promote 
the first step of MMP-2 activation and the catalytically active MT1-MMP form 
(60 kDa) would be required in the second one.
3.3 Discussion
3.3.1 Molecular and functional significance of MT1-MMP processing
depending on its membrane partitioning
In MTl-MMP-transfected A375 melanoma cells, the majority of MT1- 
MMP is associated with DRM in accord with previous reports (Annabi et al., 
2001; Annabi et al., 2004). In contrast, it was recently reported that a MT1-MMP 
deletion mutant lacking the cytosolic C-terminal tail, but not the full-length 
protein, is stably partitioned into DRM (Rozanov et al., 2004a). I extended these 
findings by analyzing the relationship between proteolytic processing and 
membrane subdomain association. I found that MT1-MMP undergoes proteolytic 
processing only if associated with detergent-soluble membranes. The mature 60 
kDa form is catalytically active, directly involved with gelatin degradation and 
rapidly processed. On the other hand, the immature 63 kDa form remains stably 
associated with DRM-enriched membranes and persists following the processing 
of the detergent-soluble proMTl-MMP and its degradation. In other words, the
132
metabolic fate and thus the activity of MT1-MMP is directly dependent on its 
differential association with the two membrane subdomains. A first consequence 
is that two cellular and possibly functionally distinct pools of MT1-MMP can thus 
be defined: one that is normally and completely processed and thus available for 
ECM degradation and/or other proteolytic activities, a second, whose function 
remains to be better understood, that is however potentially available at the 
plasma membrane for interactions with other molecules. A second consequence is 
that this phenomenon, if undetected (depending on the experimental procedures 
used), could have generated some discrepancies in the interpretation of MT1- 
MMP processing. The biochemical analysis of MT1-MMP processing was mainly 
performed from total cell lysates (Cao et al., 1996; Yana and Weiss, 2000): 
detection of mature MT1-MMP is experimentally not easy depending on both the 
antibodies used and the preparation of cell lysates (see Fig. 3.1 A).
Most recently MT1-MMP was found in DRM and thus suggested to be 
associated with caveolin-1 (Annabi et al., 2001); also, it was recently 
hypothesized that MT1-MMP is internalized via caveolae in addition to the 
clathrin-mediated pathway (Remade et al., 2003). In my experiments, I did not 
find morphological evidence of MT1-MMP association to caveolae-like domains 
(see Chapter 4). This is not incongruous since caveolae represent only a 
subpopulation of the total DRM-fraction and can actually be separately isolated 
from them (Schnitzer et al., 1995).
3.3.2 Characterization of MT1-MMP association with detergent-
resistant membranes
In contrast to GPI-anchored proteins, which use their GPI anchor to 
associate with lipid rafts, the ability of the MT1-MMP molecule to promote the 
formation of “lipid-enriched” DRM might be not only encoded in protein 
structure but might also be a consequence of protein oligom erization.
133
Interestingly, sequence alignment analysis of MT1-MMP resulted in close 
matches to aromatic-rich consensus caveolin-binding motifs (FXFXXXF, 
FXXXXFXXF or FXFXXXXFXXF, where F represents Trp, Phe or Tyr), 
reported to interact with the caveolin-scaffolding domain (Couet et al., 1997). 
Four of these potential sequences were found in several members of the MMP 
family and were all located in their haemopexin-like domain, a region known to 
have a functional role in substrate binding and/or in interactions with TIMPs 
(Massova et al., 1998). The most conserved caveolin-binding motif found in 
MTI-MMP was found in its haemopexin-like domain and was located between 
Tyr323 and Phe333 (YFFRGNKYYRF), whereas the three other less well 
conserved sequences were also found in the haemopexin-like domain and were 
located respectively between Phe229 and Phe236, Phe277 and Phe285, and Tyr371 
and Phe381. Interestingly, all of the four caveolin-binding motifs were located at 
each of the putative antiparallel four-stranded p sheets within the hydrophobic 
core of the proposed topology of the haemopexin-like domain of MMPs (Gohlke 
et al., 1996). The most likely candidate for membrane targeting is thus the 
haemopexin-like region of MTI-MMP close to the membrane which might allow 
partitioning into a lipid-rich environment, either by its physical properties by 
binding directly to a raft structural protein (Scheiffele et al., 1997).
Sorting determinants in MT1-MMP membrane partitioning could also 
reside in the cytoplasmic domain, membrane anchor or other extracellular 
domains. Cytoplasmic domain determinants include the basolateral-targeting, 
tyrosine-based and dileucine motifs (Matter et al., 1994), PDZ-domain-binding 
motifs and a growing list of unrelated sequences (Altschuler et al., 2003; Muth 
and Caplan, 2003). Of note, Strongin and coworkers analyzed a mutant MT1- 
MMP consisting of a deletion of the cytosolic domain, described to be essential 
for endocytic routes by binding adaptor proteins (Rozanov et al., 2004a): this 
mutant protein was still found to be highly enriched in DRM. This evidence 
would imply the role of intracellular adaptor proteins in regulating M TI-M M P
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membrane partitioning.
Determinants in membrane partitioning also include the transmembrane 
domains of some apically targeted viral proteins (Kundu et al., 1996) and GPI 
anchors. The latter usually confer localization to the apical membrane (Lisanti et 
al., 1989) but alone are not always sufficient (Brown and London, 2000). Both N- 
and 0-glycosylation of the extracellular domain have been implicated in apical 
targeting (Scheiffele et al., 1997).
From this discussion, it might be interesting not only to investigate, by 
using specific inhibitors, whether N- and D-glycans are involved in regulating 
DRM-association of M TI-M M P as well as its intracellular trafficking and 
processing but also whether the transmembrane domain or the cytosolic tail are 
somehow involved in MTI-MMP membrane partitioning.
3.3.3 DRM-associated proMTl-MMP
At steady state, I observed transfected proM Tl-M M P to be mainly 
associated with DRM, with a significant fraction residing at the plasma 
membrane. This suggests that: 1) intracellular removal of the propeptide domain 
is not a prerequisite for MTI-MMP cell surface presentation; 2) DRM-associated 
proM Tl-M M P is not subject to intracellular furin-dependent activation and 3) 
proM Tl-M M P is not directly functioning as a gelatinase. A possible 
mechanicistical explanation is provided by my observation that furin is excluded 
from detergent-resistant membranes. In fact, physical interaction between proteins 
associated with different membrane subdomains is extremely unlikely, as recently 
suggested for other proteins (Ehehalt et al., 2003). In this context, colocalization 
of furin and MTI-MMP in common structures (see Chapter 4), supports the idea 
that detergent soluble and resistant M TI-MM P pools might coexist albeit not 
necessarily interact. This suggests that partitioning of M TI-MM P into different 
lipid subdomains could be a mechanism for the regulation of its processing and 
activity similarly to the Alzheimer precursor protein (Ehehalt et al., 2003).
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In this chapter, I reported several experiments performed in HT1080 
fibrosarcoma cells revealing the differential role of immature and mature MT1- 
MMP forms in MMP-2 activation. Although it is not definitively demonstrated, I 
could speculate that the DRM-associated pool of MT1-MMP is somehow 
responsible for the regulation of MMP-2 activation and is involved in the stable 
presentation of proMMP-2 at the plasma membrane. DRM-associated proM Tl- 
MMP could also be a reservoir of yet to be defined activities (e.g signaling events, 
MMP-2 activation). Interestingly, it was recently proposed that the cholesterol 
content of tumor cells is critical for the regulation of M TI-MM P cell surface 
presentation and MMP-2 activation (Atkinson et al., 2004). Again, although the 
role of DRM-associated proM Tl-M M P is still obscure, this pool could be 
potentially available for extracellular interactions, since it seems to be stably 
expressed over the plasma membrane. Of note, lipid raft domains represent a 
preferred platform for a number of signaling receptors; hence, DRM-associated 
proM Tl-M M P pool at the plasma membrane could be involved in signalling- 
related functions. A recent paper has indirectly identified a role for MTI-MMP, 
overexpressed in different cell lines, in the regulation of cell proliferation by 
affecting cyclin-dependent kinases (Hotary et al., 2003); this event could be in 
line with my proposed hypothesis that will be discussed in-depth in Chapter 5.
136
CHAPTER 4
Functional and Morphological 
Characterization of the Intracellular 
Activation Compartment of MT1-MMP
4.1 Introduction
The activation of proM Tl-MM P has been under intense debate. Some 
reports have suggested that proMTl-MMP has to be processed to activate MMP2 
(Cao et al., 1998; Deryugina et al., 2004; Pei and Weiss, 1996; Yana and Weiss, 
2000; Yu et al., 1997). At variance with this, others have reported that the full- 
length proM Tl-MM P could act as an active enzyme. Moreover, several groups 
have also found proMTl-MMP at the plasma membrane of different cell lines, 
adding weight to the proposition that the propeptide domain of M TI-M M P is 
required for the efficient trafficking of the enzyme to the cell surface (Cao et al., 
2000; Sato et al., 1994; Sternlicht and Werb, 2001), and that MT1-MMP 
activation would occur on the plasma membrane (Mayer et al., 2003). Still, the 
exact site of MTI-MMP activation remains obscure.
By investigating MTI-MMP processing and activation, I have found that 
the association of MTI-MMP with different membrane subdomains establishes 
divergent metabolic fates and might be crucial in the control of its different 
activities. In particular, I have shown that only the detergent-soluble fraction of 
M TI-M M P undergoes processing to the mature form in a furin-dependent 
manner. Only the mature form is catalytically active and directly responsible for 
ECM degradation. These data also demonstrate that the vast majority of MT1- 
MMP is indeed localized to the cell surface in its precursor form. This means that,
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although the propeptide domain does not interfere with MTI-MMP trafficking to 
the cell surface, it might have to be cleaved to allow activation.
Of note, recent data also show that furin and proMTl-MMP colocalize in 
the Golgi apparatus, in intracellular post-Golgi/endosomal structures as well as at 
the plasma membrane (Mayer et al., 2003). Thus, furin appears to be associated 
with M TI-MM P in the secretory pathway independently of the cleavage of the 
M TI-MMP propeptide domain. Indeed, this was directly confirmed for proMT3- 
MMP in MDCK cells (Kang et al., 2002). These results imply that, besides pro­
domain processing, furin could be involved in the trafficking of proproteins to the 
cell surface.
The definition of the M TI-M M P activation compartment and the 
characterization of the possible, not strictly enzymatic, interaction between furin 
and proMTl-MMP are the subjects of this chapter.
4.2 Results
4.2.1 Analysis of the subcellular localization of MT1-MMP
As mentioned above, the MTI-MMP processing compartment still needs 
to be defined. To address this issue, I first analyzed by indirect 
immunofluorescence light microscopy the subcellular distribution of MTI-MMP 
at steady state in A375 melanoma cells by using the immuno-purified polyclonal 
anti-M Tl-MM P antibody (MMR2): M TI-MM P presented a perinuclear patchy 
distribution with scattered cytoplasmic elements and plasma membrane staining 
(Fig. 4.1). Next, I compared the localization of M TI-MM P to markers of the 
secretory pathway. MT1-MMP showed no significant colocalization with 
endoplasmic reticulum (PDI, protein disulfide isomerase) and Golgi apparatus 
(Giantin) (4.1 C and F). Instead, when I tested an anti-TGN46 antibody in M Tl- 
MMP-transfected A375 cells, a patchy asymmetrical perinuclear distribution was
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Fig. 4.1. Subcellular distribution of M T1-M MP in A375 melanoma cells by 
immunofluorescence (I). A375 cells transfected with MTI-MMP were plated 
on coverlips for 16 hours, then fixed and analyzed at the confocal microscope 
as described in Material and Methods section. Cells were double-labeled with 
immunopurified polyclonal anti-MTl-MMP antibody MMR2 (A, D) and with 
monoclonal antibodies respectively directed against PDI (B), Giantin (E). 
Merged staining is also shown on the right (C, F). Scale bars: 10 pm.
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observed, with a high, albeit not complete, colocalization with MTI-MMP (Fig.
4.2 C); TGN46 is a protein known to cycle between the trans-Golgi network, the 
plasma membrane and the endosomal compartment, and although generally 
considered to be a trans-Golgi network marker, its actual distribution depends on 
the cell type (for a review, see Keller and Simons, 1997). In contrast, as bona fide 
early and late endosome markers, I tested the distribution of transferrin receptor (a 
plasma membrane-endosome recycling protein) and mannose-6-phosphate 
receptor (a TGN-endosome recycling protein) respectively, and found them to be 
only partially overlapping with MTI-MMP (Fig. 4.2 F and I, respectively).
In which of these compartments, therefore, does furin-dependent 
activation actually occur? My pulse-chase analysis showed that fully processed 
MTI-MMP appeared only after at least 20 minutes, suggesting that it might occur 
in a late station along the biosynthetic-secretory pathway (see Fig. 3.6). In 
addition, a furin-dependent proteolytic activation is not expected to occur before 
the trans-Golgi network (Molloy et al., 1999). Still, to formally rule out the 
possibility that MTI-MMP activation occurs in an early station of the secretory 
pathway, I took advantage of the properties of the fungal toxin Brefeldin A 
(BFA). Treatment with BFA leads to intermixing between the endoplasmic 
reticulum and the Golgi apparatus and blocks exit of a secretory cargo from the 
Golgi apparatus itself (Fujiwara et al., 1988; Lippincott-Schwartz et al., 1989). 
Upon BFA treatment, proteins normally present in the endoplasmic reticulum and 
the Golgi apparatus would still be modified by any processing enzymes contained 
in those compartments: even so, I observed no proteolytic processing of proM Tl- 
MMP (Fig. 4.3 A); moreover its cell surface presentation is strongly reduced (Fig.
4.3 B). Interestingly, the intracellular MT1-MMP pool does not follow the fate of 
the rest of the Golgi fusing into the ER upon short BFA treatment (Fig. 4.3 C), 
although it appears to be more tubulated if compared with the normal profile (see 
Fig. 4.1 D-F). Given that some intracellular compartments becomes more 
tubulated but resistant to BFA (TGN, lysosomes,
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Fig. 4.2. Subcellular distribution of MT1-MMP in A375 melanoma cells by 
immunofluorescence (II). A375 cells transfected with MTI-MMP and 
pcDNA3.0 (A-I) or MTI-MMP and Furin-GFP (J-L) were plated on coverlips 
for 16 hours, then fixed and analyzed at the confocal microscope. Cells were 
double-labeled with immunopurified polyclonal anti-MTl-MMP antibody 
MMR2 (A, D, G, J) and with antibodies directed against TGN46 (B), 
transferrin receptor (E) and mannose 6-phosphate receptor (H). Furin-GFP 
staining is shown in red (K). Merged staining is also shown (C, F, I, L). Scale 
bars: 10 pm.
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Fig. 4.3. Effect of BFA on M TI-M M P processing, cell surface presentation 
and intracellular distribution. (A) Untransfected (NT) and MTl-MMP- 
transfected A375 cells were lysed with 1% Triton X-100-containing TNE 
buffer, as described in Materials and Methods. Insoluble (P) and soluble (S) 
fractions were separated from total lysates (T) by ultracentrifugation at 4°C 
(120,000 x g, 1 hour), resuspended in sample buffer and subjected to SDS- 
PAGE, transferred to nitrocellulose membrane and visualized by Western 
blotting with the MMR2 antibody. (B) Untransfected (NT) and MTl-MMP- 
transfected A375 cells were biotinylated at 4°C and then lysed with a TNE 
containing 1% Triton X-100, as described in Materials and Methods. After 
centrifugation at 4°C (13,000 x g, 10 minutes), intracellular proteins (Int) were 
separated from biotinylated plasma membrane proteins (PM) by capture with 
streptavidine-conjugated agarose beads. Each fraction was subjected to SDS- 
PAGE and transferred on nitrocellulose membrane. The MTI-MMP 
distribution profile was analyzed with polyclonal anti-MTl-MMP antibody 
M3927. The 65, 63 and 60 kDa forms are indicated on the right. Where 
indicated, cells were treated with BFA (10 pg/ml) for 2 hours prior to 
processing. (C) MTl-MMP-transfected A375 cells, treated with BFA for 15 
min, were double-labeled with immunopurified polyclonal anti-MTl-MMP 
antibody MMR2 (MTI-MMP) and with monoclonal antibody directed against 
a Golgi marker (Giantin). Merged staining is also shown on the right. Scale 
bar: 10 pm.
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early and recycling endosomes) (Lippincott-Schwartz et al., 1991), it seems clear 
that, at steady-state, M TI-M M P is concentrated in a TGN/post-TGN 
compartment, where its furin is highly concentrated.
To further determine whether furin activates proMTl-MMP in the trans- 
Golgi network, I investigated the subcellular localization of furin and MTI-MMP 
in more detail by confocal microscopy. Furin is, depending on the cell type, 
typically expressed at very low levels and distributed throughout the various 
proprotein processing compartments including the trans-Golgi network, cell 
surface and endosomes (Mayer et al., 2004b; Molloy et al., 1999). I thus 
cotransfected A375 cells with MTI-MMP and a furin-GFP chimera. The double­
labeled cells were subsequently sectioned optically with z-series on a Zeiss 
LSM510 confocal system. Extensive overlap between M TI-MM P and furin was 
observed in the perinuclear area (Fig. 4.2 L).
4.2.2 MTI-MMP processing takes place in an intracellular, post-trans-
Golgi network compartment
Considering this evidence, I further searched for the M TI-M M P 
activation compartment. The first possible station considered for M TI-M M P 
processing was thus the trans-Golgi network, a complex structure located at the 
distal-most region of the Golgi apparatus, which plays a central role in the sorting, 
processing and targeting of proteins of the secretory pathway en route to their 
final destination. When MTI-MMP was accumulated in the trans-Golgi network 
through the application of a 20°C temperature block (Griffiths et al., 1985) (Fig.
4.4 A), it remained unprocessed (Fig. 4.4 B). Within 30 minutes after temperature 
shift to 37°C (release from the block), intracellular trafficking as well as MT1- 
MMP processing resumed (Fig. 4.4 B). Hence, my results are consistent with a 
MTI-MMP processing event occurring after exit from the trans-Golgi network. It 
should be mentioned previous reports have shown that, in these conditions, the
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Fig. 4.4. Effect of 20°C block on M T1-M M P processing in A375 melanoma 
cells. (A) A375 cells transfected with MTI-MMP were plated on coverlips for 
16 hours, incubated at 20°C for 30 min, where indicated, and then fixed and 
analyzed at the confocal microscope. Cells were double-labeled with 
immunopurified polyclonal anti-MTl-MMP antibody MMR2 (MTI-MMP) 
and with polyclonal sheep antibody directed against TGN46 (TGN46), Merged 
staining is also shown. Scale bars: 20 pm. (B) MTl-MMP-transfected A375 
cells were pulse-labeled with [:°S]methionine/cysteine for 5 minutes. Labeled 
proteins were accumulated in the trans-Golgi network by incubating the cells at 
20°C for 30 minutes, then released at 37°C for different lengths of time, as 
indicated. Triton X-l00-soluble (S) and insoluble (P) fractions were separated 
by ultracentrifugation, immunoprecipitated and analyzed by SDS- 
PAGE/ autoradi ography.
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enzymic activity of furin is not blocked (Song and Fricker, 1995). Considering all 
the above and that proteins blocked in the trans-Golgi network at 20°C are known 
to exit rapidly (Polishchuk et al., 2000), I suggest that the processing of MT1- 
MMP takes place beyond the trans-Golgi network during transport to the plasma 
membrane.
Next, I determined whether processing of MTI-MMP takes place prior 
to, or after, delivery to the plasma membrane. Tannic acid has been used as an 
inactivator of fusion events at the plasma membrane (Newman et al., 1996; 
Polishchuk et al., 2004). I thus proceeded to use this experimental approach to 
prevent delivery of MTI-MMP to the cell surface after a 20°C temperature block. 
In the presence of tannic acid, proMTl-MMP processing still occurred albeit not 
completely (Fig. 4.5 A). Even though some toxic effects of the treatment can be 
inferred from the increased degradation of MT1-MMP, this is taken only to 
indicate that MTI-MMP processing can occur intracellularly in a post-trans-Golgi 
network compartment and prior to arrival at the plasma membrane. To validate 
that tannic acid indeed functioned to block fusion at the plasma membrane in our 
experimental system, the delivery of a temperature sensitive mutant (ts045) of 
vesicular stomatitus virus G protein (VSV-G)-GFP chimera to the plasma 
membrane was verified. This protein is blocked in the endoplasmic reticulum 
while cells are maintained at 40°C, is regularly transported through the Golgi 
apparatus up to the TGN (where it remains) at 20°C and is finally transported to 
plasma membrane at the permissive temperature of 32°C. As shown in Fig. 4.4 B, 
control cells feature a clearly defined plasma membrane staining 60 minutes after 
release from the 20°C block; cells treated with 0.5% tannic acid, instead, are 
unable to deliver (VSV-G)-GFP to the cell surface. Thus, in A375 cells treated 
with tannic acid, fusion of transport intermediates with the plasma membrane is in 
fact impaired (see graph in Fig. 4.5 B).
The extracellular face of the plasma membrane has been recently 
suggested to be the location where MTI-MMP processing by furin might occur
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Fig. 4.5. M T1-M MP processing takes place in an intracellular, post-Golgi 
com partm ent. (A) MTl-MMP-transfected A375 cells were pulse-labeled with 
[35S]methionine/cysteine for 5 minutes. Labeled proteins were accumulated in 
the trans-Golgi network by incubating the cells at 20°C for 30 minutes, then 
released at 37°C for different lengths o f time, as indicated. Triton X-l00- 
soluble (S) and insoluble (P) fractions were separated by ultracentrifugation, 
immunoprecipitated and analyzed by SDS-PAGE/autoradiography. Tannic acid 
0.5% was added during the 20°C block, 10 minutes prior to release at 37°C for 
60 minutes. (B) Tannic acid completely blocks arrival of proteins to plasma 
membrane. A375 cells were transfected with the ts045 temperature sensitive 
mutant of VSV-G-GFP chimera, incubated at 40°C over night, blocked at 20°C 
for 30 minutes then chased at 32°C for the indicated time in the absence or 
presence of 0.5% of tannic acid. Images illustrate representative control (top) 
and treated (bottom) cells. VSV-G staining on PM as detected from non 
permeabilized cells with an antibody raised against its extracellular domain is 
shown in red. Scale bar 10 pm. The graph shows ratio o f VSV-G on plasma 
membrane to total VSV-G at indicated chase time. This experiment was 
performed in collaboration with Massimiliano Baldassarre (Consorzio Mario 
Negri Sud).
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(Mayer et al., 2003). Since my results are at variance with this notion, I further 
tested this possibility. Furin is a calcium-dependent enzyme (Molloy et al., 1992) 
and as such it would be completely inhibited in the absence of free (i.e. 
unchelated) Ca2+. Fig. 4.6 shows that MTI-MMP processing can still occur when 
extracellular Ca2+ is chelated with a supramaximal concentration of EGTA (5 
mM), A minor fraction of proMTl-MMP does not appear to mature (see graph in 
Fig. 4.6), possibly due to a plasma membrane component of processing (Mayer et 
al., 2003) or leakage of EGTA into the processing compartment via fluid-phase 
endocytosis.
4.2.3 Ultrastructural features of the MTl-MMP/furin-positive post-
trans-Golgi network compartment
To gain a better understanding of the processing compartment, M Tl- 
M M P-transfected A375 cells were processed for cryoim m uno-electron 
microscopy and immunolabeled with immunopurified anti-M Tl-MM P antibody 
(MMR2). We thus determined the intracellular distribution of labeling densities 
for MTI-MMP throughout the various compartments of the secretory pathway, 
identified on the basis of their morphology. The distribution of M TI-MM P was 
not homogeneous and presented a clear high peak of 76.6% (Table 4.1) in tubulo- 
saccular structures located between the trans-Golgi network and the plasma 
membrane as illustrated in Fig. 4.7 (A-C). Of note, MTI-MMP expression levels 
had no effect on the morphology of the secretory structures (not shown). This 
compartment, on the basis of our biochemical experiments and on the 
morphological observation that, at the ultrastructural level, it was not specifically 
labeled by the TGN marker TGN46 at steady state (Fig. 4.8), was thus defined as 
a post-trans-Golgi network compartment. This compartment might also contain 
endosomal elements as suggested by our immunofluorescence studies, consistent 
with recent reports suggesting a recycling loop for M TI-MM P {Remade, 2003
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Fig. 4.6. Effect of EGTA on M T1-M MP processing. After incubating the 
cells at 20°C for 30 minutes, the MTl-MMP-transfected pulsed A375 cells 
were treated (lane 3) or not (lane 2) with 5 mM EGTA for 30 minutes at 37°C. 
Only the soluble fraction is shown. MT1-MMP molecular forms in lanes 2 and 
3 were quantified with the public domain ImageJ v.1.3 software and plotted on 
the reported chart as a ratio of MT1-MMP processing.
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Table 4.1. Distribution of MT1-MMP over cellular membrane 
compartments in MT1 -MMP-tra 11 sfected A375 cells
Gold particles Labeling density
l.E R -2.3% 0.04 ±0.03
2. ER to Golgi intermediate compartments 0.4% 0.07 ± 0.04
3. Golgi cisternae -1% 0.006 ± 0.01
4. TGN 1.14% 0.017 ±0.01
5. post-TGN 76.6% 0.87 ± 0.05
6. Plasma membrane 18.5% 0.25 ± 0.07
To determine the distribution of MT1-MMP throughout the seeretoiy pathway 
in transfected A3 75 cells, quantification was performed as described in Materials and 
Methods. Labeling densities are expressed as the number of gold particles per 
intersections of the morphometrical grid. This quantification was performed by 
Galina Beznoussenko (Consorzio Mario Negri Sud).
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Fig. 4.7. C haracterization of a M T1-M MP- and  Furin-positive post-Golgi 
com partm ent in A375 melanoma cells by cryo-immuno-electron 
microscopy. MTl-MMP-transfected A375 cells were fixed and prepared for 
cryo-immunogold labeling as decribed in Materials and Methods by using 
differently sized gold particles, as indicated. Subcellular colocalization of 
MT1-MMP with endogenous furin: 10 nm, anti-furin; 15 nm, anti-MTl-MMP 
(immunopurified antibody MMR2). Arrows mark the positions of specific 
regions containing both MT1-MMP and furin. Scale bars: 100 nm (A), 75 nm 
(B, C). Experiment performed in collaboration with Galina Beznoussenko 
(Consorzio Mario Negri Sud).
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Fig. 4.8. Subcellular colocalization of M T1-M M P with endogenous TGN46 
and furin by cryo-immuno electron microscopy. MTl-MMP-transfected 
A3 75 cells at steady state (A) or incubated for 30 min at 20°C (B) were fixed 
and prepared for ciyo-immunogold labeling as described in Materials and 
Methods by using differently sized gold particles, as indicated: at 37°C, 15 nm, 
anti-TGN46; 10 nm, anti-MTl-MMP (immunopurified antibody MMR2); at 
20°C, 5 nm, anti-TGN46; 10 nm, anti-MTl-MMP. Arrows mark the positions 
o f specific areas containing TGN46, arrowheads mark MT1-MMP. Asterisks 
mark proteins detected at 20°C in Golgi cisternae. O f note in these conditions, 
MT1-MMP and TGN46 colocalization appears to increase. Scale bar: 200 nm. 
MTl-MMP-transfected A375 cells at steady state (C) or incubated for 30 min 
at 20°C (D) were fixed and prepared for cryo-immunogold labeling as 
described in Materials and Methods by using differently sized gold particles, as 
indicated: 15 nm, anti-furin; 10 nm, anti-MTl-MMP (immunopurified 
antibody MMR2). Arrows mark the positions o f specific areas containing both 
furin and MT1-MMP. Asterisks mark proteins detected at 20°C in Golgi 
cisternae. Scale bar: 150nm. This experiment was performed in collaboration 
with Galina Beznoussenko (Consorzio Mario Negri Sud).
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#269; Wang, 2004 #224}.
When the labeling density of MT1-MMP in different compartments was 
compared to that of endogenous furin, we established that 64.6% of the MT1- 
MMP-positive structures contained furin, furthermore 84.8% of the furin-positive 
structures contained MT1-MMP. This localization coincided with the post-trans- 
Golgi network compartment, where MT1-MMP was enriched and that also 
represented the foremost reservoir for endogenous furin in A375 cells (Fig. 4.7, 
A-C). Of note, the post-TGN compartment where furin and MT1-MMP 
colocalize, was not significantly affected by a 20°C block (see Fig. 4.8 B).
MT1-MMP had been previously hypothesized to be localized to caveolar 
DRM (Annabi et al., 2001); it was also recently suggested that MT1-MMP is 
internalized via caveolae in addition to the clathrin-mediated pathway (Remade et 
al., 2003). I thus examined whether the protein caveolin-1, a typical component of 
caveolae, colocalized with MT1-MMP at the plasma membrane. Fig. 4.9 clearly 
shows that MT1-MMP at the plasma membrane is not preferentially localized in 
caveolin-l-enriched domains. This does not conflict with the biochemical data in 
Fig. 3.4 C showing that both MT1-MMP and caveolin-1 partition into DRM; in 
fact, caveolae represent only a subset of the total DRM fraction (Schnitzer et al.,
1995).
4.2.4 Analysis of the subcellular localization of mature MT1-MMP
I have thus far discussed a set of data suggesting that MT1-MMP 
processing occurs inside the cell and most likely in association with furin- 
enriched tubulo-saccular structures located between the trans-Golgi network and 
the plasma membrane. To better define the subcellular distribution of processed 
mature MT1-MMP, I made use of a FLAG epitope-tagged MT1-MMP cDNA 
(defined F112-MT1-MMP for the introduction of the FLAG epitope at the 
Argl 12) (Fig. 4.10 A). Introduction of the FLAG epitope tag at the immediate
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Fig. 4.9. Subcellular and plasma m em brane colocalization of M T1-M M P 
with endogenous caveolin by cryo-immuno-electron microscopy. M Tl- 
MMP-transfected A375 cells were fixed and prepared for ciyo-immunogold 
labeling as decribed in Materials and Methods by using differently sized gold 
particles, as indicated: 10 nm, anti-caveolin-1; 15 nm, anti-MTl-MMP 
(immunopurified antibody MMR2). PM indicates plasma membrane rims. C 
indicates caveosome. Arrows mark the positions of specific regions containing 
MT1-MMP or caveolin-1. Scale bar: 150 nm. Experiment performed in 
collaboration with Galina Beznoussenko (Consorzio Mario Negri Sud).
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Fig. 4.10. M olecular characterization of the F112-MT1-MMP m utant. (A)
Schematic representation of the modular domain structure of MT1-MMP with 
the insertion of a FLAG epitope (red) between the propeptide and the catalytic 
domains and soon after the fiirin binding site (Wu et al., 2004). (B) 
Untransfected (NT) and FI 12-transfected A375 melanoma cells were lysed and 
resuspended in sample buffer and subjected to SDS-PAGE, transferred to 
nitrocellulose membrane and visualized by Western blotting with different 
antibodies raised against the FLAG epitope: a) FLAG, an immunopurified 
polyclonal antibody; b) M2, an immunopurified monoclonal antibody; c) M l, a 
CaCl2-sensitive immunopurified monoclonal antibody. Different molecular 
forms o f MT1-MMP were detected and respectively defined as 
immature/mature forms depending on their expected molecular weights.
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C-terminal of the propeptide cleavage site permits the use of immunological 
methods to monitor propeptide cleavage and correlation of this event with 
enzymic activity. Importantly, the FLAG tag at this position does not significantly 
affect propeptide cleavage or enzyme activity (Wu et al., 2004). By employing 
different FLAG peptide-specific antibodies (polyclonal anti-FLAG, mAb M l and 
mAb M2), the immature form of MT1-MMP (which reacts with polyclonal anti- 
FLAG and monoclonal M2 antibodies only) can be distinguished from the mature 
form (propeptide-less) of MT1-MMP generated by autoproteolytic cleavage C- 
terminal to A rg ll2  (Fig. 4.10 B), which reacts also with monoclonal M l 
antibody. These results show that the tested antibodies perform as predicted and 
should therefore serve as highly selective probes for elucidating the intracellular 
routing and processing of MT1-MMP in cells.
To determine the steady-state location of mature MT1-MMP, A375 cells 
transfected with MT1-MMP were fixed 12-16 h post-transfection and processed 
for immunofluorescence microscopy with the different primary antibodies (see 
Materials and Methods). Under these conditions the staining patterns obtained 
with M l and M2 (Fig. 4.11) were apparently quite similar, when compared to the 
polyclonal anti-FLAG antibody, and consisted of a prominent perinuclear Golgi- 
like concentration similarly to previous experiments with MMR2 antibody (see 
Fig. 4.1). In fact, the Ml-specific staining was substantially different from that of 
M2 because only it partially overlapped with the staining pattern obtained with the 
anti-FLAG antibody. This evidence is in line with the biochem ical 
characterization I performed to define the subcellular compartment where MT1- 
MMP activation occurs: the mature form of MT1-MMP is processed and mainly 
present out of the perinuclear Golgi-like area.
To better determine in which compartment mature MT1-MMP was 
concentrated, a series of colocalization experiments was performed with 
antibodies directed against a variety of secretory pathway marker proteins. 
Similarly to the previous analysis performed with the MMR2 antibody,
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ci-FLAG merge
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Fig. 4.11. Subcellular distribution of F112-MT1-MMP in A375 melanoma 
cells by immunofluorescence. A375 cells transfected with F112-MT1-MMP 
were plated on coverlips for 16 hours, then fixed and analyzed at the confocal 
microscope as described in Materials and Methods section. To test the anti-Ml 
antibody, all the solutions were prepared with ImM CaCl2. Cells were double­
labeled with different anti-FLAG antibodies, as indicated. Merged staining is 
also shown on the right. Scale bar: 10 pm.
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the distribution of mature MT1-MMP overlaps extensively with that of TGN46 
and furin (Fig. 4.12).
4.2.5 Mature MT1-MMP is associated with intracellular recycling 
membranes
The colocalization analysis indicates that mature MT1-MMP resides in 
the post-Golgi area, likely where MT1-MMP processing occurs. This 
compartment might also contain endosomal elements as suggested by a 
preliminary morphological analysis I performed with specific markers (see 
transferrin receptor and mannose-6-phosphate receptor patterns in Fig. 4.2). This 
would be consistent with recent reports suggesting a recycling loop for MT1- 
MMP with the plasma membrane (Remade et al., 2003; Wang et al., 2004b). In 
these reports, morphological analysis was performed with antibodies that detected 
both immature and mature MT1-MMP forms. In particular, MT1-MMP was 
shown to be internalised from the cell surface and to be colocalised with various 
endocytic compartment markers: EEA1, an early endosomal antigen interacting 
with Rab5 and phosphatidylinositol-3-phosphate to facilitate early endosome 
fusion (Christoforidis et al., 1999); Rab4, enriched in recycling endosomes 
(Sonnichsen et al., 2000), and p230, enriched in the trans-Golgi network (Gleeson 
et al., 1996). Given these results, it was concluded that MT1-MMP is internalized 
through the early endosomes and then routed through the trans-Golgi network 
from where it is recycled back to the cell surface.
Given this context, to better understand the subcellular distribution of 
mature MT1-MMP within endosomal compartments, I examined whether any of 
the Rab proteins, Ras-related GTPases known to have a role in endosomal 
trafficking, colocalized with mature MT1-MMP. Due to the lack of good 
immunological reagents for the detection of endogenous Rab proteins, I 
transiently cotransfected A375 cells with FI 12-MT1-MMP and various
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merge
Fig. 4.12. Subcellular distribution of m ature M T1-M M P in A375 
melanoma cells by immunofluorescence. A375 cells co-transfected with 
FI 12-MT1-MMP and furin+GFP chimaera (FurGFP) were plated on coverlips 
for 16 hours, then fixed and analyzed at the confocal microscope as described 
in Material and Methods section. Cells were double-labeled with the CaCl2- 
sensitive immunopurified monoclonal anti-FLAG antibody (M l) and with the 
sheep polyclonal antibody directed against TGN46. Combined stainings are 
shown with different combinations and the relative colours are also indicated. 
A region of interest of the merge staining is shown at a 10X magnification.
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GFP-tagged Rabs. It is known that the GFP tag does not affect either localization 
or function of Rab proteins (Sonnichsen et al., 2000). Moreover, when 
overexpressed at low levels, most Rab proteins do not affect the morphology of 
the subcellular compartments (Weigert et al., 2004). Mature MT1-MMP was 
partially colocalized with Rab4 (not shown), but was completely divergent from 
Rab7 (Fig. 4.13 A), a protein involved in trafficking from early endosomes to late 
endosomes/lysosomes and localized in late endosomes (Press et al., 1998). 
Strikingly, mature MT1-MMP showed a distinct, highly overlapping pattern with 
R ab ll (Fig. 4.13 A), a protein localized to the recycling endosome, the TGN and 
specialized storage membranes of regulated secretory pathways (Ullrich et al.,
1996).
In conclusion, these data define: 1) the presence of mature MT1-MMP in 
association with endocytic membranes and, in particular, 2) the presence of 
mature MT1-MMP in a Rab 11-positive compartment supporting the idea that 
MT1-MMP activation compartment is associated with recycling membranes, 
likely available for polarized/regulated delivery to the PM (e.g. GLUT-4, MHC-I 
compartments) (Fig. 4.13 B).
4.2.6 Co-immunoprecipitation between furin and proMTl-MMP
Pei and coworkers have recently found that a major portion of 
internalized M Tl-M M Ps are co-localized with furin, a protein “bicycling” 
between the trans-Golgi network and endosomes as well as between endosomes 
and the plasma membrane (Wang et al., 2004). In addition, they also found that 
the colocalization pattern between MT3-MMP and furin was observed even upon 
inhibiting furin activity or proMT3-MMP processing (Kang et al., 2002).
The interaction between furin and MT3-MMP was thus found to be 
relatively strong and resistant to a wide variety of treatments although a more 
detailed characterization was not performed. Since this tight interaction could be
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Fig. 4.13. Association of m ature M T1-M MP with Rab 11-positive recycling 
membranes. (A) A375 cells co-transfected with F112-MT1-MMP and Rab7- 
GFP or Rabll-G FP were plated on coverlips for 16 hours, then fixed and 
analyzed at the confocal microscope as described in Materials and Methods 
section. Cells were labeled with the CaCl2-sensitive immunopurified 
monoclonal anti-FLAG antibody (M l). (B) A schematic representation o f a 
hypothetical recycling compartment enriched with furin and R abll (modified 
from Maxfield et al., 2004).
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common to other MT-MMPs, I decided to verify the interaction between furin and 
MT1-MMP by performing co-immunoprecipitation experiments. Furin-GFP 
(GFP-tagged at its C-terminal) and wild-type MT1-MMP were co-expressed in 
A375 melanoma cells. As shown in Fig. 4.14, M T1-M M P was co- 
immunoprecipitated with furin-GFP when I used a commercial polyclonal anti- 
GFP antibody (Abeam) but there was no co-immunoprecipitation when I used the 
anti-M Tl-M M P antibody (MMR2). A possible explanation for this conflicting 
observation comes from the fact that the polyclonal anti-M Tl-M M P antibody 
used in these experiments (MMR2) is raised against the propeptide-deleted 
extracellular region of MT1-MMP. Since it is likely that furin interacts with MT1- 
MMP within its extracellular region, it is possible that furin binding could 
interfere with the interaction between MT1-MMP and the MMR2 antibody, but 
not between the C-terminal GFP tag and the anti-GFP antibody.
Considering this evidence, at this level, I can only assume that MT1- 
MMP and furin form a complex via either direct or indirect interaction. Of note, 
furin appears to interact only with immature proMTl-MMP. For this reason, it 
could be hypothesized that this complex requires also the propeptide of MT1- 
MMP. The characterization of this interaction is now under investigation and I 
have preliminary indications that it has a functional role in the regulation of MT1- 
MMP activation by regulating MT1-MMP association with DRM (see section 
4.3.3).
4.3 Discussion
4.3.1 Intracellular activation of MT1-MMP
Previous findings (Yana and Weiss, 2000) have suggested that MT1- 
MMP processing is dependent on a furin-like activity, while others have proposed 
that MT1-MMP does not require the cleavage of its propeptide to activate MMP2
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Fig. 4.14. ProMTl-MMP can be coimmunoprecipitated with FurinGFP.
A375 melanoma cells untransfected (NT) or transfected with: MT1-MMP, 
FurinGFP or MTl-MMP+FurinGFP were labeled with [35S]- 
methionine/cysteine for 2 hours and then lysed with RIPA buffer (150mM 
NaCl, l%NP-40, 0.5% DOC, 0.1% SDS, 50mM Tris pH 8.0). As indicated, 
small amounts o f cleared lysates from differently transfected cells were 
immunoprecipitated, as described in the Materials and Methods section, with a 
polyclonal immunopurified antibody raised against MT1-MMP, MMR2 (a- 
MT1) or with polyclonal immunopurified antibody raised against GFP (a- 
GFP). The black arrows mark the position o f specific bands detected by 
autoradiography. The relative standard molecular weights are reported on the 
right.
in certain cell types (Cao et al., 1996). In addition, activation of MT1-MMP could 
also occur by plasmin at the cell surface (Okumura et al., 1997). To verify the 
activation mechanism in our experimental system, we co-transfected MT1-MMP 
with the furin inhibitor al-PD X  in A375 cells. In these conditions, MT1-MMP- 
dependent gelatin degradation was completely inhibited, indicating that MT1- 
MMP needs to be processed to express direct or indirect gelatinolytic activity. In 
addition, since in such conditions the mature 60 kDa form is undetectable, 
alternative pathways of activation, e.g. extracellular plasmin (Okumura et al.,
1997) can be excluded. Finally, BB94, a broad-range metalloprotease inhibitor 
(Davies et al., 1993), did not affect MT1-MMP processing excluding that, at least 
in our conditions, MT1-MMP was functioning as a self-convertase as proposed by 
one group (Rozanov and Strongin, 2003). These data enhance the essential role of 
furin in the regulation of MT1-MMP processing and activity.
Despite the central role played by furin in many pathophysiological 
processes, the exact subcellular sites of processing and activation of its substrates 
remain elusive. This is also the case for MT1-MMP. Hence, a major concern is to 
identify the cellular location(s) where endoproteolytic cleavage of MT1-MMP 
occurs. A number of studies have established that furin is mainly localized in the 
trans-Golgi network but undergoes extensive cycling between the Golgi complex, 
endosome compartments and the plasma membrane (for a review, see Molloy et 
al., 1999). Of note, a high-resolution immunogold electron microscopy-based 
study has recently shown that, in addition to the Golgi apparatus, furin was clearly 
localized to endosomes and plasma membranes of a number of cell types (Mayer 
et al., 2004a). M y finding that MT1-MMP processing takes place in an 
intracellular, post-Golgi, pre-plasma membrane compartment, are consistent with 
this widespread distribution of furin.
The extracellular face of the plasma membrane was recently proposed to 
be the MT1-MMP activation compartment solely based on experiments showing 
that, after chemical cross-linking, furin co-immunoprecipitates with proM Tl-
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MMP at the plasma membrane (Mayer et al., 2003). The same study also showed 
a colocalization of the two proteins on the plasma membrane. I show that, at least 
in A375 melanoma cells, furin-dependent processing of MT1-MMP occurs in a 
post-TGN, pre-plasma membrane compartment.
4.3.2 M orphological and functional characterization o f the
intracellular activation compartment of MT1-MMP
At steady-state, I find MT1-MMP to be mainly localized to vesiculo- 
tubular structures distal to the Golgi apparatus and close to the plasma membrane, 
possibly corresponding to the MT1-MMP activation compartment.
Since this compartment also contains recycling endosomal elements (e.g. 
Rab4, R ab ll)  and considering that I also find that MT1-MMP processing occurs 
during the exocytic process and not after re-entry through endocytic recycling, it 
appears that MT1-MMP is sorted to a recycling endocytic compartment where its 
maturation occurs. I am currently investigating the possibility that this is a 
transient storage compartment where MT1-MMP is available for rapid 
polarized/regulated trafficking to the plasma membrane. This hypothesis is 
particularly intriguing because pericellular matrix degradation during cancer 
invasion is dependent on activation of MMP2 by MT1-MMP. This activation has 
generally been considered to be a relatively slow process occurring as a result of 
enhanced expression of MT1-MMP. Cao and co-workers have recently reported 
that concanavalin A treatment of HT1080 fibrosarcoma cells is followed by MT1- 
MMP-induced activation of MMP2 on the cell surface within 1 hour. MT1-MMP 
function at the cell surface was also accelerated by treatment of cells with 
cytochalasin D, a drug which depolymerizes actin filaments, PMA, a stimulator of 
protein kinase C, and bafilomycin A, an inhibitor of lysosome/endosome function. 
A functional pool of intracellular MT1-MMP available for trafficking to the cell 
surface was demonstrated by repetitive ConA stimulation (Zucker et al., 2002).
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These data further support my hypothesis that MT1-MMP is sorted to a transient 
storage compartment (trans-Golgi network/endosomes), where it is available for 
rapid trafficking to the plasma membrane and cell surface proteolytic activity.
4.3.3 A possibile role of furin in MT1-MMP intracellular trafficking
Furin, a low abundance protein present in multiple cell types, is a 
member of the proprotein convertase family that include Kex2, PCI/3, PC2, PC4, 
PACE4, PC5/6, and PC7. It is translated in the endoplasmic reticulum as an 
integral membrane precursor prior to activation (for a review, see Thomas, 2002). 
Autoproteolysis cleaves an N-terminal peptide that binds, in part, to the catalytic 
domain and inhibits enzymatic activity. Once translocated to the Golgi stack, this 
peptide is cut and released to produce fully active furin. Although, at steady state, 
furin is primarily (>80%) localized to the trans-Golgi by a signal on its carboxyl 
cytoplasmic tail, a significant amount of furin cycles between the Golgi and the 
plasma membrane and small amounts have been detected in the extracellular 
space. Thus, even though furin is available to cleave MT-MMPs, inhibition of the 
furin catalytic activity as well as mutation of the furin binding site in proMT3- 
MMP does not prevent the intracellular trafficking, the posttranslational 
processing, or the furin colocalization of MT3-MMP (Kang et al., 2002).
These unexpected results are consistent with my observation of a co- 
immunoprecipitation of proMTl-MMP with furin. The physical features of this 
interaction (direct or indirect) as well as the exact station of the secretory pathway 
where this interaction would occur are still not defined and are beyond the scope 
of my thesis. At any rate, I can speculate that proMT-MMPs traffic through the 
trans-Golgi and progress to the plasma membrane via a furin-regulated pathway, 
either separately or complexed with regulatory proteins. Exposure to 
environmental changes (pH, ions, etc.) could result in conformational changes that 
trigger cleavage of the propeptide domain by a membrane-anchored furin within a 
post-trans-Golgi network compartment to facilitate subsequent MT1-MMP cell-
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surface presentation and activity. Together with membrane partitioning, my data 
identify furin as another possible regulator of MTl-MMP-dependent activities.
Of note, I recently found that MT1-MMP distribution profile within 
different membrane subdomains from A375 melanoma is considerably altered 
when furin is overexpressed (Fig. 4.15 A). This effect seems to be dependent on 
furin expression levels and indeed did not occur when I cotransfected the specific 
furin inhibitor al-PD X .
Taken together, I found that furin is responsible for intracellular pro- 
MT1-MMP activation and, at least in A375 cells, is associated only with 
detergent-soluble membranes and co-immunoprecipitates only with proM Tl- 
MMP. Considering this, my working hyphothesis is now that furin could be a 
possible molecular “bait" for proM Tl-M M P, regulating its partitioning with 
different membrane subdomains and therfore its biochemical processing and 
biological activities (Fig. 4.15 B).
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Fig. 4.15. MT1-MMP m em brane partitioning depends on furin 
expression levels. (A) A375 cells transfected with MT1-MMP and pcDNA, 
or with MT1-MMP and Furin-GFP were labeled with 
[35S]methionine/cysteine for 2 hours and lysed with TNE buffer containing 
1% Triton X-100 on ice. Soluble (S) and insoluble (P) fractions were 
separated by ultracentrifugation, immunoprecipitated with a polyclonal anti- 
MTl-MMP antibody and analyzed by SDS-PAGE/autoradiography. The 
processing ratio o f MT1-MMP (MTl-MMP/Total) was determined with the 
Fuji BAS software and plotted graphically. (B) Proposed model for the role 
of furin on MT1-MMP membrane partitioning and activation. Legend: DRM 
(detergent-resistant membranes), F (furin). The propeptide domain o f MT1- 
MMP (black stick) is shown in red.
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CHAPTER 5
Final Discussion
5.1 Intracellular Processing and Activation of MT1-MMP
Depends on its Partitioning into Lipid Domains
It has clearly emerged that MT1-MMP (and perhaps other membrane- 
type MMPs) is essential for the growth of human cancers, and that it acts by 
disrupting the three-dimensional matrix which would otherwise impede cell 
proliferation (Hotary et al., 2003) (Fig. 5.1). Hence, full understanding of MT1- 
MMP physiology is crucial for developing strategies aimed at preventing the 
escape of cells from a primary tumor. In the present study I show that only a 
subpopulation of MT1-MMP, associated with detergent soluble membranes, is 
activated and rapidly degraded. In contrast, DRM-associated MT1-MMP retains 
its propeptide and is stably linked with the plasma membrane. These findings 
establish a novel mode of regulation of MT1-MMP activity and suggest a 
potential molecular basis for its diverse functions in cancer progression (see Fig. 
1.7 from Introduction).
The results obtained by combining biochemical experiments with an in- 
depth morphological analysis indicate that the metabolic fate of proM Tl-MM P is 
dependent on its partitioning into different membrane domains. In particular, 
furin-dependent activation, shown here to occur in a post-Golgi, pre-plasma 
membrane compartment, occurs exclusively in the detergent-soluble fraction (Fig. 
5.2). Also, this processed MT1-MMP is the sole form responsible for ECM 
degradation in vitro.
The functional role of DRM-associated MT1-MMP remains to be 
unveiled. A potential indication stems from the findings that wild-type
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collagen or fibrin mesh MT1-MMP Cells expressing MT1-MMP
Fig. 5.1. M T1-M MP usurps tum or growth control imposed by the three- 
dimensional extracellular m atrix (reproduced from  H otary et al., 2003).
Cancer cells are able to proliferate at accelerated rates within the confines o f a 
three-dimensional (3D) extracellular matrix (ECM) that is rich in type I 
collagen. The mechanisms used by tumor cells to circumvent endogenous 
antigrowth signals have yet to be clearly defined. We find that the matrix 
metalloproteinase, MT1-MMP, confers tumor cells with a distinct 3D growth 
advantage in vitro and in vivo. The replicative advantage conferred by MT1- 
MMP requires pericellular proteolysis o f the ECM, as proliferation is fully 
suppressed when tumor cells are suspended in 3D gels of protease-resistant 
collagen. In the absence of proteolysis, tumor cells embedded in 
physiologically relevant ECM matrices are trapped in a compact, spherical 
configuration and unable to undergo changes in cell shape or cytoskeletal 
reorganization required for 3D growth. These observations identify MT1-MMP 
as a tumor-derived growth factor that regulates proliferation by controlling cell 
geometry within the confines of the 3D ECM.
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Fig. 5.2. Proposed model: Intracellu lar Processing and Activation of MT1- 
MMP Depends on its Partitioning into Lipid Domains. The majority (80%) 
of MT1-MMP is sorted to detergent-resistant membrane fractions (blue); 
however, it is only the minor (20%) detergent-soluble fraction o f MT1-MMP 
that undergoes intracellular processing to the mature form. Also, this processed 
MT1-MMP is the sole form responsible for ECM degradation in vitro. Finally, 
furin-dependent processing of MT1-MMP is shown to occur intracellularly 
after exit from the Golgi apparatus and prior to arrival at the plasma 
membrane, in a post-Golgi compartment. O f note, in this model, furin is 
exclusively associated with detergent-soluble membranes (S). The association 
of MT1-MMP with different membrane subdomains might be crucial in the 
control o f its different activities: for instance in cell migration and invasion and 
other less defined ones such as MTl-MMP-dependent signaling pathways.
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MT1-MMP overexpression triggers different signaling pathways (see next 
section). Since DRM domains represent a preferred platform for a number of 
signaling receptors and cytoskeleton interactors (Toomre et al., 2000), a 
possibility that remains to be tested is whether the DRM-associated proM Tl- 
MMP pool that I characterized in this work may be involved in the transduction of 
intracellular signal pathways.
5.2 DRM-associated MT1-MMP may induce intracellular signal
transduction via its cytoplasmic domain
A number of recent findings support the idea that the localization of 
plasma membrane MT1-MMP in DRM, specialized membrane domains rich in 
receptors and signaling intermediates, could induce signal transduction and 
regulate gene expression via its cytoplasmic domain.
The cytoplasmic domain of MT1-MMP is distinct from those of MT2-, 
MT3-, and MT5-MMP, and is well characterized. In addition to playing an 
important role in MT1-MMP localization and proMMP-2 activation through 
homophilic complex formation at the cell surface (see section 1.8.3), the 
cytoplasmic domain of MT1-MMP could participate in the following cell 
signaling events.
In cells transfected with MT1-MMP, the cytoplasmic domain of MT1- 
MMP is involved with the activation of the extracellular signal-regulated protein 
kinase (ERK) cascade during cell migration (Gingras et al., 2001). More recently, 
Takino et al. have demonstrated that MTl-MMP-mediated ERK activation leads 
to tumor cell invasion in type-1 collagen gel (Takino et al., 2004).
The cytoplasmic tail of MT1-MMP is also required for the activation of 
the Src-tyrosine kinase pathway involved with VEGF up-regulation during 
tumoral angiogenesis (Sounni et al., 2004). More recently, Uekita et al. have 
identified a new 19 kDa MT1-MMP cytoplasmic tail binding protein-1 (MTCBP-
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1), by yeast two-hybrid screening. This protein, homologue to members of cupin 
superfamily, is distributed between three subcellular compartments (membrane, 
cytoplasm and nucleus) and may inhibit the invasion and migration-promoting 
activities of MT1-MMP (Uekita et al., 2004).
Interestingly, it has been recently described that hyaluronic acid (HA) 
cell surface binding to its receptor, the membrane glycoprotein CD44, is inhibited 
by the overexpression of full-length MT1-MMP in endogenously MT1-MMP- 
expressing tumor cells (Annabi et al., 2004). This inhibition is dependent on the 
cytoplasmic domain of MT1-MMP and may be overcome by shifting part of the 
MT1-MMP pool out of DRMs by cholesterol extraction in presence of collagen 
(Annabi et al., 2004). This evidence strongly supports my idea that DRM- 
associated proM Tl-M M P pool may induce intracellular signalling pathways 
inhibiting cell functions associated with an increased CD44-mediated HA binding 
(e.g. tumor cell migration). For this reason, I will discuss this topic in further 
detail in the following section.
5.3 DRM-associated MT1-MMP may regulate CD44-mediated
tumor cell migration
MT1-MMP is a multifunctional protein that regulates several biological 
processes at the cell surface of cancer cells (i.e. cell migration). As already 
mentioned (Annabi et al., 2004), it has been recently proposed that MT1-MMP 
regulates increased CD44-mediated HA binding of some tumor cells (e.g. highly 
invasive glioma cells). HA is an important glycosaminoglycan ECM constituent 
believed to be implicated in angiogenesis, the formation of new blood vessels 
from preexisting vasculature. Although the serum level of HA is already used as 
an indicator of progressive malignant disease, its effects on in vivo angiogenesis 
and endothelial cell (EC) function are complex and have been reported to depend 
on HA concentration and molecular size. Accordingly, although high molecular
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weight HA was shown to inhibit EC functions, low molecular weight HA 
stimulated EC proliferation, tubulogenesis, and neovascularization (for a recent 
review, Adamia et al., 2005). Moreover, small HA polymers efficiently regulated 
CD44 cell surface functional expression and thus promoted CD44-dependent 
tumor cell migration. In fact, elegant studies demonstrated that CD44 directed 
MT1-MMP to lamellipodia by associating with its hemopexin-like domain, and 
that cell surface MTl-MMP-mediated cleavage of CD44 subsequently played a 
critical role in promoting tumor cell migration (Kajita et al., 2001; Mori et al., 
2002).
More recently, Beliveau et al. dem onstrated that M T1-M M P 
overexpression inhibits CD44-mediated HA binding through a ERK-dependent 
pathway, and this effect is antagonized by MMP inhibitors when collagen is 
present (Annabi et al., 2004). In this process, ECM components are also involved. 
Type I collagen, for example, not only triggers MTl-MMP-dependent proMMP-2 
activation through the formation of a trimolecular complex involving TIMP-2 
(Fig. 5.3), but also induces a profound cytoskeletal reorganization that signals an 
increase in HA cell surface binding to CD44.
Although the cytoplasmic domain of MT1-MMP is unnecessary for 
proMMP-2 processing, it is crucial for MT1-MMP cell migration and activation 
of the MAPK pathway, as well as CD44 cell surface functional expression. Down- 
regulation of HA binding activity by inhibition of the MAPK cascade further 
suggests that an MTl-MMP/CD44/ERK-dependent regulatory signaling regulates 
HA cell surface binding in tumor cells (Annabi et al., 2004).
Cholesterol depletion also increases the cell surface binding of HA in 
synergy with type I collagen (Annabi et al., 2004). Cholesterol depletion may 
trigger a further increase in type I collagen interaction with caveolae-associated 
proteins, such as DRM-associated proMTl-MMP, but this needs to be confirmed.
This study suggests that DRMs represent a new modality in regulating 
the functional activity of MT1-MMP in malignant cells, and that the yet-to-be
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MT1-MMP
PEX1 CD44 OUT
MAPK pathway Actin
caveolae
EGCg or 
llomastatActivated" state
Type I 
collagenP  MMP-2
proMMP-2
HA Type I 
collagen
TIMP-2
CD44 OUT
MAPK pathway —► Cytoskeleton —► Actin
caveolaeCell migration
Fig. 5.3. MT1-MMP and its caveolar location may regulate the CD44- 
mediated HA cell surface binding in tumor cells (reproduced from Annabi 
et al., 2004). In the basal state, MT1-MMP regulates CD44 cell surface 
expression through a MAPK-dependent pathway, and this is antagonized by 
two inhibitors o f MMP functions: llomastat and EGCg, a green tea catechin 
with anticancer and anti-angiogenic properties. In the "activated" state, type I 
collagen triggers proMMP-2 activation through the formation o f a trimolecular 
complex involving TIMP-2, which subsequently releases an active form of 
MMP-2 (A). The profound cytoskeletal reorganization induced by type I 
collagen signals an increase in HA cell surface binding to CD44 (double 
arrow, B). Although the intracellular domain o f MT1-MMP is unnecessary for 
proMMP-2 processing, it was crucial for MT1-MMP cell migration and 
activation o f the MAPK pathway, as well as CD44 cell surface functional 
expression (Q . Down-regulation o f HA binding activity by inhibition o f the 
MAPK cascade further suggests that an MTl-MMP/CD44/ERK-dependent 
regulatory signaling regulates HA cell surface binding in tumor cells. 
Cholesterol depletion may also trigger a further increase in type I collagen 
interaction with caveolae-associated proteins such as caveolar MT1-MMP (Z)), 
but this needs to be confirmed.
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identified intracellular signal transduction pathways involving the 
cytoplasmic tail peptide sequence are likely to regulate DRM-associated proMTl- 
MMP-dependent activities.
Overall, these data, taken together with the data we recently published 
(Mazzone et al., 2004), provide new insight into the regulation of the metastatic 
processes based on the interaction of tumor cells with their ECM environment.
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